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1 
SUMMARY  
Chronic pain is a common medical condition that affects approximately 20% of young adults 
and 50% in older people in Australia, with similar prevalence in other Western countries. 
Clinically, opioids are one of the most commonly used analgesics for the management of this 
condition. However, opioids have been reported to be closely associated with substantial 
adverse effects that have significant impact on patients’ quality of life. In addition, 
dependence on opioids has hindered patients’ participation in programmes that encourage 
active self-management of chronic pain. Therefore, effective management of chronic pain 
remained a significant challenge. Identifying and developing non-pharmacological approaches 
to reduce opioid intake is an important strategy in pain management. 
Electro-acupuncture (EA), as part of the acupuncture practice, has a long history of being 
used as a pain relief therapy.  The underlying neural mechanism of EA analgesia is believed 
to be associated with activation of endogenous inhibitory systems and release of endogenous 
opioid peptides. In parallel, there have been a number of randomised controlled trials (RCTs) 
on EA and opioid like medication (OLM) consumption published over the last four decades. 
Although the quality of the trials varies significantly, the majority of these studies produced 
consistent and positive findings that EA was effective in reducing OLM consumption for 
operative and post-operative pain patients, in comparison with sham EA, placebo control or 
non-EA treatment control. In the meantime, there is inadequate evidence to support any claim 
of EA for reducing adverse effects of OLM. There have been no RCTs on EA for OLM 
consumption in patients with chronic pain.  
The present study aimed to determine the benefit of EA on OLM consumption and related 
adverse effects in patients with chronic pain in comparison with sham EA; in addition, the 
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potential effect of EA on chronic pain related variables such as depression and quality of life 
was also evaluated.  
A randomised, double-blind (patient/assessor) and sham-controlled study was conducted to 
evaluate the effect of EA in reducing OLM consumption by patients with chronic pain. 
Thirty-five volunteers met all inclusion criteria after being assessed by medical pain 
management specialist and thus included in this study. After a two-week baseline assessment, 
subjects were randomly assigned to one of the two groups using computer software with 17 in 
the real EA (REA) and 18 in the sham EA (SEA). All subjects were given either REA or SEA 
treatment twice a week, 30 minutes each session, over a period of six weeks. REA group 
received 2/100 Hz EA stimulation on the two-paired acupoints, Zusanli (ST36) with Fenglong 
(ST40), and Hegu (LI4) with Quchi (LI11). SEA group only received superficial needling on 
non-acupoints without Deqi sensation and electrical stimulation. The assessor and subjects 
were blinded from treatment allocation. 
The primary outcome measures were OLM consumption, related adverse effects, and daily 
records of the intensity and unpleasantness of pain. The secondary measures were depression 
and quality of life as measured by the Beck Depression Inventory-II (BDI-II) and SF-36, 
respectively. Both primary and secondary outcome measures were conducted throughout the 
baseline and treatment period. Data were analysed with independent t-tests or repeated 
measure analysis of variance (ANOVA) where appropriate and per protocol analyses were 
employed.  
At baseline, the two groups were comparable in terms of OLM consumption, non-opioid 
analgesics, the history, diagnosis, duration, and intensity of pain except for the average of 
pain, which was higher in the SEA group (p < .05). At the end of six weeks of treatment, 
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subjects reduced 64% and 46% of OLM consumption for REA and SEA groups respectively 
(p < 0.05). The effect lasted up to four weeks after completion of the six-week treatment. In 
addition, REA significantly reduced the severity of sedation compared with SEA treatment (p 
< 0.05). Subjects in the REA also had a lower overall incidence of OLM related adverse 
effects than those in SEA group. The intensity and unpleasantness of pain as well as 
depression were reduced during treatment period, however, there were no significant 
differences between the two groups. Within group comparison, the majority of domains of the 
SF-36 were not significantly improved except for bodily pain (BP), vitality (VI) and role 
physical (RP) for both groups. However, no significant group differences in these changes 
were shown. Both REA and SEA were well tolerated by subjects participated in this trial.  
At the end of the treatment period, over 90% of the subjects were satisfied with the 
interventions given and indicated that they would recommend EA to others. The blinding 
procedures were successful. In addition, 61% of the subjects thought the interventions were 
effective for their chronic pain. 
The main limitation of this study is the small sample size, which might have contributed to a 
lack of group difference on pain reduction. In recognition of heterogeneity of chronic pain, 
variations due to types and locations of pain as well as dosages and forms of OLM also need 
to be taken into consideration for the interpretation of these findings.  
In conclusion, this study demonstrated that alternating 2/100 Hz of REA is more effective in 
reducing OLM consumption and related sedation for subjects with chronic pain when 
compared with SEA. The findings suggest that EA may be a safe and effective adjunct 
therapy in chronic pain management. Further studies with a larger sample size are warranted.  
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1.CHAPTER ONE: INTRODUCTION 
Pain is the most common human subjective experience. The International Association for the 
Study of Pain (IASP) defines pain as an unpleasant sensory and emotional experience 
associated with actual or potential tissue damage (Merskey, Lindblom, Mumford, Nathan, & 
Sunderland, 1994). Chronic pain is mostly defined as pain lasting more than six months and 
may persist for years (Melzack & Wall, 1996b). Chronic pain is not considered as just a 
symptom but a medical problem (Helme & Katz, 1993). 
Chronic pain is a highly prevalent condition worldwide. Epidemiological studies have 
indicated that approximately 20% of Australian adults have suffered from chronic pain (Blyth 
et al., 2001). A similar prevalence of chronic pain is observed in the United States (US) and 
European countries (Breivik, Collett, Ventafridda, Cohen, & Gallacher, 2006; Eriksen, 
Jensen, Sjogren, Ekholm, & Rasmussen, 2003; National Research Council, 2001). The 
impacts of chronic pain include physical, psychological and social effects. Chronic pain is 
also associated with deterioration in the sufferer’s quality of life (QoL) and frequently 
accompanied by disability (Blyth, March, Brnabic, & Cousins, 2004; Blyth, March, & 
Cousins, 2003).  
Chronic pain conditions are heterogenous, which is evident from the classification of chronic 
pain. It consists of five axes including regions, systems, temporal characteristics, intensity and 
etiology. Based on the anatomic locations of the pain, chronic pain can be defined as 
headache, neck pain, lower back pain and etc. Based on the system affected, it includes pain 
in the musculoskeletal system, nervous system, respiratory and cardiovascular systems and 
others. Based on etiology, it includes pain due to injury, degeneration, tumour etc. Based on 
pathophysiology, it can be further divided into inflammatory and neuropathic pain. The 
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former arises from inflammation of skin or other tissue; the later is from injury to the 
peripheral or central nervous system (Basbaum et al., 2005; Merskey & Bogduk, 1994). 
Increases in our understanding of the complexity of pain has led to the development of 
multidisciplinary pain management (Bonica, 1990b; R. Melzack & Casey, 1968). This 
strategy embraces various therapeutic approaches focused on improving patient’s pain 
management and quality of life. Opioids are among these therapeutic options and 
recommended as one of the widely-used analgesics for the management of chronic pain 
(Grahmann, Jackson, & Lipman, 2004). Australian studies have revealed that an increasing 
number of patients with chronic pain have been prescribed opioids medication (Bell, 1997; 
Richards, 1995).  
Although the majority of chronic pain may be diminished by opioid treatment (Cowan, 
Wilson-Barnett, Griffiths, & Allan, 2003a; Jamison, Anderson, Peeters-Asdourian, & 
Ferrante, 1994), these medications produce a high rate of adverse effects. The most frequently 
observed symptoms involve both the central nervous and gastrointestinal systems, and drug-
dependence has also been documented (Gourlay, 1999; Kalso, McQuay, Edwards, & Moore, 
2004). In addition, tolerance to opioid medication which leads to an increased dose is also a 
significant problem. Recognition of these limitations has hindered the acceptance of opioids 
in the management of patients with chronic pain, and many clinicians are reluctant to 
prescribe opioids as a longer-term therapy. Therefore, the use of non-pharmacologic 
approaches to reduce opioid intake may be beneficial for chronic pain patients.  
There are a range of non-pharmacological therapeutic approaches used for managing chronic 
pain. Acupuncture is one of these therapies increasingly being used by patients and physicians 
(Aanjesen, Senstad, Lystad, & Kvaerner, 2002; Easthope, Gill, Beilby, & Tranter, 1999; 
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Easthope, Tranter, & Gill, 2000). Moreover, pain clinics have increasingly employed 
acupuncture as a treatment option (Woollam & Jackson, 1998). The National Institute Health 
(NIH), World Health Organization (WHO) and British Medical Association (BMA) have 
supported the use of acupuncture in the treatment of a wide range of pain conditions, such as 
post-operative pain, obstetric pain, dental pain, chronic lower back pain, osteoarthritic pain, 
headache and fibromyalgia (BMA, 2000; NIH, 1998; WHO, 2002).  
Electro-acupuncture (EA), based on traditional acupuncture practice, applies needling 
stimulation and electric pulses to acupuncture meridians and points in order to strengthen the 
stimulating effect of treatment. Several studies have demonstrated that EA is an effective 
technique for the management of acute and subacute pain and can reduce opioid-like 
mediation (OLM) consumption in patients with acute pain (Chen et al., 1998; Lin et al., 2002; 
Wang et al., 1997). The main underlying mechanism of EA analgesia (EAA) is thought to be 
activation of endogenous inhibitory systems and the release of endogenous opioid peptides 
(EOPs) (White, 1999).  
A few systematic reviews conclude that the effect of acupuncture on chronic pain is, however, 
inconclusive (Ezzo et al., 2000; Mendelson, 1977; ter Riet, Kleijnen, & Knipschild, 1990). 
Clinical studies of acupuncture in the treatment of chronic pain have yet to demonstrate 
greater pain reduction with real acupuncture when compared with sham acupuncture. These 
reviews attributed the inconclusive results to poor research methods and small sample sizes 
employed in clinical trials.  
It is reasonable to argue that acupuncture alone cannot sufficiently address the complex 
factors involved in chronic pain, and therefore, is unable to provide adequate therapeutic 
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benefit. It is necessary that practitioners and researchers develop an understanding of the 
specific role of acupuncture in pain management for optimal patient management.  
The current study examines the hypothesis that EA may reduce OLM consumption and 
related side effects in patients with chronic pain. A prospective, randomised, double-blind 
(patient/assessor), sham-controlled study was designed to test this hypothesis.   
This thesis includes the following other chapters: 
• Chapter Two describes the epidemiology of chronic pain, its impacts on patients and 
society, clinical measurements and current management. Neural mechanisms of EAA 
are discussed. A critical review of RCTs of EA on consumption of OLM in pain 
patients is conducted to highlight the current state of knowledge.  
• Chapter Three provides the general methods of the clinical trial, including sample size 
and recruitment, eligibility criteria, trial procedures, outcome measures, data collection 
and analysis.  
• Chapter Four reports the short term effects of EA on OLM consumption, pain and 
related variables. The data are analysed using both per-protocol analysis and intention-
to-treat analysis. 
• Chapter Five presents the long term effects of EA on OLM consumption, pain and 
related variables.   
• Chapter Six, the final chapter, examines the findings in relation to previous studies, 
discusses the limitation of the current study and proposes recommendations for future 
research.   
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2.CHAPTER TWO: LITERATURE REVIEW 
2.1  Part One - Chronic pain and opioid use 
2.1.1  Impact of chronic pain  
Numerous prevalence studies of chronic pain indicate the condition is becoming a significant 
public health burden internationally. Australian epidemiological studies have shown that 
approximately 20% of adults report chronic pain (Blyth et al., 2001). Comparable prevalence 
rates have been documented in the US and Denmark (Eriksen et al., 2003; National Research 
Council, 2001) and greater than half (50.4%) of a community sample in the United Kingdom 
(UK) (Elliott, Smith, Penny, Smith, & Chambers, 1999) reported suffering due to chronic 
pain. Moreover, 19% of adult Europeans surveyed in 15 European countries and Israel 
reportedly suffer moderate to severe chronic pain that negatively impacts on their QoL 
(Breivik et al., 2006). 
Chronic pain has significant health care, social and economic implications worldwide 
(Bonica, 1990b). Chronic pain is one of the most common reasons that people consult medical 
practitioners. A recent survey indicated that 78% of chronic pain patients had visited a 
healthcare practitioner for their pain in the past 6 months (Blyth et al., 2003). Patients with a 
high level of pain-related disability use health services more frequently than those with a low 
level of disability (Blyth et al., 2004). The cost of managing pain are enormous with costs 
estimated at greater than US$150 billion each year in direct medical expenditures in the US 
(National Research Council, 2001b). In Australia, annual health expenditure for 
musculoskeletal diseases alone was estimated to be AUS$879 million in 2000-2001 and 
chronic pain accounted for 19% of the total health system costs (Australian Bureau of 
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Statistics, 2001). Indirect economic costs associated with the condition include the loss of 
work productivity (i.e. days at work). A study of 302 patients in Sweden estimated that the 
annual cost of chronic pain in lost work productivity was estimated at US$16,600 per patient 
(Ekman, Jonhagen, Hunsche, & Jonsson, 2005).  
The impact of chronic pain includes both physical and psychological effects, restricting 
patient’s daily lives and causing serious social effects. When patients suffer pain for greater 
than three months, their physical problems may become more complicated, resulting in many 
changes to their lives as they must try to adapt to their difficulties. These physical effects 
include interference with daily activities, sleep disturbance, muscular deterioration, and side 
effects from excessive medications. An Australia study indicated that 11% males and 13.5 % 
of females reported some degree of interference with daily activities due to pain (Blyth et al., 
2001). Poor quality of sleep has been reported in 42% of patients with chronic pain (Becker et 
al., 1997). Patients with high levels of pain reportedly experience less total sleep time, 
increased sleep latency and more frequently woke during the night compared with patients 
reporting low intensity of pain (Morin, Gibson, & Wade, 1998). Patients with chronic pain 
may also be afraid of physical movement or may limit their movement, resulting in muscular 
deconditioning, which may lead to further pain aggravation with movement.  
The psychological impacts of chronic pain include helplessness, unhelpful beliefs, anxiety, 
and depression, and associated decline in memory and concentration. A US cross-sectional 
survey revealed that the prevalence of major depressive disorder was 52% in patients with 
chronic pain (Elliott, Renier, & Palcher, 2003). Higher estimates were reported in a Hong 
Kong survey that 71.1% of Chinese patients with chronic pain experienced concurrent 
depression (Lee et al., 2005). Depression accounted for 35% of memory complaints (Munoz 
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& Esteve, 2005) and a study of patients referred to a pain centre found that 54% reported 
problems with short term memory, concentration and attention (McCracken & Iverson, 2001). 
Chronic pain contributes significantly to deterioration in Health Related Quality of Life 
(HRQL) and sufferers have significantly poorer HRQL compared with normal healthy 
populations (Dysvik, Lindstrom, Eikeland, & Natvig, 2004; Kerr et al., 2004). Becker et al. 
(1997) studied 150 patients with chronic non-malignant pain (CNMP) and found that HRQL 
assessed with the Short Form 36 Health Survey (SF-36) were much poorer than in normative 
samples (Becker et al., 1997). Similarly, Breivik et al. examined the profiles of US 
interdisciplinary pain management centres and found all CNMP patients (242) had lower than 
normal SF-36 scores for QoL (Elliott et al., 2003).  
Chronic pain is also associated with significant disability. High levels of pain related 
disability was reported in 27% of the respondents from a Sydney community sample (Blyth et 
al., 2003). Furthermore, there was a close relationship between the levels of pain related 
disability and the use of analgesic medication and health services (Blyth et al., 2004; Blyth et 
al., 2003). Long-term use of analgesics can result in several side effects, such as 
gastrointestinal problems, constipation, fatigue and concentration difficulty.  
2.1.2  Management of chronic pain 
An increased understanding of the complexity of pain has resulted in establishment of a 
conceptual framework utilizing multidisciplinary pain management (MPM) as the main 
strategy (Bonica, 1990a). MPM programmes have been expanded widely in recent decades 
and are advocated by the Working Party on the Management of Severe Pain for the National 
Health and Medical Research Council (NHMRC) in Australia (Atkinson et al., 1988). The 
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Australian Pain Society also provides a framework for pain management programmes for 
patients with chronic pain (Australia Pain Society, 2002).  
MPM emphasizes a holistic approach to managing pain and improving patients’ QoL rather 
than attempting solely to reduce or remove pain. The approaches include patient education, 
cognitive-behavioural therapy, physiotherapy, exercises, and pharmacological treatment. The 
efficacy of MPM has been demonstrated in different clinical settings, including hospital 
inpatients and outpatients and home management programs (Becker, Sjogren, Bech, Olsen, & 
Eriksen, 2000; Chapman, 1994; Helme, Bradbeer, Katz, & Gibson, 1997).   
Numerous studies have confirmed that patients obtain benefits from MPM programmes in 
terms of reduction of pain, improvements in mood, increased activity and return to work 
(Becker et al., 2000; Helme et al., 1996; Johansson, Dahl, Jannert, Melin, & Andersson, 1998; 
Robbins et al., 2003). A recent study showed that patients with chronic pain who completed a 
MPM programme were also able to improve their coping skills and their HRQL (Dysvik et 
al., 2004). A review concluded that a higher proportion of chronic back pain patients in 
multidisciplinary clinics had greater levels of functioning than those receiving other therapies 
(Flor, Fydrich, & Turk, 1992). 
2.1.3  Measurements of chronic pain and related variables 
As a subjective experience, pain is influenced not only by pathological factors, but also by 
cultural and social factors (Munden et al., 2003). Individual pain threshold and tolerance may 
also affect one’s experience of the pain. In particular, chronic pain is a complex and 
multidimensional condition. It impacts physical, psychological and socials aspects of one’s 
life. Thus, multiple outcome domains, such as physical functioning, emotional  
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functioning, adverse effects and participant disposition are recommended in the design of 
clinical trials of the efficacy and effectiveness of treatment for chronic pain (Turk et al., 
2003). These measurements commonly include self-reports, behavioural observations, mood 
inventories, and QoL evaluation.  
2.1.3.1  Self report measures 
Self-report is one of the most common measurement methods that require patients to record 
their pain. This method identifies the patients’ subjective view of their pain and roughly 
assesses the pain experience regarding the intensity, affect, location and quality of the pain 
(Jensen & Karoly, 2001).  
The most common self-reported measure of pain include word descriptor scales, such as 
verbal and numerical rating scales (NRS), visual analogue scales (VAS) and the McGill Pain 
Questionnaire (MPQ). Each kind of self-report measurement has different strengths and is 
chosen depending on the purpose of the study. These methods assess the sensory aspects of 
pain including its intensity and quality, as well as the affective domain of pain, such as 
unpleasantness or anxiety (Jensen & Karoly, 2001). Among these methods, the VAS and 
MPQ are the most frequently used measurements in both clinical and experimental studies, 
and have been widely recognised as reliable and valid measurement tools. 
Visual Analogue Scales 
A VAS is a 10 cm long line; the beginning of line indicates “no pain” and the end of the line 
indicates “the worst pain imaginable” (Huskisson, 1983). Patients are required to draw a 
perpendicular line on the scale to show the intensity of pain experienced during a specific 
period of time. A VAS provides consistent results and is used to assess changes in pain 
severity induced by pain modulation (Price, 1994). The validation and reliability of VAS as a 
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ratio scale measure for chronic pain has been recognised (Corran, Helme, & GIbson, 1991). A 
VAS can be and should be used repeatedly when applied to pain measurement.  
One must be aware that chronic pain intensity fluctuates and changes may depend upon the 
patients’ activities. In a clinical study, patients with chronic pain were asked to rate their pain 
intensity every 2 hours and pain intensity varied over the course of a day (Jensen & Karoly, 
2001). It has been shown that current pain levels tend to influence the recall of previous pain. 
Hence, simple measures of current pain or single time point pain measures are not sufficient. 
Current pain levels may serve as anchors to influence the averaging of pain (Haythornthwaite 
& Fauerbach, 2001). It has been recommended that clinical trials on patients with chronic 
pain should document average pain, highest and lowest levels and present pain experience on 
a daily basis (Dworkin, Nagasako, Hetzel, & Farrar, 2001).  
The McGill Pain Questionnaire (MPQ) 
Developed by Melzack and colleagues, the MPQ attempts to measure the multiple dimensions 
of pain experience (Melzack, 1975). It is a frequently used pain assessment tool for both acute 
and chronic pain (Gagliese & Melzack, 1997; R. Melzack, Abbort, Zackon, Mulder, & Davis, 
1987). The questionnaire, using 78 sensory adjectives in 20 categories, consists primarily of 
three major classes of descriptors reflecting sensory (item 1-10), affective (item 11-15), and 
evaluative (item 16) aspects of pain. Some miscellaneous descriptors (item 17-20) are also 
included. In each group, there are 2-6 descriptors to describe the similar aspect of the 
experience of pain. In any one group, only one word should be chosen to best describe their 
pain. The questionnaire also contains drawings of the body on which patients can draw the 
spatial distribution of their pain, and select words describing temporal properties as well as 
the Present Pain Intensity (PPI) (Melzack & Torgerson, 1971).  
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The validity and reliability of the MPQ have been tested extensively in acute and chronic pain 
(Melzack & Perry, 1975; Reading, 1989; Reading, 1982; Wilkie, Savedra, Holzemer, Tesler, 
& Paul, 1990). The MPQ has been used to distinguish between different pain syndromes. 
Dubussion and Melzack reported that each type of pain is characterised by a distinctive set of 
descriptors (Dubussion & Melzack, 1976). 
The Gracely Box Scales  
Although the MPQ has been widely used and found to measure changes in levels of pain as a 
response to pain reduction treatments, the MPQ takes time to complete and requires good 
language skills. Gracely argued that two essential aspects of pain are sensory and affective or 
unpleasant aspects, and developed the Gracely Box Scales (GBS) to assess them (Gracely, 
1983).  
The Gracely Box Scales provides quantification by ratio-scaling procedures (Gracely, 1983; 
Gracely, McGrath, & Dubner, 1978). It has two parts; each consists of 12 verbal descriptors 
written over a 21-point scale with a minus sign at bottom and a plus sign at the top. Patients 
are asked to rate the intensity and unpleasantness of their pain by selecting a verbal 
descriptors adjacent to number, which scales from zero to 20. The verbal descriptor chosen is 
converted to the nearest number on the ratio scale, and separate score could be obtained by the 
severity and unpleasantness score (Doctor, Slater, & Atkinson, 1995). A few studies have 
demonstrated the Gracely Box scales being a valid and reliable instrument with ratio-scale 
properties (Doctor et al., 1995; Gracely et al., 1978), when tested against pain induced by 
physical stimuli in health human.  
 
15 
2.1.3.2  Behavioural measurements   
There are various definitions concerning pain behaviours. Vlaeyen et al. suggested that 
chronic pain behaviour may involve nine components. Included are anxiety, attention seeking 
complaints, verbal pain complaints, medication intake, general verbal complaints, distorted 
posture and mobility, fatigue, insomnia, and depressive mood (Vlaeyen, Van Eek, Groenman, 
& Schuerman, 1987).  
Observations of pain behaviour not only provide a detailed description of pain behaviour such 
as facial expression, postures and gross movement, but also help to understand the variables 
controlling those behaviours. The purpose of the descriptive data is to identify problems that 
may serve as targets during treatment, to establish an initial baseline measure against which 
the effects of treatment can be compared, and to assess patient’s response to treatment. Thus, 
a reliable and valid observation system of pain behaviour requires a high frequency of 
observation and simple descriptors in order to minimize the inference by the observers (Keefe 
& Willams, 2001).  
Measurements include verbal and nonverbal behaviours. Behavioural measurement indirectly 
measures the subjective experiences of pain (Melzack & Katz, 1999). However, they do 
contribute unique information to pain assessment (Hadjistavropoulos & Craig, 2002), and a 
meta-analysis indicated that self-report of pain intensity and direct observations of pain 
behaviour are significantly correlated (Labus, Keefe, & Jensen, 2003).  
Patients with chronic pain who visit pain clinics and pain management programmes have 
consistently shown a pattern of pain behaviour of excessive dependence on pain medications. 
Medication intake and frequency of patients request for medication may be an important 
measure of pain behaviour (Keefe & Willams, 2001). Jensen et al indicated that pain 
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behaviour and medication intake was correlated statistically, thus, the behavioural observation 
can provide reliable and valid information about patients suffering persistent pain (Jensen, 
Bradley, & Linton, 1989). In addition, behavioural measurements also demonstrate the 
interference persistent pain exerts on activities of daily living and social roles (Dworkin & 
Sherman, 1999). 
2.1.3.3  Beck Depression Inventory 
Depression is often experienced by chronic pain suffers and interacts with chronic pain. Thus, 
understanding change in the level of a patient’s depression may assist the investigation and 
evaluation of pain with respect to treatment effects (Moss, Lawton, & Glicksman, 1991). 
The Beck Depression Inventory (BDI) was designed to measure cognitive and somatic 
components of depression, and has become a widely used measurement tool to assess the 
severity of depression in previously diagnosed patients and to identify possible depression in 
patients with chronic pain (Beck & Steer, 1987). The inventory consists of 21 items. These 
items are described according to the severity of the symptoms and attitudes, and each item is 
rated on a 4-point scale ranging from 0 to 3 levels of severity. Patients endorse one statement 
in each item that seems to fit best with their mood during the past two weeks (Beck, Ward, 
Mendelson, Mock, & Erbaugh, 1961).  
The reliability and validity of the BDI in chronic pain patients have been well-established 
(Beck, Steer, & Garbin, 1988; de C Williams & Richardson, 1993; Flor et al., 1992). Several 
investigations on the BDI have shown its high sensitivity and specificity in identifying 
depression in patients with chronic pain (Geisser, Roth, & Robinson, 1997). The BDI may 
also distinguish depressed patients with typical cognitive biases, who require specific 
treatment for depression together with pain management ( Morley, Williams, & Black, 2002). 
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The BDI-II, revised by Beck and colleagues in 1994, is based on the first version of the BDI. 
Its purpose is to assess the symptoms corresponding to the criteria for diagnosing depressive 
disorders listed in the American Psychiatric Association’s Diagnostic and Statistical Manual 
of Mental Disorders-Fourth Edition (DSM-IV, 1994). Research has demonstrated that the 
BDI-II has adequate reliability and validity (Grothe et al., 2005; Kuhner, Burger, Keller, & 
Hautzinger, 2006; Osman, Kopper, Barrios, Gutierrez, & Bagge, 2004). 
2.1.3.4  Quality of life  
One of the commonly used QoL measurements is the SF-36 (Ware, Kosinski, Snow, & 
Candek, 2000). The SF-36 is a self-administration questionnaire, and assesses patients’ 
perception of their physical and mental aspects and general well being in eight domains, 
including physical functioning (PF), social functioning (SF), bodily pain (BP), general health 
(GH), vitality (VT), role physical (RP), role emotional (RE) and mental health (MH). 
The reliability and validity of the SF-36 is well documented (McHorney, Ware, Lu, & 
Sherbourne, 1994; Stewart, 1988; Ware, Jr., 2000; Ware, Jr. & Sherbourne, 1992; Ware et al., 
2000). It has been used in assessing chronic pain patients’ QoL and evaluating their responses 
to treatment (Solomon, 1997; Ware & Candek, 1994). There are numerous studies that 
employ SF-36 for investigating the relationships among QoL, pain severity, and analgesic 
outcomes (Bombardier & Raboud, 1991; Mauskopf, Austin, Dix, & Berzon, 1994). 
A few studies demonstrated that SF-36 scores were reduced in domains of physical, 
psychological and social well-being in patients with chronic pain (Becker et al., 1997; Kerr et 
al., 2004; Lee et al., 2005).  
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2.1.4  Pharmacotherapy  
Analgesic pharmacotherapy is the mainstay of management of chronic non-malignant pain. 
Analgesic medications consist of non-opioid and opioid analgesics. A therapeutic strategy, 
known as “ladder of analgesia”, was developed by the WHO (WHO, 1996). It is based on 
three-step analgesia and provides a useful means of determining the type of analgesics to be 
used for pain of varying severities.  
Table 1: Three step pain relief ladder, adapted from WHO’s Pain relief ladder 
 
2.1.4.1  Non-opioid analgesics 
Non-opioid analgesics are commonly used to treat either nociceptive or neuropathic pain. 
They include aspirin, non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol. In 
recent years, cyclo-oxygenase-2 (COX-2) inhibitors, such as Celebrex and Mobic, have been 
developed and are considered to be within the first step of the pain relief ladder (Basbaum et 
al., 2005). The effectiveness of these agents is mostly limited to the relief of mild pain, but 
some NSAIDs can reduce moderate pain as well as treat inflammation, in conjunction with 
opioid analgesics to achieve pain relief (Munden et al., 2003).  
1. Non-opioid  
+/- adjuvant therapy  
(Aspirin, Paractamol, Iburofen) 
3. Opioid for moderate to severe pain  
+/- non-opioid  
+/- adjuvant therapy 
(Oxycodone, Morphine, Hydromorphone, Fentanyl) 
2. Opioid for mild to moderate pain  
+/- non-opioid 
+/- adjuvant therapy 
(Codeine, Hydrocodone) 
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NSAIDs and paracetamol are commonly used in chronic pain condition, especially chronic 
inflammatory musculoskeletal pain. The mechanism of the action of NSAIDs is inhibition of 
prostaglandin formation through acting on the COX enzyme. NSAIDs have anti-
inflammatory, analgesic and antipyretic pharmacologic effects and therefore are commonly 
used for chronic pain in rheumatoid, osteoarthritis and musculoskeletal pain (Kung, Gibson & 
Helme 2000). The main side effects of NSAIDs are gastrointestinal upset. Other adverse 
effects may present with “salicylism” symptoms, and include asymptomatic hepatitis and 
dilation of peripheral blood vessels (Katzung & Furst, 1998). 
Paracetamol has antipyretic activity and minimal anti-inflammatory effects, but has no effect 
on platelets. The exact mechanism of the antinociceptive effects of paracetamol remains 
unclear. Clinically, paracetamol has become a commonly used, first-line non-opioid analgesic 
for chronic pain due to relatively less adverse effect profile and excellent tolerability (WHO, 
1996).  
The COX-2 inhibitors selectively block one of the two major isoforms of the COX enzyme, 
COX-2, and produce analgesic effects of NSAIDs without intestinal damage.  However, one 
of them, Vioxx, has been recently taken off the market due to an increased rate of 
cardiovascular complications (Basbaum et al., 2005) 
2.1.4.2  Opioid analgesics 
Opium is an addictive narcotic drug which is extracted from the unripe seed pods of the 
opium poppy. It was commonly used as an analgesic until the development of morphine. 
Opium contains many different compounds, and morphine is the principal active agent. Other 
constituents of opium include alkaloids such as codeine, papaverine and thebaine (Way, 
Howard, & Way, 1998) 
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Opioids contain derivatives of the opium plant, and other synthetic drugs that imitate natural 
narcotics. The term opioid applies to any substance which produces a morphine-like effect 
that antagonists to the µ-opioid receptor, such as naloxone or naltrexone (Portenoy, 1999). 
Based on the interactions of opioid analgesics with opioid receptors, the classification of 
opioid analgesics can be divided into pure agonists such as Morphine, Oxycodone and 
Methadone, and other mixed or partial agonist-antagonists, for example, Nalbuphine and 
Buprenorphine (Table 2).  
The pure agonists selectively bind to and activate µ receptors to produce clinical analgesia. 
The mixed opioid agonist-antagonist drugs are capable of producing agonistic effects at κ 
receptors, while at µ receptors the effects are antagonistic. The partial agonist drugs, although 
act selectively at the µ receptor but generate less intrinsic efficacy, have a 'ceiling response' 
above which an increase in dose does not produce an additional increase in effect (Portenoy, 
1999). 
Table 2: Classification of opioids based on their interactions with opioid receptors 
Endogenous 
Opioid Peptides 
Opioid 
receptors 
Natural 
opioids 
(agonists) 
Semisynthetic 
opioids 
(agonists) 
Synthetic 
opioids 
(agonists) 
Opioid 
antagonists 
Endorphins 
Enkephalin 
Dynorphin 
µ 
δ  
κ 
Morphine 
Codeine 
 
Oxycodone 
Hydrocodone 
Hydromorphone 
Oxymorphone 
Heroin 
Pethidine 
Fentany1 
Tramadol 
Methadone 
Naloxone 
Naltrexone 
 
The dose of opioid required may vary between patients, depending on the degree to which a 
patient develops tolerance to medication, pain threshold, experience with pain, and the 
condition being treated (Galbraith, 2001). Each patient must be assessed individually.  
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In the clinical setting, different opioids have been generated from three molecules, 
Oxycodone, Hydromorphone, and Oxymorphone. Each has similar analgesic activity although 
their potency and duration of effect are quite different. The strength of all analgesics can be 
expressed by comparison with the equivalent dose of morphine. Table 3 summarises the 
morphine equivalence of commonly used opioid-containing substances (Halpern, 1989; 
Margoles, 1999; Twycross, 1999). 
The central nervous system (CNS) produces analgesic peptides acting at µ and other 
receptors. The main compounds released are EOPs such as β-endorphins, enkephalins and 
dynorphins. There are three main opioid receptors: µ, δ and κ, that are widely distributed in 
the spinal cord, brainstem and peripheral tissues. The functions of various receptors are 
different, as summarised in Table 4. They may promote the opening of potassium or inhibit 
the opening of calcium channels, which is a process further mediated by G-protein, affecting 
descending modulatory pathways of pain (Portenoy, 1999). 
Table 3: Morphine dose equivalent to various opioid-like or opioid-containing substances 
(mg, p.o.) 
Morphine 30 Codeine 200 Hydrocodone 60 
Hydromorphone 7.5 Levorphanol 4 Meperidine 300 
Oxycodone 30 Oxymorphone 6 Methadone 20 
Tramadol 150 Fentany1  0.2 Pentazocine 165 
Table 4: Function of receptors in CNS 
Endogenous peptides  β-endorphins Dynorphins Enkephalins 
Receptor µ (mu) κ (kappa) δ (delta) 
Receptor location 
Dorsal horn of spinal cord 
Thalamus 
Spinal cord 
Hippocampus, 
Amygdala 
Function 
Analgesia, 
Major unwanted side 
effects, sedation, 
dependence 
Analgesia, 
Sedation, dysphoria, few 
unwanted effects, no 
dependence 
Analgesia 
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Opioid binding to presynaptic receptors in the CNS inhibits the release of neurotransmitters, 
while binding to postsynaptic receptors directly inhibits the firing of neurons in pain pathways 
and modulates the descending inhibitory pathways from the brain to prevent transmission of 
pain impulses.  
Exogenous opioid analgesia and other pharmacological effects are induced by copying the 
function of endogenous peptides in the CNS and peripheral nervous systems (PNS). Most 
exogenous opioid drugs being used in clinical practice are morphine-like pure agonists that 
selectively bind to µ receptors. It is thought that µ receptors are responsible for most of the 
analgesic effects, and for some major unwanted effects, such as respiratory depression, 
sedation and dependence (Quinn, Coupar, Keily, & Burcher, 1990). Morphine also acts on δ 
and κ receptors, which partially produce analgesia at the spinal level. Thus, even a receptor-
selective ligand can initiate actually at multiple synapses and transmitters (Way et al., 1998).  
Opioid receptor systems are complex and changeable. The expression of opioid receptor may 
vary depending on the type of noxious stimuli, disease processes or the characteristics of the 
particular analgesic used. For example, nociceptive pain may increase numbers of receptors 
while neuropathic pain may decrease numbers of receptors, Neuropathic pain may therefore 
respond less well to opioid analgesics (Rang, Dale, Ritter, & Moore, 2003). 
The role of opioid analgesics in chronic non-malignant pain relief 
While the use of morphine and other strong opioids for control of severe pain in cancer is 
fully acknowledged and endorsed, their use for CNMP has been debatable, but is gaining 
acceptability in the management of chronic osteoarthritis (Caldwell et al., 2002; Ringe, 2003), 
fibromyalgia (Grahmann et al., 2004), chronic musculoskeletal pain (Dominick et al., 2004; 
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Khor, 2003), other nociceptive pains (Jadad, Carroll, Glynn, McQuay, & Moore, 1992), and 
neuropathic pain, particularly in peripheral pain syndromes (Rossi, 2004) and low back pain 
(Bartleson, 2002). The consumption of morphine and other opioids has significantly increased 
and currently accounts for 40-90% of CNMP cases (Clausen, 1997; Richards, 1995). In the 
US, opioid prescriptions doubled for chronic pain during 1980 to 2000 (Caudill-Slosberg, 
Schwartz, & Woloshin, 2004). In Australia, the use of Schedule 8 oral opioids has increased 
from 117 to 578 kg during the period 1986-1995. In New South Wales (NSW), the authority 
prescription of opioids for non-malignant pain have increased 73% during 1990-1996 (Bell, 
1997). Moreover, the use and prevalence of narcotic analgesics are higher in patients suffering 
neurological or non-musculoskeletal conditions as the primary cause of pain (Kung et al., 
2000). 
The administration of opioid to patients with CNMP is reportedly associated with a 72.5% to 
83% improvement in their condition (Cowan, Wilson-Barnett, Griffiths, & Allan, 2003b; 
Jamison, Anderson, Peeters-Asdourian, & Ferrante, 1994). Some chronic pain patients have 
achieved considerable benefits in terms of improved pain control, functional improvement 
and improved QoL (Ballantyne & Mao, 2003; Breivik, 2005; Maier, Hildebrandt, Klinger, 
Henrich-Eberl, & Lindena, 2002). A recent systematic review demonstrated that, in the 
majority of included studies, pain intensity decreased by at least 30% with opioids (Kalso et 
al., 2003). The benefit of long-term opioid treatment of chronic non-malignant pain, however, 
only applied to a minority of patients with 44% still on opioids after therapy for between 7 
and 24 months (Kalso, Edwards, Moore, & McQuay, 2004).  
Problems associated with using opioids  
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Although strong analgesics such as morphine sufficiently relieve pain, they might produce 
various adverse effects, such as constipation, nausea, sedation and micturition disturbance 
(Gourlay, 1999). Studies showed that 58% of the patients on morphine medication 
experienced moderate to severe adverse effects (Caldwell et al., 2002; Maier et al., 2002). 
Recently, a systematic review revealed a high rate of adverse events among people using 
opioids, with 80% of patients suffering from at least one adverse event (Kalso, Edwards et al., 
2004).  
A large number of patients requiring long-term opioids use may experience problems 
resulting from physical dependence and addiction (Adriaensen, Vissers, Noorduin, & Meert, 
2003; Gourlay, 1999; Tedeschi, 2006). Opioid dependence may be associated with cognitive, 
behavioural, and physiological symptoms that cause individuals to continue opiate use despite 
significant physiological and psychological harm caused by the ingestion of the drugs. 
Dependence may lead to dose escalation. Physical dependence is defined by the development 
of withdrawal symptoms associated with a sudden decrease in opioid dose, abrupt termination 
of regular opioid use, or when an opioid antagonist is administered. It may play a considerable 
role in contributing to persistent pain and global dysfunction in some patients (Gourlay 1999). 
While tolerance and physical dependence are physical changes in the body, addiction is 
defined by aberrant changes in behaviour. It is a biopsychosocial disorder characterized by the 
compulsive use of a drugs and the preoccupation with obtaining it, despite evidence that its 
continued use results in physical, emotional, social or economic harm (Savage et al., 2003). 
However, if there is no history of addiction in the past, addiction to opioid used to treat non-
malignant pain is rare. 
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An increase in abuse of opioids is a growing problem in public health (Gilson, Ryan, 
Joranson, & Dahl, 2004). In Denmark opioid abuse is a major problem with 40% of those 
suffering CNMP considered “problematic opioid users”. Meanwhile, 3-19% of chronic pain 
patients are estimated to suffer from addictive disorders (Eriksen et al., 2003).  
Problems of addiction create dilemmas in the prescription of opioids. A survey of physician’s 
attitudes toward using opioids for chronic pain revealed that 35% of physicians are never 
willing to prescribe schedule II opioids (eg, sustained-release morphine) for patients with 
CNMP (Potter et al., 2001, Feb.). Data from another survey highlight similar results in 
Canada, with 35% of GPs and 23% of primary care practitioners reporting they would not 
prescribe opioids for non-malignant pain patients even when pain was considered severe 
(Morley-Forster, Moulin, Clark, & Speechley, 2003). Concerns about physical dependence, 
tolerance, and addiction to opioids by patients and physicians are major barriers against their 
use.  
Strategies of employing opioids should be used in order to appropriately manage CNMP 
(Kalso, McQuay, & Wiesenfeld-Hallin, 1999). Prescription of opioids for patients with 
chronic pain should be the last solution when other pharmacotherapy fails to produce benefit 
to the patients. Importantly, the balance between providing pain relief drugs and its potential 
adverse effects should be considered.  
2.1.4.3  Adjuvant analgesics 
Adjuvant analgesics are also used to treat chronic pain. These analgesics include 
antidepressants and anticonvulsants. They may be used alone or in combination with opioids.  
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Antidepressants include two main types of medication: Tricyclic antidepressants (TCAs) and 
serotonin-selective reuptake inhibitors (SSRI’s). TCAs are highly effective in neuropathic 
pain, such as peripheral neuropathy, which often responds poorly to opioids (Bryson & Wilde, 
1996; Sindrup & Jensen, 1999). The mechanism of the action for TCAs remains unclear. They 
may act centrally by inhibiting noradrenalin reuptake at nerve endings and in the spinal cord, 
and through being a potent blocker of voltage-gated Na channels (Song, Ham, & Shin, 2000). 
The common drugs include clomipramine, imipramine and amitriptyline. Amitriptyline is one 
of the most effective antidepressants in pain conditions (Bryson & Wilde, 1996). The SSRI’s 
include sertraline, fluoxetine and fluvoxamine. These drugs have not demonstrated efficacy in 
treating persistent pain. 
Antidepressants are also effective in lifting mood, improving the sleep quality and QoL and 
reducing chronic fibromyalgia pain (Arnold, Lu, & Crofford, 2004; O'Malley, Balden, & 
Tomkins, 2000). Moreover, Tomkins et al reported that these medications have beneficial 
effects in preventing chronic migraine and tension headache (Tomkins, Jackson, O'Malley, 
Balden, & Santoro, 2001). Antidepressant medications may cause some adverse effects, such 
as dry mouth, constipation, blurred vision and drowsiness, and may even affect concentration 
and judgment. Sexual dysfunction is another adverse effect caused by most antidepressants 
(Kalso, 2005). The dosages used to manage chronic pain are usually lower than that used to 
manage depression (McQuay, Carroll, & Glynn, 1992).  
Anticonvulsant medications were initially used to manage epilepsy. Now it has been found 
that some types of chronic neuropathic pain, especially the pain manifested as lancinating or 
stabbing pain, respond beneficially to anticonvulsants. Blocking of the Na+ channel is one of 
the mechanisms of anticonvulsant action (Kalso, 2005). Anticonvulsant drugs include 
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carbamazepine, gabapentin, pregabalin and clonazepam, which likely act on the spinal cord 
and brain to block messages caused by nerve injury or neuropathic pain. They can also 
improve mood. Carbamazepine is one of the effective anticonvulsants used to treat chronic 
pain (Johnson, 1997). The common side effects of these agents are mental and motor 
dysfunction, such as sedation. Clinically, a lower dosage is recommended for pain control 
than that used for seizure control. 
Other pharmacologic management includes local anaesthetic agents, for instance, sympathetic 
nerve blocks, nerve blocks and neurolysis, which are employed for neuropathic pain. A 
systematic review demonstrated the efficacy of intravenous lidocaine in chronic pain (Kalso, 
Tramer, McQuay, & Moore, 1998).  
2.1.5  Non-pharmacological treatment approaches  
There are a wide range of non-pharmacological treatment approaches used for managing 
chronic pain. These therapies may not only reduce the pain, but also offer some other benefits, 
such as reducing depression, improving mood, changing negative thoughts, restoring 
functionality and promoting well-being. Many of these approaches can be used alone or 
combined with analgesics. The combination approach may improve pain relief by enhancing 
the effects of medications, thus lowing required dosages of the medications.  
Non-pharmacological strategies include three major categories: physical therapies, cognitive 
behavioural therapies, and alternative and complementary therapies.  
2.1.5.1  Physical therapies 
Physical therapies (PTs) are a common part of pain management programmes. These 
therapies aim to reverse the effects of deconditioning, which contribute to and can confound 
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other chronic pain factors. In deconditioning syndrome, the “fear-avoidance” model plays an 
instrumental role. Pain-related fear of movement, tissue damage, or re-injury can lead to 
avoidance of movement or can increase the distress associated with specific movements. 
Deconditioning, disuse atrophy, and lower levels of fitness therefore can perpetuate in a 
cyclical fashion (Vlaeyen, De Jong, Onghena, Kerckhoffs-Hanssen, & Kole-Snijders, 2002; 
Vlaeyen & Linton, 2000).  
PTs aim to reverse the effects of deconditioning by increasing activity, improving functional 
status, and reducing the pain causing the disability associated with pain. Then patients can 
decrease their medication intake, self manage pain and return to work (Harding & Watson, 
2000).  
PTs include exercise, transcutaneous electrical nerve stimulation (TENS), and relaxation. An 
appropriate exercise program specifically aims to build muscle strength, increase range of 
motion, improve balance, and raise pain tolerance. Exercise also makes people feel better and 
helps relieve some of the side effects seen with medications, for example, constipation. More 
recently, a summary of systematic review has shown that exercise is effective for patients 
with a wide range of chronic disorders, for example knee osteoarthritis and low back pain 
(Smidt, de Vet, Bouter, & Dekker, 2005). 
TENS is a popular analgesic option. Its mechanism is unclear; but is probably best explained 
by the gate control theory, which activates large nerve fibres, inhibits local pain circuits and 
closes the gate to the entering pain message (Munden et al., 2003). It is believed to be an 
effective and safe therapy which can provide pain relief in some conditions, such as back 
pain, arthritis, neuropathic pain, surgical pain, migraine and headache (Hansson & Lundeberg, 
1999). The effectiveness of TENS in chronic pain lacks evidence (McQuay, Moore, 
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Eccleston, Morley, & Williams, 1997) A recent systematic review also demonstrates that it is 
difficult to provide useful evidence-based information with TENS for treating chronic pain 
(Carroll et al., 2005).  
In addition, training patients to use relaxation techniques may assist to control the pain by 
reducing muscle tension, and develop a state of emotional calmness (Harding & Watson, 
2000). Nevertheless, scientific evidence for the effectiveness of relaxation is lacking 
(McQuay et al., 1997).  
2.1.5.2  Cognitive behavioural therapies 
Cognitive-behavioural therapy (CBT) consists of education, skills acquisition, cognitive and 
behavioural rehearsal, and generalisation and maintenance. The goals of this intervention are 
to teach patients to effectively manage their problems and provide them with strategies to 
monitor the suffering component of pain and to reduce the impact of chronic pain on lifestyle 
(Bradley 1996). CBT has been proved useful in a variety of patients with chronic problems, 
for instance, low back pain, fibromyalgia and upper limb problems (Flor et al., 1992; Nielson, 
Harth, & Bell, 1997; Spence, 1989; Williams, 2003). 
CBT interventions for the treatment of chronic pain focus on reductions in pain perception 
and pain behaviours. They also aim to reduce or cease the use of pain related medications and 
the inappropriate use of health care services, improve physical function, change unhelpful 
thinking and return to aspects of life previously restricted by their responses to pain (Nicholas, 
2003). General treatment objectives of CBT pain management programs also include 
empowering patients to become resourceful and able to problem solve their circumstances 
(Bradley 1996), assisting patients to learn self-monitoring and to identify relationships 
between cognitions, behaviours and environmental change.  
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There are numerous controlled studies evaluating CBT programs that have shown benefits in 
different age populations suffering from chronic pain (Cook, Cinciripini, & Floreen, 1998; 
Johansson et al., 1998). The patients obtained significant benefits in terms of reductions in 
analgesic medication use, changes in pain behaviour and improvements in physical 
functioning and employment status (Johansson et al., 1998; Skinner et al., 1990; Williams et 
al., 1993). A meta-analysis of 25 randomized controlled trails showed that CBT is very 
effective in achieving a range of improvements, such as, pain experience, mood/affect, 
cognitive coping and appraisal, and activity level (Stephen Morley, Eccleston, & Williams, 
1999). Several studies have also demonstrated the efficacy of pain management programmes 
in improving patients’ QoL and well-being (Dysvik, Vinsnes, & Eikeland, 2004; LeFort, 
Gray-Donald, Rowat, & Jeans, 1998; Patrick, Altmaier, & Found, 2004).  
Selections of patients to undergo a CBT program varies depending on the pain management 
service provided but have in common the following criteria: daily life is seriously affected 
due to pain, habitual overactivity leading to increased pain, using excessive medication, 
reducing or withdrawal from work due to pain, and related mood disturbance. Also, the 
patients must be motivated with a desire to achieve a degree of independence, and a desire to 
gain control of their lives; and they must not have any major personality or psychiatric 
disorder. 
Given the fact that patients who are referred to pain clinics are already likely to be using 
opioid-like drugs, reducing the dose of opioid-like drugs to an acceptable and satisfactory 
level is a useful first strategy in the pain management for patients entering into a CBT 
programme.  
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2.1.5.3  Complementary and alternative therapy  
Patients are becoming more willing to accept complementary and alternative therapy (CAT) 
in order to appropriately manage pain and health problems that do not respond to 
conventional treatments (Lewith & Machin, 1983; Snyder & Wieland, 2003; White, Resch, & 
Ernst, 1997). These therapies might have relatively less adverse effects in comparison with 
western medicines, and predominantly focus on balancing the whole body rather than 
symptomatic control. A recent survey indicated that 35% patients with chronic pain sought 
the use of alternative therapy which is higher than previously estimated (Haetzman, Elliott, 
Smith, Hannaford, & Chambers, 2003). In Australia, 21% of patients with chronic pain 
consulted an alternative practitioner for pain relief in the previous 6 months (Blyth et al., 
2003). Higher rates of alternative medicine usage have been observed in Canada, with 39% of 
adults reporting use for chronic back pain (Foltz et al., 2005).  
Amongst the most commonly used CAT, acupuncture is increasingly chosen by patients and 
physicians (Aanjesen et al., 2002). In Australia, most GPs accept acupuncture as a common 
medical practice and about 66%-90% of GPs who participated in two surveys referred their 
patients to acupuncture treatment at least once in the last one year (Easthope et al., 2000). 
Another earlier survey of 249 GPs shows that acupuncture is the second most commonly used 
CAT for chronic pain in Auckland after chiropractic therapy (Marshall et al., 1990), and a UK 
survey reported that 84% of responders used acupuncture as a treatment method for chronic 
pain in their pain clinic (Woollam & Jackson, 1998). Survey data from the US reveals that 
69% of responders who are pain specialists use or refer their patients to acupuncturists.  
Systematic reviews on acupuncture in pain treatment have demonstrated moderate to strong 
evidence of effectiveness, for dental pain (Ernst & Pittler, 1998), osteoarthritis (OA) pain 
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(Ezzo, 2001) and neck pain (White & Ernst, 1999). The Consensus Development Panel on 
Acupuncture of the NIH in the United State concluded that acupuncture is effective for 
various painful conditions, such as post-operative pain, dental pain, tennis elbow and 
fibromyalgia (NIH, 1998). A report to the NHMRC in 1989 also pointed out the potential role 
for acupuncture in Australian health practice. Acupuncture was considered to be useful and 
safe in producing analgesia for post-operative pain, obstetric pain and dental extraction pain 
(NHMRC, 1989). WHO commissioned a report in which 293 acupuncture controlled clinical 
trials were reviewed. Eighty-nine of them were related to pain. Acupuncture was 
recommended to treat headache, painful condition of the locomotor system, postoperative 
pain, and pain associated with dentistry and surgery (WHO, 2002). 
The role of acupuncture in managing chronic pain, however, remains unclear. The results of 
one review paper and two systematic literature reviews on clinical trials show that the effect 
of acupuncture on chronic pain is inconclusive (Ezzo et al., 2000; Mendelson, 1977; ter Riet 
et al., 1990). Compared to sham, intramuscular, or placebo acupuncture, acupuncture 
produces improved analgesia. However, it is only occasionally more effective than non-
treatment. The three review papers attribute the inconclusive results to poor research methods 
and small sample sizes employed in included trials.  
Other forms of alternative and complementary approaches include relaxation therapy, 
biofeedback and chiropractic treatment. The main benefits that chiropractic treatment 
provides are to relieve musculoskeletal pain and disability, and adjust internal organ function. 
The theory of chiropractic treatment is to restore the free flow of neural impulses, and relieve 
symptoms by adjusting the spine with regular manipulation. Chiropractic treatment is 
commonly used for specific conditions, for example, headache, neck, shoulder, back pain and 
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spinal problems with visceral conditions (Jamison, 1995; Paramore, 1997). A systematic 
review has shown that chiropractic manipulation is not effective for other non-spinal pain 
conditions, such as fibromyalgia, dysmenorrhoea and chronic pelvic pain (Ernst, 2003).  
2.2  Part Two - Neural mechanisms of electro-acupuncture analgesia  
EA, developed in 1970s, has been widely studied for its pain relieving effects (Clement-Jones 
et al., 1980; Han, 1989; Tsui & Leung, 2002b). EA employs pulses of weak electrical current, 
which are delivered through acupuncture needles to acupoints in and under the skin. EA has 
been incorporated into studies mainly due to its convenience and ability to deliver stable and 
consistent stimulation. However, an increasing number of studies have demonstrated that EA 
may be a more effective means of pain relief than manual acupuncture (Saletu et al., 1975; 
Tsui & Leung, 2002a; Ulett, Han, & Han, 1998; White, 1999). 
The current understanding of the neural mechanisms of EAA is largely based on neural 
mechanisms of endogenous pain control and EOPs (Han & Terenius, 1982). The following 
section will address the mechanisms of EAA in three steps. Firstly, the findings from decades 
of research into neural mechanisms are outlined; secondly, studies on EOPs and EA are 
summarised; and thirdly, the optimal parameters of EA are discussed.  
2.2.1  Neural mechanisms of electro-acupuncture analgesia  
Three popular neurophysiologic theories have been proposed to explain EA analgesic 
mechanisms of action: gate control theory or segmental inhibition (Bekkering & Bussel, 1998; 
Melzack, 1984), diffuse noxious inhibitory controls (DNIC) (Le Bars, Dickenson, & Besson, 
1979) and limbic systems attenuation (Campbell, 1999). A fourth theory, the involvement of 
EOPs, has also been identified (Han & Terenius, 1982).  
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2.2.1.1  The gate control theory and segmental inhibition  
The gate control theory states that pain signal conduction along the spinal cord may open or 
close depending on the nature of the incoming signal (Melzack, 1965). Activation of large 
myelinated afferent fibres (A-β) in the skin or muscles inhibits incoming pain signals 
transmitted by small afferent (C) fibres. As a result, pain signals are intercepted before they 
travel along the ascending pain pathway and register as pain in the brain. It has been 
hypothesised that EA impulses of high frequency may activate large myelinated afferent 
fibres (A-β) and prevent pain transmission similarly to TENS (Melzack, 1984). Currently no 
research has confirmed the association between EAA and A-β afferent fibre involvement.  
Developed from gate control theory, segmental inhibition of acupuncture or EA (Bekkering & 
Bussel, 1998) implies that the interception of pain signals not only reduces pain at the spinal 
segment level, but can also alter subsequent actions taken by humans or animals following 
painful stimulation. For instance, the withdrawal reflex, local muscle contraction, and local 
ischemia, can be suppressed or ceased through acupuncture. 
These observed actions of acupuncture are related to the segmental arrangement of the spinal 
neurons, where information from the skin, muscles, tendons, bones and viscera at the same 
segment converges on transmission interneurons. Inhibition of these neurons leads to a change 
of the action taken in response to pain, within the same nerve segment, dermatome, myotome, 
sclerotome or viscerotome. 
EAA can only be partly explained by gate control theory. According to the theory, only 
concurrent stimulation of A-β fibres and C fibres can intercept painful information from C 
fibres, and this effect is only brief (lasting a few minutes) (Melzack & Wall, 1996a). This may 
explain why EA appears to have an immediate effect on the local stimulation area, but fails to 
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explain why EA often produces analgesia in remote parts of the body, and pain relief which 
may last up to a few days. 
2.2.1.2  Diffuse noxious inhibitory control  
Experiments in rats have demonstrated that noxious inputs from one part of the body can 
inhibit the activity of dorsal horn neurons that lay distant from the stimulated segment. 
Because such effects are not somatotopically organised, but do concern the whole body, they 
have been called DNIC. DNIC is the underlying mechanism of the counter-irritation 
phenomenon, which means that pain in one part of the body inhibits pain responses in another 
part of the body (Le Bars & Dickenson, 1979). DNIC has been demonstrated in healthy 
humans by submerging the left hand in the hot water at 47°C which is above pain level. This 
reduced the participants subjective pain rating and withdrawal reflexes induced by electrical 
stimulation (ES) to the right ankle (Willer, Roby, & Le Bars, 1984). Interestingly, water 
temperature appeared to be inversely correlated with subjective degree of pain response and 
suppression of withdrawal reflexes, in response to electrical stimulation. 
Analgesia from DNIC is often short-lasting for a few minutes, widely spread in the body, and 
is induced by very strong pain stimulation. DNIC may explain why EA produces wide spread 
analgesia (Zaslawski, Cobbin, Lidums, & Petocz, 2003) and improvement in pain reduction 
with stronger EA stimulation (Wang et al., 1997). However, it does not explain prolonged 
analgesic effects in response to EA.  
2.2.1.3  Limbic system attenuation  
Another proposed analgesic mechanism for AA is the modulation of the hypothalamic-limbic 
system. The limbic system theory may be derived from the feelings of calm and relaxation 
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often experienced by patients and healthy humans volunteers during and following 
acupuncture treatment (Campbell, 1999).  
Functional magnetic resonance imaging (fMRI) studies have indicated acupuncture regulates 
the limbic system. Using fMRI, investigators observed needling LI4 (Hegu) and ST36 
(Zusanli) with Deqi sensation effectively deactivated the limbic system, and no such effects 
were attained with shallow needling of non acupoints (Wu, Hsieh, & Xiong, 1999). Similar 
results have been demonstrated in other fMRI studies in animals (Chiu & Chung, 2003) and 
healthy human subjects (Hui et al., 2000; Wu et al., 2002). A recent study supports the 
hypothesis that the limbic system is central to acupuncture effect regardless of specific 
acupuncture modality (Napadow et al., 2005).  
Chronic pain patients appear to have a highly active limbic system that might be related to  
greater levels of depression and anxiety experienced by these patients (Apkarian, Thomas, 
Krauss, & Szeverenyi, 2001). The deactivation effect of acupuncture on the limbic system 
could contribute to the feeling of enhanced wellbeing in chronic pain patients who have 
received acupuncture (Paterson & Britten, 2003).  
2.2.2  Endogenous opioid peptides and electro-acupuncture analgesia   
Studies have demonstrated that both manual acupuncture (Mayer, Price, & Rafii, 1977a) and 
EA (Cheng & Pomeranz, 1979) mediated-analgesia is modulated through a central 
mechanism involving the release of EOPs (Han & Terenius, 1982). The present review will 
briefly discuss acupuncture analgesia (AA) and EOPs from the following aspects: naloxone 
blockade of AA; the common brain regions involved in morphine analgesia and AA; and 
release of various EOPs by EA of different frequencies. 
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2.2.2.1  Naloxone blockade of acupuncture analgesia 
The initial evidence suggesting the involvement of EOPs in AA was that naloxone, an opioid 
receptor antagonist, blocked AA in mice and humans (Mayer, Price, & Rafii, 1977b; 
Pomeranz & Chiu, 1976). Pomeranz and Chiu performed an experimental study in mice 
divided into one of the following groups: EA alone, EA plus saline, EA plus naloxone, sham 
EA at a non-acupoint, naloxone alone, saline alone, and no treatment at all. EA was applied at 
(an anatomically equivalent point to) LI4 (Hegu). Latency to mouse squeak onset induced by 
radiant heat was measured as pain threshold. Naloxone, but not saline, was observed to 
completely block AA. Naloxone alone did not cause analgesia but induced hyperalgesia 
instead. The results indicated that EAA was likely to be mediated by endorphins in mice and 
not due to psychological effects (Pomeranz & Chiu, 1976).  
Similar results have been noted in a human experiment. Mayer et al. (1977) studied AA on 
acute laboratory-induced tooth pain in healthy human volunteers. Needling stimulation of LI4 
(Hegu) increased the pain threshold measured by ES of dental pulp by an average 27%. The 
subjects were then injected either naloxone or saline. The results showed that pain threshold 
was reversed by naloxone injection, but not by saline injection (Mayer et al., 1977b). In 
contrast, a double blind study conducted by Chapman et al., subjects demonstrating AA 
during low frequency EA on LI4 received either 1.2 mg naloxone or saline injection. Pain 
thresholds elevated by EA failed to reverse following administration of naloxone (Chapman, 
Benedetti, Colpitts, & Gerlach, 1983).  
Further studies revealed that naloxone (1 mg/kg) could block analgesia induced by EA at 4 Hz 
but not by 200 Hz. Cheng and Pomeranz suggested that analgesia induced by low frequency 
EA is associated with endorphins, whereas analgesia induced by high frequency EA may 
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occur through non-opioid mechanisms (Cheng & Pomeranz, 1979). In contrast, Han et al. 
found that analgesia induced with 100 Hz EA was naloxone reversible only with a much 
higher dosage than that used to block EA induced analgesia at 2 Hz (Han, Ding, & Fan, 
1986). These results suggest that the effect of high-frequency EA might also be mediated by 
EOPs, which is unlikely to be affiliated to mu receptors (Huang, Wang, Han, & Wan, 2002).  
2.2.2.2  Similar brain regions involved in morphine and acupuncture analgesia  
Previous findings suggest that EA and morphine analgesia share the same or similar 
mechanisms (Han 1981). Zhou et al. demonstrated that the effect of AA was significantly 
attenuated when naloxone was microinjected into the nucleus accumbens, amygdala, habenula 
and periaqueductal grey matter (PAG) of the rabbit but little anti-analgesia effect following 
injection into other brain regions. Administration of morphine to the same four regions also 
produced significant analgesia (Zhou, Du, Wu, Jiang, & Han, 1981) suggesting that brain 
regions involved in morphine analgesia are also involved in AA. Damage of these sites 
reduced both morphine and AA. 
EA release EOPs to produce an analgesic effect. However, repeated application of EA 
stimulation at short intervals can cause tolerance and dependence similar to observations for 
morphine (Ren & Han, 1979). This phenomenon has been demonstrated in other studies. A 
parallel experiment was performed in rats which received either EA or morphine. Rats were 
given EA at 2-15 Hz for 30 mins at repeated 30 minute intervals. A gradual decline in 
analgesia was observed. After the sixth EA stimulation, the analgesic effect of EA was only 
24% of the original value, whereas, the effect of morphine analgesia was 39% of the original 
value. The results demonstrated that similar mechanisms underlie acupuncture and morphine 
tolerance (Han, Li, & Tang, 1981). 
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It has been considered that subjects responding poorly to EA may genetically lack opioid 
receptors (Peets & Pomeranz, 1978). The incidence of non-responders in rats accounts for 
approximately 15%-20% of the experimental animals. Takeshige et al. observed that 40% of 
rats were poor responders to AA due to a deficiency in total brain endorphins measured by a 
receptor binding assay (Takeshige, Kamada, Oka, & Hisamitsu, 1978). It has been suggested 
that endogenous opioids can be released by both EA and morphine. The decreased ability to 
release opioids and an increased capability of releasing endogenous antagonists to opioids 
might be the mechanisms underlying the non-responsiveness to EA and morphine (Han, 
1989). 
2.2.2.3  Release of opioid peptides in the central nervous system induced by electro-
acupuncture of different frequencies  
Antibody microinjection and radioimmunoassay of spinal perfusate techniques were used to 
study the types of opioid peptides associated with EAA. The neuropeptides recognised by the 
antibody injected are selectively inactivated, whereas other peptides are intact and act on the 
receptors (Han, 1984). Using this technique, a series of studies were performed. Collectively 
it appears the effect of AA is blocked by enkephalin antibodies at both the spinal cord and 
PAG; by β-endorphin antibodies at the PAG; dynorphin antibodies following injection into 
subarachnoid space, and not in the PAG (Han, 1989).  
Furthermore, using the same technique, other studies explored whether analgesia induced by 2 
and 100 Hz are mediated differentially in the spinal cord by enkephalin and dynorphin, 
respectively. Rats administered intrathecal injection of enkephalin antiserum resulted in a 
significant decrease in analgesia induced with 2 Hz stimulation. Rats similarly administered 
dynorphin antiserum produced an equally remarkable decrease in analgesia induced with 128 
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Hz EA but did not abolish analgesia induced by EA at 4 Hz (Han, 1993). Furthermore, 
injection of β-endorphin antiserum into rat PAG resulted in significantly decreased analgesia 
induced with 2 Hz EA when compared with 15 Hz, and the  injection failed to block the 
analgesic effect of 100 Hz EA (He & Han, 1990). Injection of endomorphins antiserum into 
the cerebral ventricle of mice (Huang, Wang, Chang, & Han, 2000) and the spine of rats 
(Zhou Han et al., 1999) dose-dependently reduced the analgesic effect produced by 2 Hz, but 
not 100 Hz. Taken together, the type of EOPs release depends on the frequency of EA. It 
seems that EA at 100 Hz stimulates the release of dynorphin in the spine, whereas EA at 2 Hz 
and 15 Hz stimulates the release of β-endorphin and dynorphin.  
Studies utilising radioimmunoassay further confirmed the EA frequency-dependent EOPs 
release. It was found that 2 Hz EA significantly increased the release of the immunoreactive-
Met5-enkephalin whereas 100 Hz EA increased the release of dynorphins (Fei, Xie, & Han, 
1987). 
Frequency-dependent opioid release initially observed in animal models has also been 
confirmed in humans. Transcutaneous acupuncture electrical stimulation (TAES) was given to 
37 patients at LI4 and ST36 with either 2 or 100 Hz for 30 minute. Met-enkephalin-Arg-Phe 
(MEAP) in the cerebrospinal fluid (CSF) was significantly increased upon 2 Hz EA, and 
dynorphin A (Dyn A) was increased at 100 Hz EA (Han et al., 1991; Ho & Wen, 1989), also 
showed that following EA at a frequency of 2-3 Hz, no significant change of dynorphin 
immunoreactivity in the CSF was detected compared with before EA (Ho & Wen, 1989).  
Rats made tolerant to 2/15 Hz were still reactive to a frequency of 100 Hz, and vice versa. 
This phenomenon further proves that EA at different frequencies produces analgesia via 
different pathways. EAA at 2 Hz is mediated by µ/δ-receptors, 100 Hz-EAA by κ-receptor, 
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and 2/100 Hz-EAA by combined action on all of three receptors in the CNS (Chen et al., 
1992; Han, 2003). All three kinds of EOPs, β-endorphin, met-enkephalin, and dynorphin 
could be fully released to maximise the analgesic effect when using alternate 2/100 Hz (Chen, 
Guo, Chang, & Han, 1994; Chen & Han, 1992; Han et al., 1999). Table 5 summarises the EA 
frequency, the types of EOPs and opioid receptors.  
Table 5: Summary of EOPs upon EA 
Types of EOPs EA frequency Types of opioid receptors 
Enkephalin 2 Hz µ,δ; can be blocked by naloxone 
Dynorphins 100 Hz κ; relatively resistant to naloxone 
β-Endorphin 2 and 15 Hz µ,δ, κ; can be blocked by naloxone 
 
A recent study demonstrated that peripheral release of opioids also plays a role in AA. Using 
a rat model of unilateral inflammatory hyperalgesia, pain behavioural changes were measured 
by paw withdrawal latency (PWL) to a noxious thermal stimulation. The results showed that 
rats receiving EA produced a significantly longer PWL, lasting up to three hours following 
EA treatment, compared with the non-EA controls. The analgesic effect was blocked totally 
by naloxone administrated at the inflammatory site 30 mins following EA treatment. The 
results suggested that EA might have induced peripheral EOPs release and activates 
peripheral opioid receptors (Zhang, Yu, Lee, & Lao, 2005). 
2.2.3  Optimal parameters of electro-acupuncture for analgesia  
In general, the parameters of EA include frequency, intensity, size of electrodes, pulse 
duration and depth of stimulation. So far, there is no common understanding of optimal 
parameters for the best possible analgesia. In a recent review, Zheng concluded that the ideal 
parameter of EA may vary according to the condition of the patient. Alternating frequency 
with strong but tolerable intensity of stimulation is recommended.  EA with needles applied at 
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traditional acupoints may offer extra analgesic (Zheng, 2001). This section summarises recent 
evidence from animal studies and aims to gain further understanding of the ideal parameters 
of EA. 
As discussed previously, the frequency of EA seems to play an important role in the releases 
of EOPs. On the basis of experimental data, to obtain the maximal release of central opioid 
peptides, an alternate frequency between 2/15 or 2/100 Hz may be the ideal to produce EAA 
and minimise tolerance (Han, 2003). Evidence from clinical trials currently is not consistent 
with this conclusion and details will be discussed in the Part three of this chapter.  
Intensity of ES is another factor determining the effectiveness of EA. In one experiment, 
anaesthetised rats were given EA on the hind limbs at intensity of 1, 10 and 20 times the 
threshold of muscle contraction. The radian heat-induced latency of the tail withdrawal reflex 
was measured as pain threshold. EA at 20 times threshold increased the latency by 74% for 
more than 75 minutes after the treatment; EA at 10 times threshold increased the latency by 
50% for 10 minutes, whereas EA at the threshold intensity had no effect. The results 
suggested that the powerful and persistent antinociceptive effect was elicited by high-intensity  
(Romita, Suk, & Henry, 1997). Furthermore, a recent study of EA on persistent hyperalgesia 
and Fos protein expression in rats supported the above finding. It was found that most anti-
hyperalgesia was induced by ES at 3 mA when compared to EA 1 mA and 2 mA (Lao et al., 
2004).  
The depth of stimulation comprises another important factor. One study investigated the 
effects of EA on pain threshold in various tissues in healthy humans. The EA consisted of 
both insulated and non-insulated acupuncture needles. Non-insulated needles induced a 
significantly increased pain threshold in the skin, fascia and muscles, whereas insulated 
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needle induced analgesia only in the muscles and periosteum. The results indicated that 
insulated needles could produce an analgesic effect at a deeper level compared with 
uninsulated needles. It therefore suggests that the depth of  stimulation might play an 
important role in the depth of analgesic effects (Ishimaru, Kawakita, & Sakita, 1995).  
The effect of the duration of the pulse has yet to be clearly evaluated and there remains no 
agreement on an appropriate EA pulse width for AA. A range of pulse widths have been used, 
varying from 0.1 to 5 ms (Huang et al., 2000; Cheng Huang et al., 2002; Ishimaru et al., 1995; 
Koo, Park, Lim, Chung, & Chung, 2002; Romita et al., 1997). One previous study showed 
that with a pulse duration of 0.2 ms at 10 times threshold, a brief analgesic response was 
produced but the persistent response was markedly attenuated; whereas ES with a pulse width 
of 5 ms or 2 ms produced persistent responses (Romita et al., 1997). A more recent study 
showed within a given period of time and at a frequency of 10 Hz EA, short term anti-
hyperalgesia was induced with 2 ms /10 Hz EA stimulation, which was similar to that induced 
with 0.1 ms/ 100 Hz. It appears that effects produced by increased pulse width is the same as 
by increased frequency, as the amount of stimulation to acupoint was increased by either 
pulse width or frequency within a given time unit (Lao et al., 2004).  
The ideal duration of EA stimulation has been suggested to be 30 minutes, which is the 
induction period necessary for the full development of AA in humans (Research Group of 
Acupuncture Anesthesia, 1973).  
Taken together, it is clear that optimal parameters of EA for pain control are ES with an 
alternate frequency at 2/100 Hz with high intensity. The depth of stimulation is likely to be 
associated with the depth of analgesia produced. Results from clinical acupuncture research 
will be useful for understanding ES parameters and their effects on pain.  
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2.3  Part Three - A critical review of randomised controlled trials of 
electro-acupuncture on consumption of opioid like medication in pain 
patients  
2.3.1  Aims 
The aims of this review were to investigate whether EA can reduce the consumption of OLM, 
OLM related-side effects, and pain in pain patients, and to identify the ideal electrical 
parameters of EA for this function. 
2.3.2  Methodology 
2.3.2.1  Search strategies 
RCTs for EA in pain conditions were searched through commonly used health databases 
including Pubmed, the Cochrane Library and EMBASE (all from their inception to February 
2005). A combination of the following keywords was used for the search: electro-
acupuncture, electroacupuncture, TENS, transcutaneous acupuncture electrical stimulation 
(TAES), electrical stimulation (ES), opioids, analgesia, morphine, acute pain and chronic 
pain. The search was limited to clinical trials and English language papers. No time limit was 
placed on the search.  
2.3.2.2  Selection criteria 
Inclusion criteria 
To be included, a study had to fulfil the following criteria: 
• English language; 
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• randomised controlled clinical trials;  
• study population was patients with acute or chronic pain ; 
• the study intervention had ES via acupuncture needle or surface electrodes on 
classified acupoints;  
• parameters of ES were reported; and  
• outcome measures included the dosage of OLM, or the reduction of OLM 
consumption;  
Exclusion criteria 
• TENS used on non-acupoints, or 
• Trials in which participants were morphine addicts  
2.3.2.3  Methods of the review 
Data extraction 
Each eligible study was reviewed and the following information extracted: author, publication 
year, condition, sample size, intervention, parameters of EA, duration of treatment, acupoints 
used, acupoints stimulated with EA, methods of sham EA, control intervention, pain intensity 
or reduction, OLM consumption and related side effects. Where reduction of pain or OLM 
consumption was measured in different time periods in included studies data was obtained 
from total recovery period.  
Quality assessment 
The quality of reports/methodological quality of included trials was assessed using the Jadad 
scale (Jadad et al., 1996; Melchart et al., 2001). The scale includes items on: 
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• random allocation (1 point if allocation was described as randomised + 1 point if an 
appropriate method to generate the random sequence was described) 
• double-blinding (1 point if there was a statement that patients and evaluators were 
blinded + 1 point when the blinding method was described and appropriate) 
• reporting of withdrawals / dropouts (1 point if dropouts and withdrawals, as well as 
the reasons, were listed independently for each treatment group) 
The total score was obtained by adding the scores for each item together. The maximum score 
is 5. Studies scoring 3 or more points were considered high quality.  
Outcome assessment 
For assessing effectiveness of EA on the consumption of OLM, related side effects and pain, 
the results were classified the following three categories:  
• positive when the consumption of OLM, related side effects, and pain in the real 
acupuncture treatment group were significantly less than that of the control group;  
• neutral when there were no significant difference between the groups;  
• negative when these variables in the REA group were significantly higher than the 
control group. A P-value less than 0.05 was considered as significant. 
The level of evidence (LOE) of single RCTs was assessed by using the Oxford Level of 
Evidence grading. When the Jadad score of a clinical trial was equal or more than three, it was 
considered as high quality, and 1b was assigned. If the score was less than three points, then 
the LOE was assigned 2b (Centre for Evidence-based Medicine, 2001).  
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Evidence evaluation 
A best evidence synthesis method was used to evaluate the overall effectiveness of EA on 
reducing the consumption of OLM, related side effects and pain intensity. There are four 
levels of evidence (van Tulder, Cherkin, Berman, Lao, & Koes, 1999): 
• strong evidence - multiple, relevant, high-quality RCT with generally consistent 
results 
• moderated evidence - one relevant, high-quality RCT and one or more relevant, low 
quality RCT with generally consistent results  
• limited evidence - multiple relevant on low quality RCT with generally consistent 
results 
• Inconclusive evidence - only one relevant, low-quality RCT, no relevant RCT or RCT 
with conflicting findings 
2.3.3  Results 
2.3.3.1   Literature search results and study population 
In total, 25 studies were identified from 1966 - 2005. Key data from the remaining 11 studies 
are summarised in (Table 6). All of them examined EA in the management of various acute 
pain and sub-acute pain syndromes, including pain during surgery, such as oocyte aspiration, 
lower abdominal surgery, hysterectomy, hemorrhoidectomy, colonoscopy, gynaecologic 
surgery and postoperative pain. No studies examining EA on the consumption of OLM in 
patients with chronic pain were identified. 
Fourteen studies were excluded from this review. Detailed reasons for exclusion are listed in 
Table 7. Of these, four studies did report the use of analgesics but did not report the type of 
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analgesic or no OLM consumption was measured, or no ES was delivered. These studies were 
excluded. 10 studies on chronic pain were also excluded because they did not measure OLM 
consumption. 
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Table 6: Summary of Included Studies 
Study Condition 
Sample size, 
Intervention 
Parameters 
of EA 
described 
 
Acupoints 
used 
 
 
Acupoints 
stimulated 
with EA and 
Duration of 
stimulation 
Methods of 
Sham EA 
Gejervall, et 
al. 2005  
During oocyte 
aspiration  
N=160; 
EA + PCB 
vs. 
CA + PCB 
Square-wave 
pulses with 
alternating 
polarity. 2 
and 80 Hz, 
Intensity was 
high enough 
to induce 
strong  
paraesthesia 
or muscles 
contraction  
KI11, 
ST29, 
LI10, LI 4, 
ST36, 
GV20 
LI4, LI10, 
ST29 and 
KI11; 
30-45 min 
before oocyte 
aspiration 
N/A 
Humaidan 
et al., 2004 
During oocyte 
retrieval 
N= 200; 
EA+ PCB vs. 
CA+PCB 
20 Hz at a 
continuos 
pules 
duration of 
0.5 ms. 
Intensity was 
high under 
pain 
threshold. 
LI4 (bil), 
SP6 (bil), 
GV20, 2 
points in 
the low 
abdomen  
LI4 (bil); a 
few minutes 
prior to OPU  
N/A 
Stener-
Victorin, et 
al., 2003 
 
During oocyte 
aspiration 
N=268; 
EA+ PCB vs.  
Alfentanil 
nil +PCB  
continuous 
square-wave 
pules of 
alternating 
polarity with 
a 2 and 80 
Hz; intensity 
was strong to 
induce 
paraesthesia 
or muscles 
contractions 
GV20, 
ST29 (bil), 
TE5 and 
LI4 (bil), 
ST36 (bil) 
80 Hz at 
ST29, 2 Hz 
at TE5 and 
LI4; 30 min 
before OPU 
N/A 
Lin, et al., 
2002 
 
After Lower 
abdominal surgery 
N=100; 
No EA 
control vs.  
sham-EA vs. 
LF-EA vs. 
HF-EA 
2 Hz or 100 
Hz at 
constant 
current of 
0.5 mA, 1ms 
square pulse 
tolerable 
intensity  
ST36 ST36; 20 
min pre-
operation  
Needle 
insertion 
with the 
indicator 
light on but 
with no 
actual 
current 
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Sim et al., 
2002 
 
Post Gynecologic 
lower abdominal 
surgery 
N=90; 
Control group 
(placebo EA 
for 45 min 
before 
induction of 
GA)  vs. 
preoperative 
EA vs.  
postoperative 
EA  
2 Hz, 100 Hz ST36 (bil),  
PC6 (bil) 
2 Hz at ST36 
and PC6, 100 
Hz at the 
skin incision; 
45 minutes 
of EA before 
induction of 
GA; 45 
minutes of 
EA on arrival 
to the 
recovery area  
The needle 
was taped to 
the skin 
with non-
transparent 
adhesive 
tape. ES 
were 
attached to 
the needles, 
the indictor 
light on the 
mock unit 
blinked but 
no electrical 
current was 
applied. 
Chen, et al., 
1998 
 
Abdominal 
hysterectomy or 
myomectomy 
procedures  
N=100; 
Sham-TENS 
vs.  
Nonacupoint-
TENS at the 
shoulder vs.  
TENS at the 
level of the 
surgical 
incision vs. 
acupoint-
TENS  
DD model, 
alternating 2 
and 100 Hz 
every 3s, 
Intensity was 
tolerable. 
 
ST36 ST36, started 
in the PACU 
and 
continued 
using 30 min 
every 2 h 
until pain 
was 
controlled 
with oral 
analgesic 
medication.  
no electrical 
current 
Wang, et al., 
1997 
 
 
Undergo elective 
lower abdominal 
surgery  
N=101 
PCA vs.  
Sham TASE  
vs. 
Low intensity 
TASE vs.  
High 
intensity 
TASE 
DD mode, 
alternating 2 
and 100Hz 
every 3s, 
Intensity was 
low at 4-5 
mA and high 
at 9-12 mA 
depending 
on the 
treatment 
group 
 
L14 Two at the LI 
4 and the 
opposite of 
the ST 36; 
the other two 
were at either 
side of the 
side surgical 
incision; 
started in the 
PACU and 
continued 30 
min every 2 
h until pain 
was 
controlled 
with oral 
analgesic 
medication.  
No 
electrical 
current, but 
the indicator 
lights was 
on 
Christensen 
et al.,  1993 
 
Before and during 
Hysterectomy 
surgery  
N=50 
PCA + EA 
vs.  
PCA 
Constant 
current, 
pulse width 
320 ms, 
12V, chain 
freq.10 and 
100 Hz 
GV2, 
GV4, 
BL32 
(bil), SP6 
(bil),  
ST36 
GV2, GV4, 
BL32 (bil), 
SP6 (bil), 
ST36; 20 
min before 
incision and 
throughout 
the operation 
N/A 
 
51 
Christensen, 
et al., 1989 
 
Postoperative pain 
(Lower abdominal 
surgery) 
N=20 
PCA + EA 
vs.  
PCA  
Constant 
current, 
pulse width 
320 µs, 12V, 
chain freq.10 
and 100 Hz   
GV2, 
GV4, 
BL32(bil),  
SP6 (bil) 
SP6 (bil), 
from 
completion 
of surgery  N/A 
Kho, Eijk, 
Kapteijns, 
& van 
Egmond, 
1991 
 
During surgery for 
retroperitoneal 
lymph node 
dissection 
N=29  
CATA vs. 
MFA  
10 Hz ,40 
mA,  0.5% 
pulse width 
and 40 
volts.WQ-6F 
(10Hz up to 
20 mA, and 
a 0.7msec 
pulse width) 
BL14, 
BL17, 
BL19 and 
BL23  
BL14 and 
BL23, 15 
min 
N/A 
Chiu et al., 
1999 
 
Undergoing 
hemorrhoidectomy 
N=60 
TENS + PCA 
at the 
acupoints vs.  
TENS + PCA 
at non 
acupoints 
Alternating 2 
and 100 Hz, 
300µ sec 
pulse, 20-30 
mA, The 
intensity was 
adjusted 
until 
rhythmic 
flexion of 
thumb and 
index finger  
LI4, LU7  LI4, LU7  
30 min ES , 
two times per 
day 
Nonpoint at 
ulnar border 
of the 
hypothenar 
muscle 
Note: EA, electro-acupuncture; CA, conventional analgesia; DD: Dense-and-Disperse; ES: electrical 
stimulation; PCB, paracervical block; HF, high frequency; LF, Low frequency; bil, bilateral; OPU, ovum 
pick-up; GA, general anaesthesia; CATA, combined acupuncture and stimulation analgesia; MFA, 
moderate-dose fentany1; TENS, transcutaneous electrical nerve stimulation; PCA, patient-controlled 
analgesia; freq., frequency; GA, general analgesia; PACU, postanesthetic care unit 
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Table 7: Summary of Excluded Studies 
Study Condition 
Sample size, 
Intervention 
Measures Results 
Reasons for 
exclusion 
Fanti, et al. 
,2003 
 
Colonoscopy N=30; 
EA vs. sham 
vs.  
no acup. 
Demand for 
sedative drugs, 
pain, 
discomfort, 
anxiety 
Pain level and dose of 
additional midazolam 
boluses requirement 
were sig. lower in the 
EA group. 
Consumption 
of OLM was 
not measured. 
Meng, et al.,  
2003 
 
CLBP N= 55; 
EA+ 
medication  
vs. 
medication 
alone 
Roland score EA had a sig. decrease 
in modified Roland 
score at week 6; No 
group difference in 
medications changes. 
Medications 
were NSAIDs, 
non-narcotic 
analgesics, and 
muscle 
relaxants 
Zhu, et al., 
2002 
 
CNP N=29; 
EA. vs. sham 
EA  
Pain, analgesic 
medication 
count  
No group difference in 
reducing pain intensity 
and pain pill count. 
Types of 
analgesic was 
not reported 
Ekblom, et 
al., 1991 
 
operative 
removal of 
impacted 
mandibular 
third molars 
N=110; 
Preoperative-
acup. vs post 
operative-
acup. Vs.  
No 
acup.control  
Intraoperative,  
postoperative 
pain intensity 
and 
consumption of 
analgesics 
Intraoperative pain 
intensity higher in the 
preoperative acup. than 
the no acup. control 
and experienced higher 
pain intensity 
immediately 
postoperatively 
compared with 
postoperative-acup. and 
non acup. control. 
Consumption of 
analgesics was higher 
in preoperative acup. 
compared with the non 
acup. control.  
No ES was 
applied 
Tsukayama, 
et al., 2002 
Low back 
pain 
 
N=20; 
EA vs TENS  
Pain relief scale, 
LBP score 
Reduction in pain relief 
was greater in EA than 
TENS. 
OLM was not 
measured. 
Carlsson and 
Sjolund 2001 
 
CLBP N=55; 
Acup. vs. EA 
vs. mock-EA 
Pain intensity, 
analgesic intake, 
quality of sleep 
and activity 
level 
There was a sig. 
improvement of quality 
of sleep, reduction of 
analgesics intake in EA 
from a mean of 29.6 to 
11 tables/person/wk, 
32.3 to 31.8 in placebo 
group.  
Types of 
analgesic was 
not reported 
Stener-
Victorin, et 
al., 1999 
 
During oocyte 
aspiration  
N=150; 
EA+ PCB vs.  
Alfentanil 
+PCB 
Pain, 
anaesthesia, 
discomfort  
No significant group 
difference in terms of 
pain related to 
operation, adequacy of 
anaesthesia during 
operation and nausea. 
The EA group 
experienced sig. longer 
discomfort than 
alfentanil group during 
oocyte aspriation  
Types of 
analgesic was 
not reported 
 
53 
Wang, et al., 
1997 
 
Colonoscopy N=99; 
EA vs. CMA 
Pain tolerance 
score, side 
effects 
Analgesic efficacy of 
both groups were the 
same but with less side 
effects such as nausea, 
vomiting and dizziness 
in the EA group 
Consumption 
of OLM was 
not measured. 
Thomas and 
Lundberg 
1994 
 
CLBP N=40; 
Acup. vs. LF-
EA vs. HF 
EA 
Activities of 
daily life, pain 
Long term 
improvement in LF & 
HF than controlled 
group, both after 
treatment and follow 
up 
Consumption 
of OLM was 
not measured. 
Deluze, et al., 
1992 
 
Fibromyalgia N=70; 
EA vs. sham 
EA 
Pain threshold , 
number of 
analgesic tablets 
used, regional 
pain score , 
VAS   
7/8 outcome measures 
improved in EA group 
whereas none were in 
sham group. Pain 
threshold improved by 
70% in the EA group.  
Number of analgesic 
tables was reduced in 
the EA group than 
Sham EA. 
Types of 
analgesic was 
not reported 
Eriksson, 
Lundeberg et 
al., 1991 
 
OA N=32; 
EA; EA in 
patients 
pretreated 
with naloxone 
affective and 
sensory of pain 
EA significantly reduce 
of pain on the affective 
than sensory; Pain 
reduction was not 
significant after 
pretreatment with 
naloxone or diazepam.  
No control 
group, 
experiments 
Lundeberg et 
al., 1991 
 
OA N=58; 
LF-EA vs. 
HF-EA vs. 
Acup. vs. 
sham Acup.  
Pain intensity 
and 
unpleasantness 
All groups produced 
significant pain 
reduction on the 
affective than sensory. 
OLM was not 
measured. 
Ng, Leung & 
Poon, 2003 
OA N=24 ; 
LF EA vs. LF 
TENS vs. no 
treatment 
control  
Pain and TUGT There was sig. 
reduction of knee pain 
in both EA and TENS 
grops; TUGT score of 
EA group was sig. 
lower that that of the 
control group.  
OLM was not 
measured. 
Allais, et al., 
2002 
 
Migraine N=160; 
Acup. vs. CT  
Pain, analgesic 
intake 
The number of 
analgesic intake was 
sig. in acup. group than 
CT group during the 
treatment. 
No ES was 
applied; Types 
of analgesic 
was not 
reported 
Note: Acup., Acupuncture; EA, electro-acupuncture; sig., significantly; LBP, lower back pain; NSAIDs, 
non-steroidal anti-inflammatory drugs; CLBP, chronic lower back pain; OA, osteoarthritis; CNP, chronic 
neck pain; CMA, conventional meperidine analgesic; HF, high frequency; LF, Low frequency; sig., 
significant; TENS, transcutaneous electrical nerve stimulation ; TUGT, Timed Up-and-Go Test score; CT, 
conventional therapy; ES, electrical stimulation. 
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2.3.3.2  Study interventions 
EA was applied in nine studies while TENS was used in two (Chen et al., 1998; Chiu et al., 
1999). EA was given as a combination method with conversational analgesia in six studies 
(Christensen, Noreng, Andersen, & Nielsen, 1989; Christensen et al., 1993; Gejervall et al., 
2005; Humaidan et al., 2004; Kho, Eijk, Kapteijns, & van Egmond, 1991; Stener-Victorin et 
al., 2003). Another five studies used sham /placebo acupuncture-controlled (Chen et al., 1998; 
Chiu et al., 1999; Lin et al., 2002; Sim et al., 2002; Wang et al., 1997). These sham/control 
groups used non-functional EA devices with no electrical current or non-insertion of needles 
or at non-acupoints. 
2.3.3.3  EA Parameters  
Apart from EA intensity, which was adjusted below pain threshold to induce non-painful local 
muscle contraction, other EA parameters including frequency, duration, shape and width of 
pulses, acupoints stimulated, and the use of needles or surface electrodes varied widely.   
Different frequencies of EA were employed, including fixed frequency at 2 & 80 Hz, 10&100 
Hz, 20 Hz and 10 Hz respectively; or alternating frequencies between 2 & 100 Hz; or 2 & 100 
Hz at the same time on different points and 2 Hz or 100 Hz in different groups (Table 6).  
Duration of EA stimulation was another key parameter. The total duration of EA stimulation 
varied from a few minutes prior to surgical operation, 20-45 minutes before surgery, or 
stimulation throughout the whole operation (Humaidan et al., 2004; Lin et al., 2002; Sim et 
al., 2002); to 45 minutes after surgery (Sim et al., 2002).  
There are three patterns observed in the selection of acupoints. In most cases, either LI4 or 
ST36 or both were used. In addition, some studies also applied stimulation at the local 
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incision area (Chen et al., 1998; Sim et al., 2002; Wang, Chang, Liu, & Ho, 1997). Some 
others selected classic acupoints based on meridian theory. For example, SP6 was used in two 
occasions (Christensen et al., 1989; Christensen et al., 1993) for lower abdominal surgery; and 
GV 20 or PC6 was selected to calm the patients (Gejervall et al., 2005; Humaidan et al., 2004; 
Sim et al., 2002; Stener-Victorin et al., 2003) (Table 6).  
2.3.3.4  Outcome  
The reported outcome measures were consistent in included studies. OLM consumption, 
related side effects and pain intensity were reported. Of these, nine studies reported that the 
postoperative OLM requirements in the EA group was significantly less than that of the 
control group, while two studies yielded no significant difference in OLM consumption 
between the EA and control group after operation (Christensen et al., 1993; Sim et al., 2002) 
(Table 8).  
Four of 11 studies reported that the EA treatment could significantly reduce OLM related side 
effects, such as nausea, vomiting, dizziness and pruritus compared with the placebo/control 
groups; four reported no significant different and three did not report data (Table 8). 
Similarly, only three of 11 studies showed significant reduction in postoperative pain with EA 
compare with placebo/controls; five reported no significant difference, two reported more 
pain in the EA group compared with controls and another study did not measure pain outcome 
(Table 8).  
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Table 8: Results of Outcome Measures 
Study 
Consumption of OLM 
(EA vs. sham /control) / 
percentage of reduction 
 
Related side effects 
(EA vs. sham /control) 
Pain 
Gejervall, et al. 2005 + ; NA Nausea: neutral At recovery: - 
Humaidan et al., 2004 +; NA Did not measure - 
Stener-Victorin, et al., 
2003 
 
+; NA Nausea : + + 
Lin, et al., 2002 
 
Sig. reduced by 61, 43, 
21% in the high-, low- and 
sham-EA, respectively. 
Nausea and vomiting in 
the Low- and High EA 
groups: + 
neutral 
Sim et al., 2002 
 
The 24h total: neutral 
Nausea, vomiting, 
drowsiness and pruitis: 
neutral 
neutral 
Chen, et al., 1998 
 
Acupoint group compared 
with sham group: 39%; 
compared with non-
acupoint group: 38% 
Nausea and dizziness: + + 
Wang, et al., 1997 
 
 
Decreased 65, 34 and 23% 
with high-TAES, low- 
TAES, and sham TAES 
respectively. 
Nausea, vomiting, 
dizziness and pruritis in 
the high-TAES: + 
neutral 
Christensen et al., 1993 neutral Did not measure neutral 
Christensen, et al., 1989 
 
During the total recovery 
period: +; NA 
Nausea and drowsiness: 
neutral 
neutral 
Kho, Eijk, Kapteijns, & 
van Egmond, 1991 
 
+ : NA 
Nausea and vomiting: 
neutral 
Did not measure 
Chiu et al., 1999 
 
+; NA Did not measure + 
Note: + indicates outcome variable in the EA group was significantly less than that of the sham/control 
group; - indicates outcome variable in the EA group was significantly higher than that of the sham/control 
group; TAES: transcutaneous acupoint electrical stimulation; NA, percentage of OLM reduction was not 
available  
 
2.3.3.5  Methodological quality and direction of outcomes 
Of the 11 RCTs, six studies were of high quality and five studies were of low quality (Table 
9). The six high quality studies reported positive results in reduction of OLM consumption. 
Thus, significant correlation was found between methodological quality and direction of 
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positive trial outcomes. However, no significant correlation was found between side effects 
and pain. Four of the five low-quality studies also reported positive results in reduction of 
OLM consumption, two reported positive results in OLM related side effects and one reported 
positive results in pain. 
Table 9: Assessment of Methodological Quality: Jadad Scale of Included Studies 
 
Jadad Scale 
Study 
Described as 
Randomised 
Randomised 
method 
appropriate 
Double- 
blinding 
 
Method of 
blinding 
appropriate 
Withdrawals 
/dropouts 
 
Sum 
score 
Gejervall, et al., 
2005 
1 1 0 0 1 3 
Humaidan et al., 
2004 
1 1 0 0 1 3 
Stener-Victorin, et 
al., 2003 
1 1 0 0 1 3 
Lin, et al., 2002 1 1 0 0 1 3 
Sim et al., 2002 1 1 0 0 0 2 
Chen, et al., 1998 1 0 0 0 0 1 
Wang, et al., 1997 1 1 0 0 0 2 
Christensen et al., 
1993 
1 0 0 0 0 1 
Christensen, et al., 
1989 
1 1 1 1 0 4 
Kho, Eijk, 
Kapteijns, & van 
Egmond, 1991 
1 0 0 0 1 2 
Chiu et al., 1999 1 1 0 0 1 3 
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2.3.3.6  Levels of evidence 
The studies fell into two categories: comparing EA with or without conventional therapy (CT) 
either with no EA (CT only), or with sham EA. Four of six studies comparing combination 
therapy with CT alone were rated high quality and two were low quality (Table 9). The results 
of reduction of OLM requirements during surgery were conflicting. OLM reduction was 
considered positive in five studies and neutral in one study (Christensen et al., 1993). Thus, 
there is stronger evidence that EA is as effective as or more effective than CT in reducing 
OLM requirements during surgery.  
Among them, one study reported positive result for nausea, two were neutral and two had  
inadequate data. For pain intensity, one yielded positive result, three neutral and one had 
inadequate data. Therefore, the evidence is inconclusive that EA is more effective than CT in 
reducing OLM related side effects and pain.  
Two of five studies comparing EA with SEA were rated as high-quality (Chiu et al., 1999; 
Lin et al., 2002) and three were low-quality (Chen et al., 1998; Sim et al., 2002; Wang et al., 
1997). Their results in reduction of postoperative OLM consumption were consistent with all 
reporting positive results. There is therefore stronger evidence that REA is more effective 
than sham/placebo EA in reducing postoperative OLM consumption.   
Three of these studies reported positive results for side effects, such as nausea and vomiting, 
one was neutral and one had inadequate data. Similarly, in pain intensity, two reported 
positive results and another two had inadequate data. Thus, there is inconclusive evidence that 
REA is more effective than sham/placebo EA in reducing OLM related side effects and 
postoperative pain than sham/placebo EA.   
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2.3.4  Discussion 
2.3.4.1  Methodological quality  
Methodological quality is an essential factor in interpreting the validity of outcomes. In 
general, most studies reported an appropriate method of randomisation. It is notable, however, 
that only one study in this review achieved two points for blinding, the rest of studies either 
did not apply an adequate double blinded approach or could not blind the patients because 
SEA was not used (Table 9).  
Randomised placebo controlled double-blind trials are the most appropriate approach to 
evaluate efficacy of drug or therapy as double-blinding can minimise bias associated with 
patient, investigators, or assessor expectation of treatment outcome (Goldstein, 1962). It is 
almost impossible to successfully apply double blinding to clinical acupuncture research 
because blinding of the investigator (acupuncturist) delivering the treatment is too difficult. 
Alternative double-blinding methods need to be further developed. Furthermore, only six of 
11 studies adequately reported drop out/withdrawal in their studies.  
2.3.4.2   Effectiveness of EA  
Overall, the existing evidence strongly supports that EA with or without CT is more effective 
than either sham EA/TENS plus CT or CT alone in reducing the OLM consumption during or 
after operations. This review shows inconclusive evidence that EA is more effective in 
reducing incidence of opioid-related side effects and pain compare with SEA or CT. None of 
the included studies undertook research on opioid consumption in chronic pain patients. No 
evidence can be obtained regarding the effect of EA on reducing OLM consumption in 
patients with chronic pain. 
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Our findings are different from that of Lee and Ernst. which concluded that AA during 
surgery was inconclusive (Lee & Ernst, 2005). The difference may be attributed to the aim of 
the reviews. The aim of Lee and Ernst’s paper was to assess the effectiveness of acupuncture 
as an adjunctive method to standard anaesthetic procedures during surgery, while the current 
review was to investigate whether EA can reduce the consumption of OLM, related-side 
effects and pain in patients during and after operations. Thus, the included papers were 
different from Lee and Ernst. Our assessment of two papers common to both reviews was 
consistent with that of Lee and Ernst (Sim et al., 2002; Stener-Victorin et al., 2003). However, 
we assessed pain intensity in the Sim et al. (2002), but Lee and Ernst did not. Pain directly 
after oocyte aspiration was not significantly different in the Stener-Victorin et al paper (2003). 
However, reduction in pain outcomes 2 hours after oocyte aspiration was significantly less in 
the EA group compared to alfentanil group. The rest of the 17 papers in Lee and Ernst’s 
review were not included in the current review due to the use of manual acupuncture only or 
the dosage of OLM was not reported.  
We searched a number of different sources to identify all relevant studies. Only 11 RCTs 
were eligible for evaluation. The limitation was that our search did not yield studies published 
in language other than English. The exclusion of Chinese publications where acupuncture is 
widely accepted is noted. Since the majority of Chinese literature has not been covered by 
most of the English databases, some eligible studies in China might have been omitted. 
However, the evidence has to be interpreted with caution since publication bias is 
acknowledged and it has been shown that published reports from China are almost exclusively 
positive (Vickers 1998).  
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2.3.4.3  Design of a control intervention  
Inclusion of a relevant control group excludes confounding factors such as the practitioners’ 
expectation, patients’ beliefs and attitudes, the natural history of the condition, psychological 
effects of needling and the therapeutic relationship. Sham/placebo controls are designed to 
address these factors. Although an adequate control (eg. sham acupuncture) is necessary it is 
also important to assess the success of blinding. Control interventions in the present review 
are generally categorised into two major types: no EA control and placebo EA/TENS. 
Blinding patients is impossible when comparing EA with no EA group. Thus, sham design is 
essential.  
Sham EA design in clinical trials has not been standardised. The investigators have designed 
various placebo techniques that possess both advantages and disadvantages. The sham 
procedures used in the current review were inserting needles at non-acupoints, or tapping a 
plastic needle tube on the bone near the acupoints first, then taping needles to the skin without 
skin penetration, or using a stimulator with a light on but without electrical current (Table 6). 
The method of inserting needles at non-acupoints has been reported as effective in terms of 
producing positive results in several studies (Chen et al., 1998; Chiu et al., 1999). It is a 
reasonably credible method as participants are unlikely to know true acupoints and the 
outcome influenced by the participants’ needling experience may be reduced to a minimal 
level. This technique, however, may still produce some physiologic impacts as any form of 
needling seems to generate an analgesic effect through counterirritation and possibly 
endorphin release (Vickers, 1996a). Therefore, the depth of insertion may be an important 
factor for the analgesic effects.  
Sham points should be selected away from the acupoints and from the meridians. There are 
two methods being employed to determine the location of sham points. One method is 
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locating the point 1-2 cm away from real acupoints (Vincent & Richardson, 1986). Another 
was proposed by Zaslawski and colleagues that the sham acupoints should be located far 
away from any known meridians or known extra-points. In the second method, they tested the 
sites of sham points on the limbs that were four body units below the knee or elbow 
(Zaslawski et al., 1997), and the depth of needling insertions was enough to keep the needle 
upright without inadequate sensation in order to maintain the blind status of a naïve subject. 
The results demonstrated that this method appeared to offer a credible sham acupuncture 
control (Zaslawski et al., 1997).  
Sham EA/TENS involves the use of a non-functional EA stimulator or TENS machine with 
the indicator lights on only. This control strategy is known as mock TENS, and has been 
adopted by a number of studies (Chen et al., 1998; Lin et al., 2002; Sim et al., 2002; Wang et 
al., 1997). The mock TENS without needling produces little to zero physiological effect. The 
disadvantage of this method seems to be less credible because the participants may distinguish 
this stimulation from real acupuncture where needle insertion is applied (Vickers, 1996b). 
Sham acupuncture includes invasive and non-invasive approaches. The latter could be 
delivered with placebo needles developed by Park and colleagues (Park et al., 2002). A 
review however showed that there was no difference between the two types of sham 
procedures (Dincer & Linde, 2003). The placebo acupuncture reported in the current review is 
tapping a plastic needle tube on the bone near acupoints to produce discernible sensation then 
taping needles to the skin without skin penetration (Sim et al., 2002). It appears consistent 
with actual needle insertion as the patients may feel slight sensation with little physiological 
action. However, the disadvantage of this procedure was easily visualised by the participants 
when the selected acupoints are in the upper limb. Thus, this method may remain a problem in 
maintaining blinding of participants.  
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Overall, an ideal acupuncture placebo should minimize psychological and physiological 
impacts on the research outcomes. The most appropriate sham control would be inserting 
needles at non acupoints without Deqi sensation, with a depth of insertion enough to ensure 
needles remained standing and with mock electrical stimulation.  
2.3.4.4  EA Parameters  
This review shows no agreement on the ideal parameters of EA stimulation for OLM 
reduction. The commonly used frequencies were 2, 10 and 100 Hz, and the results did not 
seem to be affected by frequency used. Only one study comparing different frequencies of EA 
showed that stimulation of 100 Hz produced a greater OLM reduction than that of 2 Hz (Lin 
et al., 2002). Comparing the efficacy of the different EA intensity, Wang et al. showed that 
EA at a high intensity produced a higher reduction of postoperative OLM requirement and 
side effects (nausea, vomiting, dizziness and pruritus) than low intensity EA (Wang et al., 
1997). The duration of ES also influenced the analgesia effect. The ideal duration has not 
been identified, but most of studies applied EA prior to surgery for operative condition and 
EA after surgery for postoperative condition.  
2.3.4.5  The selection of electrical stimulation acupoints  
The current review indicates that ES applied at the acupoints was more effective than that at 
non-acupoints sites in reducing OLM consumption, related side effects and pain (L. Chen et 
al., 1998; Chiu et al., 1999). The majority of these studies selected ST36 and LI4 for EA. This 
approach is consistent with studies in healthy humans subjects in which stimulation of ST36 
or LI4 increased pain threshold (Han et al., 1991; Research Group of Acupuncture 
Anesthesia, 1973). Other acupoints stimulated with EA were SP6, PC6, LI10, ST29, KI11, 
GV2, GV4, BL32, BL23 and LU7. Some of them were selected for their calming effects, 
while others were based on meridian theory.  
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2.3.5  Conclusion 
There is strong evidence that EA reduces the opioid consumption during or after surgery, and 
is more effective than either no EA (CT alone) or SEA treatment. There is inconclusive 
evidence that EA reduces side effects, like nausea and dizziness, from OLM, and 
postoperative pain, and is more effective than SEA treatment. The effects of EA require the 
stimulation frequency at fixed 2, 10 or 100 Hz or alternating between 2 and 100 Hz with high 
intensity.   
Future studies needed to examine whether the EA can reduce OLM consumption in patient 
with chronic pain, and whether the EA is more effective in reducing OLM side effects and 
pain than SEA.  
2.4  Part Four - Research aims  
The aims of the present study were to assess the effectiveness of real electro-acupuncture 
(REA) in comparison with sham electro-acupuncture (SEA) on: 
• reducing opioid consumption in patients with chronic pain;  
• reducing opioid related side effects in patients with chronic pain; 
• chronic pain related variables including depression and quality of life.  
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3.CHAPTER THREE: METHOD 
3.1  Trial design  
The trial is a prospective, randomised, double-blind (patient/assessor), sham controlled 
clinical trial. This project was conducted with approval from the Human Research Ethics 
Committees (HREC) of RMIT University (Project No. 27/03) and St. Vincent’s Hospital 
(SVH) (Project No. 132/03 CTN), Melbourne. A Clinical Trial Notification (CTN; 031/2004) 
was approved by the Therapeutic Goods Administration (TGA). 
3.2  Participants 
Patients who had suffered non-malignant pain for over three months and subsequently 
required administration of OLM were eligible to participate in the trial. All participants were 
volunteers recruited from the Barbara Walker Centre for Pain Management (BWCPM) at 
SVH Melbourne or SVH website, or responding to newsletters circulated through Centre 
Melbourne, Eastern and Northern Divisions of General Practices.  
3.3  Selection Criteria  
The eligibility of study participants was determined by respecified inclusion and exclusion 
criteria, as listed below. 
3.3.1  Inclusion Criteria  
Patients aged 18 years or greater, suffering from non-malignant pain longer than three 
months, and who were using opioid-like pain medications for pain control, were eligible for 
the study. In addition, prospective participants were required to have sound English reading, 
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comprehension and written skills, and be able and willing to participate in the study for the 
eight week duration of the study. 
3.3.2  Exclusion Criteria 
The following patients were excluded from the study if they had: 
• Pacemaker  
• Severe arrhythmia or heart failure 
• Epilepsy  
• Pregnancy 
• Severe depression diagnosed with BDI-II > 29 
• Previous experience with EA in the last six months  
• Previous experience or exposure to cognitive-behavioural therapy (CBT) programmes. 
The first three exclusion criteria were required as EA may disrupt the pacemaker function, as 
well as trigger epilepsy or arrhythmia. There is limited evidence suggesting acupuncture is 
dangerous to pregnant women, however, pregnancy was excluded due to the frequency of 
spontaneous miscarriage in the first trimester and evidence of acupuncture use to induce 
labour in China (BMAS, 2000). Patients with severe depression were excluded due to the 
requirement for comprehensive concomitant management by a psychologist or psychiatrist. 
Patients with previous EA experience were excluded to ensure participants remained blinded 
to treatment allocation. No previous experience or exposure to CBT was required as the 
purpose of this study was to help patients reduce their medication with EA before taking part 
in the CBT programme.  
Participants were informed that they were free to withdraw from the study at any time. 
Written informed consent was obtained prior to study enrolment. An assessment of 
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participants’ competence to give consent was assessed by the BWCPM. The recruitment 
process allowed patients adequate time to consider the detailed patient information and 
consent to participate in the trial by completing an Expression of Interest (EI). The EI was 
then returned to the investigator by the patient in a pre-paid envelope. Participants were given 
further opportunity to further discuss the project and ask for more information preceding their 
participation.  
3.4  Procedure for recruitment  
Recruitment took place over an 18 month period and was carried out in one of the following 
five ways: 
• Patients who were yet to have a Multidisciplinary Assessment  
Patients referred to BWCPM, usually by their GPs, were placed on a waiting list for around 
18 months before receiving a multidisciplinary assessment (MDA). There were approximately 
200 patients in this group at recruitment. As patients had not yet been assessed by a pain 
specialist doctor and provided information about the study, patients were mailed a pamphlet 
(Appendix 1) and a letter of invitation (Appendix 2) informing them that an EA study was 
being conducted in the Centre. The HREC at SVH approved the pamphlet. Patients who 
phoned voluntarily to enquire about the study and who expressed an interest in participating 
were entered into a database. The EI (Appendix 3) and screening Questionnaires (Appendix 
4) were then sent to each of the potential participants (PP). 
• Patients who were discharged from the Centre 
A total of 800 patients were discharged from the Centre. A research assistant and investigator 
had approval to access patient files and identified PP according to the inclusion and exclusion 
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criteria. A letter of invitation was then sent to potential participants identified. Participants 
who replied by phone to express an interest in the study were entered into the database and 
sent the same screening questionnaires. 
• Patients with a MDA but were not candidates for the Selected Targets of Activity 
ReTraining programme (START) (i.e. CBT programme) 
The Centre for Pain Management has developed an intensive outpatient CBT programme, 
called START, conducted by clinical psychologists, medical specialists, physiotherapists and 
clinical nurse consultants. The aim of START is to help patients minimise the distress and 
daily dysfunction associated with persistent pain. START teaches skills to help patients 
manage their pain more effectively. Some patients were considered not suitable for the 
START programme according to the exclusion criteria of the START programme. This group 
of patients were invited to participate in the study. 
• Patients who were on the waiting list for the START programme 
START is a programme for groups of up to 12 outpatients. After a multidisciplinary 
assessment, patients considered appropriate for the multidisciplinary pain management 
programme are placed on a waiting list for a few months before entry into the programme. 
The Figure 1 illustrates the methods used to sort participants who were being processed at the 
BWCPM.
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Figure 1: Illustrates the Methods Used to Sort Participants Who Were Being Processed at the 
BWCPM 
 
 
 
 
 
 
 
 
 
• During the initial recruitment period, we realised that the process used was slow. In 
order to speed up the recruitment process, the following strategies were developed and 
approved by the HREC at SVH. Doctors from outpatient’s clinics at SVH, Melbourne 
including Rheumatology, Orthopaedics, Neurology and General Medicine were informed 
about the study through the website of SVH (Appendix 5) and through letters to Heads of 
Unit (Appendix 6). Also, advertisements in the newsletter of the Divisions of General Practice 
in letters to GPs were used to invite the GPs to refer participants to the trial (Appendix 7). 
PP were informed of the study at the BWCPM with an EI form and pamphlet containing 
information about the study. After reading the EI, PP filled out and returned the EI in a pre-
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paid envelope to the investigator. The investigator then interviewed eligible participants at the 
centre. Figure 2 illustrates the recruitment procedures.  
Figure 2: A Flow Chart Illustrating Participants Recruitment 
 
 
Local GPs Outpatients’ 
clinics  
Hospital Website 
Potential Participants (PP) identified 
PP returned the PI and EI  
to the investigator 
PP received EI form and Pamphlet 
The investigator met the eligible 
participants for initial assessment 
BWCPM 
GPs 
newsletters 
  
71 
3.4.1  Randomisation  
Patient recruitment was made difficult due to the significant travel required for a face-to-face 
interview and attendance twice weekly for six weeks. For this reason, a block randomisation 
method with 40 subjects in each block was used. Random numbers (40 numbers) were 
generated using a computer generated sequence of numbers. Following baseline assessment, 
participants were asked to select a sealed opaque envelope containing a unique random 
number which allocated the participant to the real electro-acupuncture (REA) or sham electro-
acupuncture (SEA) group. 
3.4.2  Blinding  
Successful blinding is a challenge in clinical trials of electro-acupuncture as the patient is able 
to see and feel subcutaneous needling and electrical stimulation. However, patient blinding is 
important to prevent bias in clinical studies of manipulative or ritualised procedures, such as 
acupuncture. 
A conventional double-blind trial attempts to blind both the patients and the person delivering 
the treatment. In the current study, performance bias was minimised by blinding the patient 
and outcomes assessor from the treatment allocation. The acupuncturist (study investigator) 
was unable to be blinded. Describing this procedure as a modified double-bind 
(patient/evaluator) trial is acceptable when intervention characteristics preclude investigator 
blinding (Jadad et al., 1996); The investigator delivering the treatment was blinded to 
treatment outcome and discussion of acupuncture with patients during treatment was limited. 
A research assistant (RA) entering outcome data was blinded to treatment allocation during 
the trial period. A second independent investigator who carried out the telephone consultation 
of participants’ OLM reduction was also blinded to the group assignments  
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3.4.3  Drop outs 
Any participant who dropped out of this study was analysed according to the intention-to-treat 
(ITT) method.  
3.5  Materials and Methods  
3.5.1  Materials  
3.5.1.1  Electro-acupuncture stimulation equipment  
EA was applied using a modified EA stimulator (MME 501, Meyer Medical Electronics, 
Australia) that was battery operated. As this stimulator is not registered or listed within 
Australia by the TGA, the trial was placed under the CTN scheme.  
The stimulator was originally designed to deliver ES of 1-500 Hz in frequency and constant or 
dense/disperse (D/D) square waves with a pulse width of 50–70 microseconds. In the current 
study, the D/D delivering mode was replaced with alternating frequency of 2 and 100 Hz. 
Each frequency was delivered for 6 seconds. It was operated on 8 AA batteries.  
3.5.1.2  Needles  
“Hwato” brand individually wrapped, sterilised, and disposable needles with guide tubes were 
used in this study. The needles are manufactured by Suzhou Medical Instrument Factory of 
China and are approved and listed by the TGA of Australia. The needles selected in the 
present study were 0.25mm in diameter. The lengths of the needles were 30mm - 40 mm. The 
depth of insertion of the needles varied depending on the acupoints selected. Used needles 
were placed into a sharps disposal bin. The same quality of needles was used in the REA and 
the SEA group.  
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Real and sham EA treatments were delivered by an acupuncturist who is registered with the 
Chinese Medicine Registration Board (CMRB) of Victoria, Australia. 
3.5.2  Real electro-acupuncture treatment  
3.5.2.1  Selection of acupoints 
Location of acupoints adopted in the present study followed the standard nomenclature of 
acupoints published by WHO (1993). The acupoint selection was adopted from an authorised 
book of Chinese medicine compiled by the State Administration of Traditional Chinese 
Medicine (Ming & Yang, 1997) and empirical experience. Paired acupoints selected for ES 
were Hegu (LI4), and Quchi (LI11), as well as Zusanli (ST36) and Fenglong (ST40). Each 
pair of acupoints was connected to an electrical stimulator. 
Secondary acupoints were selected to reduce the side effects of OLM, to relieve insomnia and 
promote calmness. A total of nine acupoints were chosen for every participant. They included 
four primary acupoints and five secondary acupoints which always included Shenmen (HT7), 
Sanyingjiao (SP6), and YinTang (EX-3). In addition, more supplementary acupoints could be 
added according to participants’ other accompanying complaints, or as a result of side effects 
from any medication. Table 10 summarises the acupoints used in the study.
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Table 10: Selected Acupoints 
Primary acupoints Hegu(LI 4) (negative) , Quchi (LI 11) (positive); 
Zusanli (ST36) (negative), Fenglong (ST40) (positive) 
Secondary acupoints 
1) Insomnia  
Shenmen (HT7) (bilateral), Sanyingjiao (SP6) (bilateral), Yintang (EX-3) 
Nausea  Neiguan (PC 6) 
Vomiting Geshu (BL 17), Neiguan (PC 6) 
Constipation Tianshu (ST 25)(bilateral), Zhigou (SJ 6) 
Fatigue / General weakness Guanyuan (RN 4), QiHai (RN 3) 
Drowsiness/ Sedation Yinglinqun (SP 9) 
Profuse sweating Fuliu (KI 7), Hegu (L 14) 
Night sweat Fuliu (KI 7), Yinxi (HT 6) 
Cough Lieque (LU 7),Feishu (BL 13) 
Insomnia  Taixi (KI 3) 
2) Reducing side effects from 
drugs  
 
Skin pruritus Xuehai (SP 10) 
3.5.2.2  Needling technique  
The participants in the real treatment group were required to be in a supine posture. After the 
acupoints were located, and skin sterilised, filiform disposable needles were inserted into the 
acupoints. The depth of needle insertion depended on the acupoints selected. Further 
manipulation was then delivered to achieve Deqi sensation that was characterised as a numb, 
heavy, sore and/or distending sensation.  
3.5.2.3  EA stimulator  
A pair of acupoints was used to make a circuit for conducting the electric current. In the 
present study, The MME 501 electrical stimulator was connected to the needles placed on the 
paired acupoints, of LI4 and LI11, and acupoints ST36 and ST40 via two pairs of wired clips 
after obtaining Deqi sensation. The black clips (negative) were connected to LI4, ST36, and 
red clips (positive) to LI11, ST40, respectively. The stimulator was then switched on, and the 
intensity was gradually increased from zero to reach a strong but comfortable level. The 
sensation of EA is numbness, distension and tingling. Any possible muscle contraction was 
explained to participants prior to the treatment. After 5 minutes of electrical stimulation, the 
intensity was adjusted to reach a tolerable level. Adjustments were done during a stimulation 
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of 100 Hz, i.e. the dense period. After 30 minutes of EA stimulation, the intensity knob was 
turned down to zero, the stimulator was switched off, and the needles were gently removed. 
During the treatment, the acupuncturist was not allowed to communicate with participants 
about the treatment and its effect.  
3.5.3  Sham electro-acupuncture treatment  
3.5.3.1  Location of sham acupoints 
Methods of locating sham acupoints in the present study were adapted from one commonly 
used approach (Vincent & Richardson, 1986) and one validated approach (Zaslawski et al., 
1997). In sham acupuncture, the same number of acupoints as for REA was used for each 
participant. For each real acupoint, there was a corresponding sham acupoint, and their 
method of location is described in Table 11. 
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Table 11: Location of Sham Acupoints 
Sham acupoints 
corresponding to 
Method of location of sham acupoints References 
Hegu  
(L14)  
On dorsal aspect of the hand between second & third metacarpal 
bones, about 1.5 cm proximal to metacarpal pharyngeal joint; 
insertion is transverse & caudal. 
 
Quchi  
LI 11 
On the posterior surface of the forearm, four body units distal to 
the olecranon. 
Zaslawski et al., 
1997 
Shenmen  
(HT7) 
On the palmar surface of the arm, four body units distal to the 
elbow crease 
Zaslawski et al., 
1997 
Yintang  
(EX- NH 3) 
1.5 cm above and lateral to the real acupoint  
 
 
Zusanli  
(ST 36)  
On the posterior aspect of the leg. Six body units inferior to the 
popliteal crease and one body unit lateral to the midline 
Zaslawski et al., 
1997 
Fenglong  
(ST 40 ) 
On the posterior aspect of the leg. Eight body units inferior to the 
popliteal crease and one body unit lateral to the midline  
Modified from 
Zaslawski et al., 
1997 
Sanyinjiao 
(SP 6) 
On the medial aspect of the leg.  Four body units inferior to the 
popliteal crease 
Zaslawski et al., 
1997 
Yinlingquan  
(SP9)  
At the centre of the medial aspect of the thigh  Fanti et al., 2003 
Geshu 
(BL 17) 
Three body units lateral to the spinous process of the sixth 
cervical vertebrae 
Modified from 
Zaslawski et al., 
1997 
Feishu  
(BL 13) 
Four body units, below spinous process of the T3 Modified from 
Zaslawski et al., 
1997 
Tianshu  
(ST 25) 
One body unit lateral to the anterior midline, and one body unit 
superior to the umbilicus. 
Zaslawski et al., 
1997 
Neiguan 
(PC 6) 
1.5 cm lateral of the real acupoint.  
 
Vincent & 
Richardson, 1986 
Zhigou 
(TE 6)  
On the posterior surface of the forearm, five body units distal to 
the olecranon 
Modified from 
Zaslawski et al., 
1997 
Fuliu 
(KI 7) 
One body unit directly above the real acupoint Modified from 
Zaslawski et al., 
1997 
Yinxi 
(HT 6) 
1.5 cm right lateral of the real acupoint. Vincent & 
Richardson, 1986 
Lieque 
(LU 7) 
1.5 cm left lateral of the real acupoint Vincent & 
Richardson, 1986 
Taixi 
(KI 3) 
One body unit above the real acupoint Modified from 
Zaslawski et al., 
1997 
Xuehai 
(SP 10) 
One body unit lateral to the real acupoint. Modified from 
Zaslawski et al., 
1997 
  
77 
3.5.3.2  Needling technique  
In the SEA group, the needling depth was approximately 5 mm, so that the insertion was 
superficial, but deep enough to keep the needle standing. Neither manipulation technique, nor 
Deqi was applied. A minimum of nine needles was applied and was equivalent to real 
acupuncture. 
3.5.3.3  Sham EA stimulator 
After inserting the needles, a modified, non-functioning, (but with a flashing light) MME 501 
EA stimulator was connected to the needles placed at the unilateral sham acupoints L14, LI11 
and ST36, ST40. No electrical current was passed through. No adjustment was applied during 
the treatment. The participants were told that they might or might not feel any sensation, 
because only a very weak current was delivered. Table 12 is a comparison of the REA and 
SEA procedures.  
Table 12: A Comparison between Real Electro-Acupuncture (REA) and Sham Electro-
Acupuncture (SEA) 
 
REA SEA 
Needle 
instruments 
“Hwato” brand needles  “Hwato” brand needles 
Acupoints ST 36 (-) + ST 40 (+) 
LI 4 (-) + LI 10 (+)  
Off meridian real acupoints  
Depth  Depending on the acupoints selected. Shallow insertion, enough depth to keep 
the needle in place 
Stimulation Obtain Deqi  sensation No Deqi  
EA stimulator MME 501, Myer Australia Modified MME 502, Myer Australia 
Parameter  Alternating frequency at 2 /100 Hz at an 
acceptable intensity.  
Non functional EA stimulator with 
flashing light only. 
Duration 30 minutes  30 minutes.  
Treatment 
Frequency 
Twice a week for six weeks Twice a week for six weeks 
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3.6  Outcome Measures  
3.6.1  Primary Outcome Measures 
The primary outcome measures were assessed daily at baseline and during treatment, one 
week immediately after completion treatment, and one week in every four during follow up.  
The McGill Pain Questionnaire was an exception and was assessed in the same way as the 
secondary outcome measures.  
3.6.1.1  Subject Dairy (Appendix 8) 
Participants were asked to complete a daily Subject Diary in which they recorded the number 
of pain medications they were taking, especially OLM, the severity of any related side effects, 
and the amount of pain that they were experiencing. This weekly Subject Diary took subjects 
approximately five minutes to complete at the end of the day. Also, the participants were 
asked to record any AE associated to acupuncture treatment. The participants were requested 
to complete the Subject Diary independently and bring it to the centre weekly. The Subject 
Diary continued for a two-week run-in period, a six-week treatment period, one week of early 
follow up immediately after treatment, and for a further three-week period starting on the 
fourth week after the end of the treatment. 
Instructions for using the Diary were provided and a sample showing how to use the scale 
enclosed and how to record the pain medication doses was enclosed. The participants were 
instructed only to rate the intensity and unpleasantness of the pain for which they were 
referred to the BWCPM. The detailed content of the Diary is described as follows. 
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Pain scale  
Pain severity was measured by asking participants to rate their pain on a VAS of 10 
centimetres length with “no pain at all” and “worst pain imaginable” at the two ends. Patients 
recorded the average level of pain, present pain, and the highest and lowest level of pain that 
they experienced today.   
Time that pain lasted on each day 
Participants were also required to draw a line representing a period of time within 24 hrs that 
they experienced pain. 
Severity and unpleasantness of pain on each day 
Participants were also asked to tick one of the boxes numbered from 0 to 20 that stated the 
severity and unpleasantness of their pain on each day. 
Medication usage 
Daily use of opioid and other pain medications was recorded by the participants. Doses of 
opioid were converted to daily equivalents of morphine in milligrams according to the 
Conversion Table 3. For example, a participant took Endone 5 mg and Tramadol 100 mg 
daily. These medications were conversed to the doses of morphine equivalent that was 25 mg 
daily. [5 mg (Endone) × 30 mg (morphine) ÷ 30 mg (Oxycodone) + 100 mg (Tramadol) × 30 
mg (morphine) ÷ 150 mg (Tramadol)]. An individual medication reduction schedule was 
formulated by a medical doctor and was released to the participant by the second investigator.  
The consumption of non-opioid analgesics was recalculated with Medication Quantification 
Scale (MQS ) (Harden et al., 2005). Each non-opioid analgesic for every participant was 
given a score based on the drug class, dosage, and detriment weight. The MQS scores for each 
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non-opioid medication were then summed to obtain a total score representing the 
consumption of non-opioid analgesics. 
Side effects of pain medication  
Participants were asked to mark the side effects of pain medication on VAS of 10 centimetres 
ranging between 0 (no symptoms at all) and 10 (very severe symptoms) at the end of each 
week throughout the study. 
Report of adverse events (AE) for acupuncture 
Participants were asked to record any perceived AE associated with acupuncture treatment, 
and the management of the symptoms at the end of each week throughout the treatment 
period. Common AE include fainting, infection, dizziness, bruising, pain and lethargy. 
Meanwhile, the severity of AE was categorised into: 0 (not at all), 1 (minimal), 2 (mild), 3 
(moderate), 4 (severe), and 5 (extremely severe).  
3.6.1.2  The McGill Pain Questionnaire  
Participants were asked to choose as many as words as required from the descriptive words of 
the MPQ to describe their pain during the baseline, 3rd and 6th week of treatment, and at the 
4th , 8th and 12th  week after the treatment. The basic scoring method of the MPQ followed 
the instructions from the study by Melzack (1975). Accordingly, results were categorised into 
three main scores. The first is the Pain Rating Index (PRI), which is based on the rank values 
of the words and is the total sum of all the 20 subclasses; and the second is the total number of 
words chosen (NWC). The third is the PPI, which is the number-word combination chosen as 
the indicator of overall pain intensity at the time of administration of the questionnaire. The 
Pain Rating Index scores are also subdivided into the following scores: 
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• The score of groups 1-10 to assess sensory components (PRI-s)  
• The score of groups 11-15 to assess affective components (PRI-a) 
• The score of groups 16 to assess evaluative components (PRI-e) 
• The score of  groups 17-20 to assess miscellaneous components (PRI-m) 
The word in each subclass implying the least pain is given a score of one, the next word is 
given a score of two, and for subsequent words a score is given determined by their 
placement. Participants were told that only one descriptor in any group should be chosen and 
not all groups need be included (Melzack, 1975). 
3.6.2  Secondary Outcome Measures 
The Secondary Outcome Measures were assessed at baseline, 3rd and 6th week during the 
treatment and at the 4th, 8th and 12th week after the treatment. The outcome measures are 
described below: 
3.6.2.1  Beck Depression Inventory-II (BDI-II)  
The questionnaire used in this study was BDI version II, a self-reporting scale. It is comprised 
of 21 items and takes approximately 5-10 mins to complete. The participants were asked to 
choose one provided statements they felt “best describes the way they had been feeling in the 
past two weeks, including today” (Beck, Rush, Shaw, & Emery, 1979).  
The summary of the rating for the 21 items is the total score on the BDI-II. Each item is rated 
on a 4-point scale ranging from 0-3. For items with multiple responses, the response with the 
higher rating is recorded. For Items 16 and 18, each of them contains seven options rated, in 
order, as 0, 1a, 1b, 2a, 2b, 3a, 3b. This is to differentiate between increases and decreases in 
behaviour or motivation. The maximum total score that can be obtained is 63. Higher scores 
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indicate more severe depressive symptomatology. Scores in the categories 0-13, 14-19, and 
20-28 indicate minimal, mild, and moderate depressive symptomatology, respectively, and a 
score equal to or higher than 29 is an indicator of severe depressive symptomatology. 
3.6.2.2  General Quality of life (SF-36)  
The SF-36 quality of life questionnaire was used to assess the impact of pain on each patient’s 
social activities and work during the previous 4 weeks. The instruments assess eight health 
domains including physical functioning (PF), role physical (RP), social functioning (SF), 
mental health (MH), vitality (VT), role emotional (RE), bodily pain (BP) and general health 
(GH). Each domain is scored from 0 to 100; a higher score indicates better health. 
3.6.2.3  Participants’ perception of EA treatment (Appendix 9) 
The participant’s perception was reported at the end of the treatment stage using 
Questionnaire Forms (Wang et al., 1997). The questionnaire consisted of four questions 
including participants’ view on effective of treatment, real treatment, paying for treatment in 
the future and recommendation to others. 
3.7  Procedure of the study 
3.7.1  Initial examination and assessment  
After PP returned their EI in a pre-paid envelope to the investigator, individual phone calls 
were made to them to ascertain and identify Inclusion/Exclusion Criteria. Once eligible, 
volunteers who met the basic selection criteria were identified, the investigator then invited 
them for an initial assessment.  
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The initial assessment was conducted at the BWCPM, St. Vincent’s Hospital. During the 
assessment, the following procedures were undertaken: 
• The Investigator greeted the PP. A verbal explanation concerning the study and PI 
(Appendix 10) was given, and any questions comprehensively answered prior to 
signing of the Consent Form (CF) (Appendix 11). A CF was provided to each PP to be 
read, signed, and witnessed. 
• A copy of the signed CF was given to each of the participants for their own records. 
• During the assessment interview, the BDI-II was given to the PP to complete. PP 
whose score was less than or equal to 29 were recruited into the baseline, and asked to 
complete the questionnaires summarized in Table 13.  
Table 13: The Summary of Instruments Used in Different Stages 
Outcomes Instruments 
Initial 
assessment 
Baseline 
Stage 
(2 weeks) 
Treatment 
Stage 
(6 weeks) 
Follow up 
Stage 
1st, 4th, 8th,  12th week 
after completion of 
treatment 
Subject Diary 
(Weekly) 
 √ √ √ Primary 
outcomes 
MPQ  √ 3rd, 6th √ 
BDI -II √ √ 3rd, 6th √ 
SF-36  √ 3rd, 6th √ 
Demographic and 
general 
information  
 √   
Secondary 
outcomes  
Perception of EA 
treatment  
  6th  
3.7.2  Baseline stage 
Once the participants completed the initial assessment, and written informed consent was 
obtained, they had a two-week baseline period prior to the treatment. During the baseline 
period, participants were required to fill out the weekly Subject Diary for two weeks, and to 
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post back a completed baseline week one Diary to the investigator with the pre-paid envelope, 
and asked to bring the baseline week two Diary with them on their next visit.  
3.7.3  Treatment stage 
Before administering the treatment, the investigator assessed the medications the participant 
was taking, especially opioid medications, as documented in the baseline Subject Diary. The 
participants were excluded if they were not taking opioid medication. Once the participants 
were eligible to participate in the study after the baseline period, each received treatment 
twice a week for a total of 12 sessions, delivered over a period of six weeks. The participants 
were required to record pain medication, related side effects, intensity of pain, and adverse 
events of acupuncture in the Subject Diary daily. Each participant was asked to fill out their 
perception of EA at the end of the treatment.  
3.7.4  Follow up stage 
After completion of EA treatment, the participants were assessed at three months follow up. 
The follow up procedure was to evaluate any potential long-term effects of EA. The 
participants were asked to complete the Subject Diary at 1st, 4th, 8th and 12th week during this 
stage, and were re-assessed with the secondary outcomes. 
3.7.5  Telephone consultation  
The purpose of the telephone consultation was to explain to participants how to reduce their 
OLM and avoid bias in the REA and the SEA groups. The second investigator indicated 
participants how to reduce their pain medication on the basis of a well-established individual 
plan for reducing OLM for each participant. The participants were informed at the second and 
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fifth week during the treatment and the third, sixth, and ninth week during the follow up 
stages.  
Figure 3 illustrates the procedure of the present study. 
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Figure 3: A Diagram of the Procedure of the Study 
 
3.7.6  Sample size calculation  
The sample size was calculated based on one of the primary outcome measures, which was 
the Dosage of Opioid Consumed (DOC). A previous study had reported that the mean DOC in 
postoperative patients when treated with sham EA was 30.2 mg with a standard deviation of 
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14.4 mg (Lin et al., 2002). In order to detect a difference of 30% or more in mean DOC 
between the two groups (REA and SEA), 44 participants were required in each group to reject 
the null hypothesis with 80% power and at a 5% significance level( two-tailed) (Warren S.B., 
Dennis B., Thomas, & B.H., 1988). Considering a 30% drop out rate, the total number of 
participants required to be randomised was 101.   
3.8  Data collection and analysis 
3.8.1  Data collection  
Data were collected during baseline, treatment stage and follow-up stage by a RA. The RA 
checked the completion of the Subject Diary and prepared a summary of medication used for 
telephone consultation. The methods employed in the present study were to ensure successful 
blinding of the acupuncturist and other investigators. Reports of AE from acupuncture in the 
Diary were checked by the acupuncturist weekly to ensure safe practice.  
All raw data from the Subject Diary were entered directly into Excel spread sheets. After the 
calculation of weekly means of variances, data were finally exported to Statistical Package for 
the Social Sciences (SPSS, version 13.0 for Windows) for statistical analysis. The SF-36 
value was calculated according to the manual for each of the subscales. 
3.8.2  Data analysis  
The data were summarised as mean ± standard deviations (SD). Per protocol analysis was 
performed for participants who completed the study. The data missed in the Subject Diary 
were replaced by carrying last value forward; the data missed in the BDI-II and SF-36 
questionnaires were dealt with according to the manual of BDI-II and SF-36. In addition, 
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participants who dropped out during the study were also recorded, and their primary outcome 
measure was analysed using the intention-to-treat analysis.  
The participants’ socio-demographic characteristics and the classification of diagnosis were 
analysed with chi-square or t-test. The data of primary and secondary outcomes measures for 
short term effects were analysed employing repeated measure of General Linear Model 
(ANOVA) with Bonferroni corrected  tests, paired-samples t-test and independent-sample t-
tests; and the data for long term effects were analysed using the paired sample t-test. Due to 
the evaluative (PRI-e) component of the questionnaire being composed of only one group of 
descriptors and the remaining four groups being composed of miscellaneous descriptors (PRI-
m), the decision was made to exclude these from individual analysis. Scores from these 
groups were included in total scores. 
The incidence of side effects of OLM and adverse effects of EA were compared between the 
two groups using chi-square analysis. Additionally, the perception of EA was crosstabulated 
with the group they were in and a chi square test performed, as appropriate.  
On the basis of the above methods, the data were generally analysed on the following aspects: 
• Comparison of the consumption of analgesics, particularly that of OLM, over time 
within and between groups.  
• Comparison of the severity of opioid related side effects within and between groups.   
• Comparison of the average intensity and duration of pain within and between groups.   
• Comparison of the severity and unpleasantness of pain within and between groups.  
• A comparison of MPQ (total and sub-category scores) within and between groups.  
• Comparison of the degree of depression and QoL within and between groups.  
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• Analysing the long term effect of EA. 
When the probability value was less than 0.05, the difference was considered to be 
statistically significant. Figures and charts were constructed in Window XP 2003 from the 
Microsoft Company. 
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4.CHAPTER FOUR: SHORT TERM EFFECTS OF ELECTRO-
ACUPUNCTURE ON OPIOID MEDICATION 
CONSUMPTION, PAIN AND RELATED VARIABLES  
 
This chapter presents the analysis of data obtained from the treatment period of the study. Per 
protocol analysis was employed to analyse both the primary and secondary outcomes, and 
these results are presented in details. Intention-to-treat analysis was also employed, a 
summary of the results is presented, and the detailed results are included in Appendix 13. A 
detailed description of these two analysis methods has been provided in the Methods chapter.  
4.1   Allocation of participants  
Between April 2004 and September 2005, 82 patients with CNMP were assessed for study 
inclusion. Of these, 40 participants were excluded for not meeting the inclusion criteria as 
shown in Table 14. Forty-two participants were enrolled during the two-week baseline period. 
Of these, seven were excluded from this data analysis. Five patients failed to return by the end 
of the baseline period and two discontinued as they had previously been scheduled for 
surgery. A total of 35 participants were randomly allocated to either the SEA or the REA 
group. Of the 35 enrolled participants, 26 completed the treatment, with four dropping out 
from the SEA group, and five from the REA group. A statistical test could not be conducted 
to find out if there were any differences between the groups as the numbers in each category 
were very small. The reasons for dropping out are summarised in Table 15 and the study 
flowchart is illustrated in Figure 4.  
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Table 14: Reasons for the Participant Exclusion  
Reasons for Exclusion  Number 
English is not good enough to understand the questionnaires 3 
Severe depression symptomatology diagnosed with BDI-II  11 
Had experience of EA in the previous six months 2 
Not taking opioids 8 
GP did not agree the patient to participate in the study  1 
Not interested in participating  in the study  1 
Didn't want to be in the sham acupuncture group 1 
Transportation problems 4 
Had malignant pain  2 
Fear of needles 1 
Pacemaker in site  1 
Failed to complete  the questionnaires 3 
Could not come regularly for treatment  2 
Total 40 
 
 
Table 15: Reasons for Dropping out Prior to Randomisation  
Dropped out reasons  SEA group 
N=4 
REA group 
N=5 
Could not tolerate needling sensation 0 1 
Had aggravation of symptoms 0 1 
Had transportation problems 2 1 
Reason unclear 0 1 
Had baby-sitting problems or family issue 1 1 
Work commitment  1 0 
Total  4 5 
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Figure 4: A Study Flowchart 
 
Note: REA, real electro-acupuncture; SEA, sham electro-acupuncture 
82 Chronic pain patients 
assessed for eligibility 
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Per protocol analysis included data from participants who completed the six-week treatment. 
In total, 26 participants were included in the per protocol analysis and the 35 patients 
randomised in the intention to treat analysis. Table 16 summaries the number of participants 
and outcome measures analysed by per protocol or intention-to-treat method. In the following 
sections, all data presented were analysed with per protocol method.  
4.2  Socio-demographic data  
The results of the univariate analyses regarding the age, gender, education level, marital 
status, living status for the two groups are presented in Table 17. There was no significant 
group difference, and the two groups were comparable in all these measures (Table 17).  
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Table 16: Number of Participants and Outcomes were Analysed Using per protocol and 
Intention-to-Treat Analysis   
 Per protocol  Intention-to-treat 
SEA group N=14 N=18 
REA group N=12 N=17 
Primary outcomes 
   Dosage of OLM 
   OLM related adverse events 
   Intensity and unpleasantness of pain                       
 
√ 
√ 
√ 
 
√ 
√ 
√ 
Secondary outcomes 
   Severity of depression 
   QoL  
 
√ 
√ 
 
 
Table 17: Demographic Variables at Baseline in Each Group  
Intention-to-treat Per protocol  
SEA 
group 
REA 
group 
χ2 
value 
or t 
value 
P 
value 
SEA 
group 
REA 
group 
χ2   
value 
or t 
p 
values 
 
 
 
Demographic Variables  
  
 
N=18 N=17    N=14  N=12    
Age (yrs) 
 (Mean ± SD) 
48.4 ± 
10.5 
51.1 ± 
13.0 
-.670 .507 50.8 ± 
9.76 
56.1 ± 
9.56 
-1.393 .176 
Gender 
     Male (N, %) 
     Female (N, %) 
 
9    50% 
9    50% 
 
9   53% 
8   47% 
.030 .862  
6    43% 
8    57% 
 
7   
58% 
5   
42% 
.619 .431 
Marital status (N) 
     Married  
     Single  
     Separated  
     Divorced  
     De facto  
     Widowed       
 
9  
3 
0 
2 
3 
1 
 
7 
3 
1 
4 
2 
0 
3.091 .686  
7 
3 
0 
2 
1 
1 
 
6 
3 
0 
2 
1 
0 
.929 .920 
Education level (N) 
     9 or more years of formal  
education    
     Less than 9 years              
 
 
15 
  
3 
 
10 
 
7 
7.389 .286 
 
 
11 
 
3 
 
5 
 
7 
8.602 .197 
Living status (N) 
     Alone 
        With spouse /partner 
and children 
     With spouse /partner only 
     With child /children only 
     With other relatives 
     With friends /housemates 
 
4 
8 
 
4 
0 
2 
0 
 
2 
7 
 
4 
1 
2 
1 
2.707 .745  
4 
6 
 
0 
2 
2 
0 
 
2 
3 
 
0 
4 
2 
1 
3.198 .525 
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4.3  Classifications of diagnosis in Western Medicine 
The participants were diagnosed by the doctors according to the Classification of Chronic 
Pain Definitions published by the International Association for the Study of Pain (IASP)   
(Merskey & Bogduk, 1994). A multiplex coding system was used, which consists of five axes 
plus an optional letter used as a suffix. These axes include: Axis I - Regions, the major body 
region or site of the reported pain; Axis II - Systems, the body system which abnormal 
functioning produces the pain; Axis III - Temporal characteristics of pain, pattern of 
occurrence;  Axis IV - Patients statement of intensity and Time since onset of pain; Axis V- 
Etiology, the presumed etiology of the pain problem. By applying this coding scheme, a five-
digit numerical code was generated that represented each participant’s diagnosis. The letters S 
and R were added after the digits a coding to identify spinal and radicular pain respectively. 
Where both occur in the same location, the letter C, for combined spinal and root pain, is 
preferred. For instance, the digital portion of the code for the syndrome of severe tension 
headache of more than 6 months’ duration is 033.97c. If a participant had pain in more than 
one region, two codes were completed for that participant. In this study, the primary pain 
means the condition that drove the participant to be treated in this study; second and third 
pains are referred to the pains located out of the site of primary pain.  
According to this coding system, many participants presented with both primary and second 
pains. The distribution of primary pain in the SEA and the REA groups are described in detail 
below (Figure 5).  
Axis I distribution (regions): Half the participants (50%) in the REA group were grouped into 
region 500 which indicates lower back, lumbar spine, sacrum and coccyx pain. Greater than 
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one third of participants (35.7%) in the SEA group were coded in region 900 which indicates 
more than three major sites of pain (Figure 5-Axis I).  
Axis II distribution (Systems): The majority of patients in the SEA (79%) and REA (92%) 
groups presented with musculoskeletal system and connective tissue pain (category 4) (Figure 
5-Axis II). 
Axis III distribution (Temporal Characteristics of pain: Pattern of Occurrence): A 
significant proportion of SEA (86%) and REA (92%) group participants suffered continuous, 
or nearly continuous, fluctuating severity pain (category 4) (Figure 5-Axis III).  
Axis IV distribution (Patient’s Intensity of Pain): Half of the participants in both groups had 
a medium level of pain intensity for greater than 6 months. Severe pain lasting longer than 6 
months represented 35.7% and 50%, of patients in the SEA and the REA groups, respectively 
(Figure 5-Axis IV).  
Axis -V distribution (Etiology): The most common etiological factors identified were 
degenerative and mechanical causes which made up 50% and 58.3% participants in the SEA 
and the REA groups, respectively. Trauma/operation/burns were the second most common 
etiological factors for both the SEA and REA comparison groups (Figure 5-Axis V). 
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Figure 5: Coding Site of Primary Pain in Each Group 
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1. head, face, and mouth                                       000 
2. cervical region                                                  100 
3. upper shoulder and upper limbs                       200 
4. thoracic region                                                  300 
5. abdominal region                                              400 
6. lower back, lumbar spine, sacrum, and coccyx500 
7. lower limbs                                                       600 
8. pelvic region                                                     700 
9. anal, perineal, and genital region                      800 
10. more than three major sites                             900 
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1. nervous system and special senses; physical   
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2. nervous system (psych and social)                         10 
3. respiratory and cardiovascular                                20 
4. musculoskeletal system and connective tissue       30 
5.cutaneous and subcutaneous and associated glands40 
6. gastrointestinal                                                       50 
7. genito-urinary                                                         60 
8. other organs or viscera                                           70 
9. more than one system                                             80 
10. unknown                                                               90 
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Pattern of Occurrence
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1. not recorded, not applicable, not known                   0 
2. single episode, limited duration                                1 
3. continuous/ nearly continuous, nonfluctuating         2 
4. continuous/ nearly continuous, fluctuating severity 3 
5. recurring irregularly                                                  4 
6. Recurring regularly                                                   5 
7. Paroxysmal                                                                6 
8. sustained with superimposed paroxysms                  7 
9. other combinations                                                    8 
10. none of the above                                                    9 
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Figure 5: Continue 
Axis IV - Intensity: Time Since Onset of Pain
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3. mild - more than 6 months                                   .2 
4. medium - 1 month or less                                    . 3  
5. medium - 1 month to 6 months                            .4 
6. medium - more than 6 months                             .5 
7. severe - 1 month or ess                                         .6 
8. severe - 1 month to 6 months                               .7 
9. severe - more than 6 months                                .8 
Axis V - Etiology 
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1. genetic or congenital                                            .00 
2. trauma, operation, burns                                      .01 
3. infective, parasitic                                                .02 
4. inflammatory, immune reactions                         .03 
5. neoplasm                                                              .04 
6. toxic, metabolic, radiation                                   .05 
7. degenerative, mechanical                                     .06 
8. dysfunctional                                                        .07 
9. unknown or other                                                 .08 
10.psychological origin                                            .09 
 
Data concerning a second diagnosis were reported by 66.7% and 35.7% participants in the 
REA and the SEA group. The result obtained was similar to the primary pain. The majority of 
participants in both groups had a second pain of the musculoskeletal system, which was 
continuous or nearly continuous/fluctuating, severe lasting more than 6 months and associated 
with degeneration. The majority of participants in the REA group had a second pain in the 
lower back/lumbar spine/sacrum region, whereas those in the SEA group were likely to report 
pain in the coccyx or cervical region.  
In addition, two participants in the REA group had a third diagnosis, which was also coded as 
musculoskeletal pain in the lower back and lower limbs of continuous or nearly continuous 
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character with medium or severe fluctuation. The pain was associated with degeneration and 
lasted more than 6 months.  
In summary, most participants in the REA group were suffering from pain in the lower back / 
lumbar spine/ sacrum and coccyx region (region, 500), and in the SEA group had pain in 
more than three major sites The majority of participants in both groups had pain in the 
musculoskeletal system (system, 30), continuous or nearly continuous/fluctuating, medium 
intensity, lasting more than 6 months and associated with degeneration. Overall, there were no 
significant differences between the two groups in terms of primary and second diagnoses of 
pain (Table 18).  
Table 18: Comparison of Primary and Second Diagnoses Variables by Participants Completed 
Study in Each Group  
Primary diagnoses Second diagnoses   
  
χ2  value df p -value χ2  value df p -value 
Region  6.552 5.0 0.256 3.846 5.0 0.572 
System  1.187 2.0 0.553 0.677 1.0 0.411 
Character 0.895 2.0 0.639 4.128 3.0 0.248 
Intensity  2.026 3.0 0.567 5.254 4.0 0.262 
Etiology 3.198 3.0 0.362 1.499 3.0 0.683 
4.4   Baseline clinical characteristics 
4.4.1  Clinical characteristics at baseline 
Twenty-six of 35 participants completed the six-week treatment with the Subject Diary 
information. Participants’ clinical characteristics at baseline in terms of consumption of OLM, 
dosage of non-opioid analgesics, pain history, intensity and unpleasantness of pain, depressive 
symptoms and quality of life in the two groups are presented in Table 19. Pain was measured 
using VAS, GBS and MPQ respectively. The two groups were comparable with respect to all 
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of the clinical characteristics except that the average pain level reported by the SEA group 
was higher than that reported by  the REA group [5.8 ± 1.7 (SD) vs. 4.5 ± 1.3 (SD), t = 2.133, 
p < .05].  
Participants were taking various types of OLM or mixed OLM. The major types of OLM 
were codeine, oxycodone, morphine and tramadol. In the REA group, the majority of 
participants took tramadol, whereas codeine was most commonly taken in the SEA group. 
The numbers of participants who took different types of opioid are presented in Table 19.  
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Table 19: Comparison of Baseline Clinical Characteristics Variables of Participants Who 
Completed the Study 
SEA 
N=14 
REA 
N=12 
t 
value 
 
P  value 
 
Clinical characteristics of participants who  
completed the study 
Mean SD Mean SD   
Consumption of OLM (mg/weekly) 212.3 177.8 348.5 303.7 -1.42 .168 
Types of OLM §              
Generic name:                Codeine                                  
                                         Oxycodone 
                                         Morphine  
                                         Tramadol 
11  
 3 
 2  
3   
5 
2 
2 
6    
MQS 6.19 6.98 5.57 9.58 .191 .850 
Pain history (yrs) 13.3 11.2 15.6 12.6 -.508 .616 
Present pain intensity -VAS 5.9 1.7 4.9 1.5 1.532 .139 
Highest levels of pain-VAS 7.0 1.6 6.4 1.4 1.182 .249 
Lowest levels of pain-VAS 3.9 2.3 2.6 1.1 1.862 .075 
Average pain-VAS † 5.8 1.7 4.5 1.3 2.133 .043* 
Duration of pain (hrs/day) 16.0 4.6 16.9 6.1 -.436 .667 
Severity of pain - GBS 14.3 2.6 12.6 3.3 1.396 .175 
Unpleasantness of pain - GBS 12.7 2.7 10.9 3.2 1.540 .137 
PRI-sensory 18.1 8.4 14.2 8.6 1.195 .244 
PRI-affective 4.8 4.1 2.8 2.8 1.448 .161 
PRI-evaluative 2.8 1.7 2.3 1.7 .668 .510 
PRI-miscellaneous 5.7 4.3 3.0 2.5 1.911 .068 
PRI-total 31.4 16.0 22.3 12.2 1.620 .118 
Present Pain Intensity (PPI) 3.0 1.1 2.7 1.2 .750 .461 
Depressive symptoms (BDI-II) 17.8 8.5 15.9 6.2 .632 .534 
SF-36 Physical Functioning (PF)  36.5 22.0 52.1 24.4 -1.244 .223 
SF-36 Role Physical (RP)  12.5 29.2 10.4 16.7 -.1400 .890 
SF-36 Bodily Pain (BP) 22.5 12.2 29.2 16.8 -1.001 .324 
SF-36 General Health (GH) 44.6 20.1 40.9 18.5 .582 .565 
SF-36 Vitality (VT) 26.3 21.5 38.8 19.1 -1.194 .241 
SF-36 Social Functioning (SF) 47.9 21.9 51.0 18.8 -.330 .974 
SF-36 Role Emotional (RE) 52.8 48.1 33.3 37.6 1.258 .217 
SF-36 Mental Health (MH) 56.9 18.7 63.0 17.2 -.217 .830 
Note.  * indicates p < .05 is significant, two-tailed, independent-sample t –tests; † indicates average pain 
was significantly higher in the SEA group than that of the REA group; § indicates the number of 
participants who took various OLM 
4.4.2  Side effects of opioid like medication at baseline  
Table 20 shows that the number and percentage of participants who experienced side effects 
of OLM at baseline. The incidence of side effects was greater in the SEA group compared to 
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the REA group. On average, the incident rate of side effects was 6.3 in the SEA group and 4.7 
in the REA group. The most common complaint was drowsiness in the SEA group (85.7%) 
and fatigue in the REA group (75%). The second most common complaints were fatigue and 
lethargy in the SEA group and constipation in the REA group. There were no statistically 
significant differences between the two groups for any side effects except for drowsiness (χ2= 
5.539, p = .019).  
Table 21 shows the average severity of side effects that participants experienced in each 
group at baseline. The most severe symptom reported in the SEA group was drowsiness, and 
fatigue in the REA group. There was no statistically significant difference in the severity of 
side effects between two groups except for drowsiness and sedation, with the SEA group 
experiencing more severe symptoms. 
In summary, the most commonly experienced and severe side effects were drowsiness in the 
SEA group and fatigue in the REA group.  
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Table 20: Number and % of Participants Who Experienced Side Effects at Baseline 
SEA  
N=14 
REA  
N=12 Experienced Side Effects 
at Baseline 
N % N % 
Nausea   7 50 5 41.7 
Vomiting   3 21.4 1 8.3 
Dizziness   7 50 3 25 
Fatigue   10 71.4 9 75* 
Drowsiness   12 85.7* 5 41.7 
Blurred vision   8 57.1 3 25 
Sedation   8 57.1 3 25 
Lethargy   10 71.4 7 58.3 
Anxiety   7 50 4 33.3 
Nightmares   5 35.7 4 33.3 
Constipation   5 35.7 8 66.7 
Other symptoms   6 42.9 4 33.3 
Total  88   56   
Incident rate 6.3   4.7   
Note: * indicates p < .05 is significant, chi-square tests. 
 
Table 21: Comparison of the Average Severity of Side effects of OLM in Each Group at Baseline 
SEA 
N=14 
REA 
N=12 
t p - value 
Average severity of side effects 
of OLM at baseline 
Mean SD Mean SD 
  
Nausea 0.9 1.4 1.6 1.6 -.358 .723 
Vomiting 0.4 0.9 0.2 0.6 .645 .525 
Dizziness 1.5 2.6 0.6 1.2 1.178 .250 
Fatigue 3.5 3.7 2.3 1.9 1.160 .258 
Drowsiness 3.8 2.6 1.6 2.2 2.234 .035* 
Blurred vision 1.8 2.3 0.8 1.5 1.295 .208 
Sedation 1.8 2.3 0.2 0.6 2.197 .038* 
Lethargy 2.6 2.6 1.3 1.6 1.489 .150 
Anxiety 1.6 2.2 0.8 1.5 1.47 .306 
Nightmares 0.9 1.8 1.1 2.7 -.280 .782 
Constipation 1.3 2.1 2.0 2.1 -.808 .427 
Other symptoms 2.6 3.7 1.1 2.4 1.169 .254 
Note: * indicates p < .05 is significant, two-tailed, independent - samples t -tests.
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4.5  The effects of EA on the primary outcomes during the treatment 
period  
4.5.1  Dosages of opioid like medication consumption 
Weekly dosages of OLM consumption were analysed with the General Linear Model (GLM) 
for repeated measures. There was a significant time effect [F (6, 144) = 13.73, p = .000] and 
group by time interaction [F (6,144) = 2.431, p = .029] but without significant group effect [F 
(1, 24) =1.278, p = .27], indicating that dosages of OLM were reduced in both groups over the 
six-week treatment period. The reduction of weekly OLM consumption between baseline and 
at the end of the treatment was more rapid in the REA group than the SEA group, with 64% 
and 46% reduction rates, respectively (Figure 6). 
Paired-sample t-tests were used to assess differences within groups. The results showed that 
significant decreases of OLM were obtained at the end of 3rd and 6th week in the REA group, 
and the end of 6th week in the SEA group when compared with the baseline value (p < .05). 
These results suggested that the effect occurred soon after the commencement of REA 
treatment and more slowly after the SEA treatment. 
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Figure 6: Consumption of OLM (Morphine Equivalent) mg/weekly in Each Group across All 
Time Points 
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Note: ‘† indicates significant differences within the REA group at the time points when compared with the 
baseline. * indicates significant differences within the SEA group at the time points when compared with 
the baseline. p < .05, paired-simple t-tests. 
 
4.5.2  Side effects of opioid like medication    
Table 22 shows the number and percentage of participants who experienced side effects 
associated with OLM at the end of the treatment. The results showed that there was a higher 
incidence of side effects in the SEA group than the REA group at the end of the treatment. On 
average, the incident rate of side effects was 2.9 in the SEA and 2.3 in the REA group after 
completion of the treatment. However, chi-square tests indicate that there were no significant 
differences between two groups for any side effects. 
The severity of each side effect was analysed individually with the GLM for repeated 
measures. There were significant time effects for sedation [F (6,138) = 4.753, p = .000], 
drowsiness [F (6,138) = 4.030, p = .001], dizziness [F (6,138) = 2.241, p = .043], blurred 
version [F (6,138) = 3.126, p = .007], lethargy [F (6,138) = 2.830, p = .013], anxiety [F 
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(6,138) = 2.171, p = .046], and constipation [F (6,138) = 2.309, p = .0037], indicating the 
severity of side effects were reduced during the treatment period.  Significant group by time 
interactions were observed only for sedation [F (6,138) = 3.176, p = .006] and drowsiness [F 
(6,138) = 3.087, p = .007]. The reduction of the severity of sedation in the REA group (100%) 
was greater than that in the SEA group (89%). However, the reduction of drowsiness was 
greater in the SEA group than in the REA group, with 66% vs. 43%, respectively (Table 23).  
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Table 22: Number and % of Participants Who Experienced Side effects at the End of the 
treatment 
SEA 
N=14 
REA 
N=12 Experienced  side effects of OLM  
at the end of the treatment 
N % N % 
Nausea   3 21.4 2 16.7 
Vomiting   2 14.3 0 0.0 
Dizziness   3 21.4 2 16.7 
Fatigue   9 64.3 8 66.7 
Drowsiness   5 35.7 4 33.3 
Blurred vision   2 14.3 0 0.0 
Sedation   2 14.3 0 0.0 
Lethargy   5 35.7 4 33.3 
Anxiety   3 21.4 2 16.7 
Nightmares   0 0.0 1 8.3 
Constipation   2 14.3 3 25.0 
Other symptoms   4 28.6 1 8.3 
Total  40  27  
Incident rate 2.9  2.3  
 
Table 23: Average Severity of Side effects of OLM in Each Group at baseline and 
the End of the Treatment 
Baseline At the end of the treatment 
SEA 
N=14 
REA 
N=12 
SEA 
N=14 
REA 
N=12 
Average severity of  side effects  
of OLM at the end of the treatment 
Mean SD Mean SD Mean SD Mean SD 
Nausea 0.9 1.4 1.6 1.6 0.6 1.3 0.2 0.4 
Vomiting 0.4 0.9 0.2 0.6 0.2 0.6 0 0 
Dizziness 1.5 2.6 0.6 1.2 1.1 2.4 0.2 0.4 
Fatigue 3.5 3.7 2.3 1.9 1.9 2.1 1.5 1.7 
Drowsiness* 3.8 2.6 1.6 2.2 1.3 2.1  0.9 1.6 
Blurred vision 1.8 2.3 0.8 1.5 0.4 1.0 0 0 
Sedation†  1.8 2.3 0.2 0.6 0.2 0.5 0 0 
Lethargy 2.6 2.6 1.3 1.6 1.0 1.5 1.0 1.8 
Anxiety 1.6 2.2 0.8 1.5 0.4 0.8 0.3 0.9 
Nightmares 0.9 1.8 1.1 2.7 0 0 0.1 0.3 
Constipation 1.3 2.1 2.0 2.1 0.4 0.9 1.4 2.9 
Other symptoms 2.6 3.7 1.1 2.4 1.5 2.9 0.8 2.6 
Note: † indicates statistically significant difference within the REA group at the end of the treatment when 
compared with the baseline. * indicates statistically significant difference within the SEA group at the end 
of the treatment when compared with the baseline. 
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4.5.3   The effects of EA on the intensity and unpleasantness of pain  
4.5.3.1  Pain assessed with Visual Analogue Scale  
Weekly means of present pain, average pain, and highest and lowest levels of pain were 
analysed with VAS. There was a significant time effect for the average pain, highest level of 
pain and present pain [average pain: F (6, 144) = 3.313, p = .004; highest level of pain: F 
(6,144) = 3.697, p = .001; present pain: F (6, 144) = 2.189, p = .047]. However, there was no 
group by time interaction. The results showed during the six-week treatment period, the 
average pain, highest level of pain, and present pain were reduced in both groups (p <.05), 
and the reduction was similar in both groups (p >.05) (Table 24). 
There were neither significant time effects nor group by time interaction for the lowest level 
of pain and duration of pain. The results showed that the lowest level of pain and duration of 
pain were not changed in both groups over the six-week treatment period (Table 24).  
Within group comparisons of average pain in the REA group indicated a significant reduction 
(p <. 05) at the 3rd and 6th week when compared with baseline value. In the SEA groups, 
significant differences were only found at the 3rd week, but not at the 6th week (Figure 7).  
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Table 24: Comparison of Pain Assessed With VAS at Baseline and at the End of the Treatment 
in Each Group 
Baseline At the end of the treatment 
SEA 
N=14 
REA 
N=12 
SEA 
N=14 
REA 
N=12 
 
Mean SD Mean SD Mean SD Mean SD 
Average Pain  5.8 1.7 4.5 1.3 5.1 2.1 3.5 1.9 
Present pain   5.9 1.7 4.9 1.5 5.4 2.4 4.0 2.3 
Highest of pain  7.0 1.6 6.4 1.4 6.1 2.1 5.3 2.2 
Lowest of pain  3.9 2.3 2.6 1.1 3.6 2.5 1.8 1.3 
Duration of pain 
 (hour) 
16.0 4.6 16.9 6.1 15.6 3.7 15.7 6.6 
 
 
Figure 7: Weekly Average Pain Scores Assessed With VAS in Each Group 
Across All the Time Points 
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Note: † indicates statistically significant difference within the REA group at the time points when 
compared with the baseline. * indicates statistically significant difference within the SEA group at the 
time points when compared with the baseline. 
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4.5.3.2  Pain assessed with Gracely Box Scales   
The results showed that there was a significant time effect in the severity and unpleasantness 
of pain across all the time points [severity of pain: F (6, 144) = 3.750, p = .002; 
unpleasantness of pain: F (6, 144) = 2.578, p = .021)], with neither group by time interaction 
nor group effect, indicating that both groups had less pain over the six-week treatment period. 
However, the reductions in the severity and unpleasantness of pain were similar in both 
groups.  
The results also showed that when compared with the baseline, unpleasantness of pain in the 
REA group was significantly reduced from the 2nd week to the 5th week (p <.05), but not at 
the 6th week. There was no significant difference in the SEA group over the six-week 
treatment period (Figure 8) 
Figure 8: Weekly Unpleasantness of Pain Scores Assessed with GBS 
in Each Group across All the Tine Points 
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Note: † indicates significant difference within the REA group at the time points when compared with the 
baseline. 
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4.5.3.3  Pain assessed with McGill Pain Questionnaire  
Weekly MPQ scores were analysed with the GLM for repeated measures. The results showed 
that there were neither time effects nor group by time interactions, indicating there were no 
statistically significant changes at the end of the six-week treatment in both groups in the 
following MPQ measures: PRI-sensory, PRI-affective and PRI-Total (Table 25). PRI-
evaluative and PRI-miscellaneous were not analysed as discussed earlier.  
4.5.3.4  Correlations of Visual Analogue Scale, Gracely Box Scales and McGill Pain 
Questionnaire at the end of the treatment  
Data were analysed with Pearson r to assess the correlations between VAS and GBS, VAS 
and MPQ, and MPQ and GBS that were obtained at the end of the treatment. The VAS 
measures of present pain, average pain and highest level of pain were highly correlated with 
GBS measures of both severity and unpleasantness of pain. Highest level of pain and average 
pain were also correlated with MPQ evaluative, miscellaneous and total scores, but not MPQ 
sensory and affective scores; and present pain was only correlated with MPQ evaluative 
score. The GBS severity and unpleasantness of pain were correlated with all of MPQ 
measures (Table 26). 
4.5.3.5  Correlation of reduction of pain and reduction of OLM consumption 
Data were analysed with Pearson r to assess the correlation between OLM consumption and 
intensity of pain before the treatment; and the reductions of pain and OLM consumption at the 
end of treatment week 6. None of these variables were well correlated apart from a weak 
correlation between reductions in OLM consumption and pain in REA group only (Pearson r 
= .612*).  
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Table 25: Comparison of MPQ PRI Scale Score at Baseline and  
 at the End of the Treatment in Each Group 
Baseline At the end of the treatment 
SEA 
N=14 
REA 
N=12 
SEA 
N=14 
REA 
N=12 
 
Mean SD Mean SD Mean SD Mean SD 
PRI - sensory  18.1 8.4 14.2 8.6 16.4 7.1 13.6 6.4 
PRI - affective  4.8 4.1 2.8 2.8 3.6 3.4 2.8 3.2 
PRI - Total 31.4 16.0 22.3 12.2 28 13.3 22.3 13 
 
Table 26: Correlation Between VAS, GBS and MPQ Scores  
in 26 Participants at Treatment Week Six 
 
Present 
pain  
Highest level  
of pain 
Average 
pain 
GBS-
Severity of  
pain 
GBS-
Unpleasantness of 
pain 
PRI - sensory 0.184 0.318 0.341 .411(*) .391(*) 
PRI - affective 0.169 0.244 0.266 .445(*) .417(*) 
PRI - evaluative .681(**) .656(**) .727(**) .684(**) .638(**) 
PRI - miscellaneous 0.324 .407(*) .486(*) .513(**) .513(**) 
PRI - total 0.3 .405(*) .450(*) .531(**) .508(**) 
Present pain 
intensity  
 .925(**) .913(**) .849(**) .842(**) 
Highest levels of 
pain 
  .919(**) .874(**) .788(**) 
Average pain    .856(**) .819(**) 
GB-Severity of pain     .898(**) 
Note: ** Correlation is significant at the 0.01 level (2-tailed). * Correlation is significant at the 0.05 level 
(2-tailed), Pearson r tests. 
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4.6  The effects of EA on secondary outcomes during the treatment period  
4.6.1  Severity of depression  
The data on severity of depression were analysed with the GLM for repeated measures. There 
was a significant time effect [F (2, 46) = 3.722, p = .032] but without group by time 
interaction [F (2, 46) = .838, p = .439], indicating the severity of depression was reduced in 
both REA group (10.7 %) and SEA group (23%) across all the time points, and the reduction 
was similar between the two groups (Figure 9).  
Figure 9: A Comparison of Severity of Depression Assessed With BDI-II in Each Group 
 Across All the Time Points  
0.0
5.0
10.0
15.0
20.0
25.0
30.0
Baseline 3rd week 6th week 
Time
 B
D
I 
Sc
or
e
M
ea
n 
± 
SD
 
 REA
 SEA
  
4.6.2  Quality of life (SF-36 Health survey) 
During the treatment period, one participant from the SEA group failed to complete items in 
the domain of physical functioning; and two did not complete items in the domains of role 
physical, bodily pain, general health, vitality and role emotional. In the REA group, one 
participant did not respond to the items in the domain of general health. Data from these 
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participants were not analysed according to the guidelines of dealing with missing data in the 
manual of SF-36.  
Eight domains of SF-36 were analysed individually with the GLM for repeated measures. The 
main effect of time was significant in bodily pain (BP) [F (2, 44) = 5.324, p = .008], vitality 
(VT) [F (2, 44) = 3.420, p = .042] and role physical (RP) [F (2, 44) = 4.838, p = .013], with no 
group by time interaction. These results indicate that the scores of BP, VT and RP in the both 
groups were increased after the six-week treatment when compared with baseline, and the 
improvement were similar in both groups (p > .05) (Figure 10).   
4.6.3  Non-opioid analgesics assessed with MQS  
Dosages of non-opioid analgesics, as indicated with MQS, at the baseline and at the end of the 
treatment period were analysed with ANOVA to detect the difference between groups and 
over time. MQS did not change significantly in either group (tw 6: REA 4.98 ± 8.66 vs. SEA 
4.12 ± 6.87).
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Figure 10: The Eight Domains of SF- 36 Health Scale Scores in Each Group at the Baseline and 
at the End of the Treatment Period  
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4.7  Summary  
The results obtained from the per protocol analysis are summarised below.  
At the end of the six-week treatment period, the consumption of OLM was significantly 
reduced in both groups. However, there was no significant difference between the two groups. 
There was a more rapid decline in consumption of OLM in the REA group than the SEA 
group. Some side effects related to OLM including drowsiness, dizziness, blurred vision, 
sedation, lethargy, anxiety and constipation were reduced in both groups. Reductions in the 
severity of these symptoms were similar in both groups except for sedation and drowsiness. 
The reduction of sedation was greater in the REA group than that in the SEA group, and 
reduction of drowsiness was greater in the SEA group. 
The intensity of pain including average pain, present pain and highest level of pain, severity 
of pain and unpleasantness of pain were significantly reduced in both groups. Reduction in 
pain was similar in both groups. Lowest level of pain, duration of pain and pain measured by 
the MPQ scores were not significantly reduced in both groups.  
The severity of depression was significantly reduced in the both groups, there were no group 
difference. The scores of SF-36 were increased in the domains of the BP, VI and RP in the 
both groups by a similar degree.  
In summary, the results of the primary outcomes obtained from the intention-to-treat analysis 
were generally consistent with the per protocol analysis method except the side effects of 
OLM. Differences were that the REA group had lower severity of drowsiness than the SEA 
group. 
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4.8  Adverse events of EA  
There were a total of 345 treatments comprising 187 SEA and 158 REA sessions. Fifty-two 
adverse events (AE) were recorded, 19 in the SEA group and 33 in the REA group. The rate 
of AE incidences per treatment in the REA group (21%) was greater than the SEA group (10 
%). The most frequently reported AE by the SEA group was needling pain, followed by 
bruising and in the REA group, bruising, followed by needling pain (Table 27). Other AE 
included minor itching, headache, sweating, and stiffness of neck in the SEA group, and 
blurring vision, tingling, sore, cramp, muscle spasm, tenderness, tiredness and weariness in 
the REA group.  
The level of impact of each AE on life was recorded. The majority participants who 
experienced an AE reported no or mild impact on life. Approximately 26% and 24% 
participants in the SEA and REA groups, respectively, reported moderate to severe impact on 
their life. Often these events were alleviated by rest and disappeared over time. There were no 
instances where an AE required any special medical management (Table 27).   
4.9  Credibility of blinding process  
Credibility of the blinding process was assessed with participants’ perception of EA treatment 
with data collected at the end of the treatment. Twenty-three participants including 10 
participants from the REA group and 13 from the SEA group completed a four-item 
questionnaire, which was designed to assess whether the participants could differentiate the 
REA from SEA treatment. No statistically significant differences were detected between the 
two groups in respect to their perception of the effectiveness of the treatment, allocation of 
real treatment, would like to pay for the service and recommend the treatment to others. The 
results indicated that the blinding procedure was successful (Table 28). Of the 23 participants 
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who completed the recommendation item of the questionnaire, 96% of them would 
recommend the treatment to others although only 61% thought the treatment was effective.   
Table 27: The Incidents and Impact of A.E of EA Reported by Participants in each Group 
SEA*  REA * 
Impact on life Impact on life  
  
  
Type of  
Event  Not 
at  all  Min. Mild Mod. Sev. Total 
Not 
at  all  Min. Mild Mod. Sev. Total 
Dizziness   1   1 2     2 
Bruising 3     3 5 1 1 1  8 
Pain 2 6   1 9 1 2 1 2 1 7 
Lethargy     1 1 1  1  2 4 
Other 1  1 1 2 5 7 3  1 1 12 
Total incidents 
of A.E 
6 6 2 1 4 19 16 6 3 4 4 33 
Total 
treatment  
     187      158 
Accidences 
/per treatment  
     10%      21% 
Note: Min., minimal; Mod., moderate; Sev., severe. 
 
Table 28: Number of Participants’ Perception of Treatment in Each Group at the End the 
Treatment  
  
  
SEA  
N=13 
REA  
N=10 
Yes 8  6  Effective of treatment  
No 5  4  
Yes 8  6  Allocation of real treatment 
No 5  4  
Yes 7  5  Pay for service in the future  
No 6  5  
Yes 13  9  Recommend the treatment to others 
No 0 1  
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5.CHAPTER FIVE: LONG TERM EFFECTS OF ELECTRO-
ACUPUNCTURE ON OPIOID LIKE MEDICATION 
CONSUMPTION, PAIN AND RELATED VARIABLES 
 
This chapter presents the analysis of data obtained from the 12-week follow-up period of the 
study. The statistical methods used were paired sample t-test within each group to assess 
whether the outcomes obtained at the end of the treatment period were maintained. In total, 26 
participants completed the treatment period. Three of them from the REA group failed to 
return for their follow-up assessment that included one dropping out at post-treatment week 8 
(pw 8) and the other two at pw 12. Their missing values were replaced with last observed data 
values carried forward for the follow-up data analysis except for the SF-36 survey. The 
missing data in the SF-36 survey were analysed according to the guidelines for dealing with 
missing data in the manual of SF-36. 
5.1  The effects of EA on the primary outcomes during the follow-up 
period 
5.1.1  Dosages of opioid like medication consumption  
Figure 11 illustrates the consumption of OLM in the REA and SEA groups during the 12-
week follow up period. Paired sample t-tests showed that the weekly dosages of OLM in the 
REA group at post treatment week 8 and week 12 (pw 8 and pw 12) were significantly higher 
than that at the end of the treatment (pw 8: 198.9 ± 146.8 mg/wk, pw 12: 215.8 ± 177.4 
mg/wk). On the contrary, the changes in the dosage of OLM in the SEA group were not 
statistically significant during the 12-week follow-up period when compared with the end of 
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treatment (113.9 ± 139.2 mg/wk). This indicates the reduction of dosage of OLM observed 
during the treatment period in the REA group was maintained for only four weeks after 
treatment, whereas the reduction in the SEA group was maintained throughout the follow-up 
period.  
5.1.2  Side effects of opioid like medication  
Results of paired sample t-tests showed that there were no significant changes in both groups 
for all of the OLM related-side effects during the 12-week follow-up period. Table 29 lists the 
average severity of side effects of OLM at the end of 6-week treatment and at pw 12. The 
most severe symptom reported by the SEA group was fatigue followed by drowsiness; and 
was constipation in the REA group followed by lethargy. 
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Figure 11: Consumption of OLM (Morphine Equivalent) (mg/weekly) In Each Group  
During the 12 Week Follow Up Period  
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Table 29: Average Severity of Side Effects of OLM in Each Group 
at tw 6 and pw 12  
At tw 6 At pw12 
SEA REA SEA REA 
N=14 N=12 N=14 N=12 
Average severity 
of  side effects 
of OLM 
Mean SD Mean SD Mean SD Mean SD 
Nausea 0.6 1.3 0.2 0.4 0.8 2.2 0.2 0.6 
Vomiting 0.2 0.6 0 0 0.3 0.6 0.3 0.9 
Dizziness 1.1 2.4 0.2 0.4 0.7 1.5 0.4 0.9 
Fatigue 1.9 2.1 1.5 1.7 2.0* 2.9 0.8 1.5 
Drowsiness 1.3 2.1 0.9 1.6 1.8 2.5 0.1 0.4 
Blurred vision 0.4 1.0 0 0 0.6 1.4 0.1 0.4 
Sedation 0.2 0.5 0 0 0.2 0.5 0.0 0.0 
Lethargy 1.0 1.5 1.0 1.8 1.3 1.7 1.6 2.4 
Anxiety 0.4 0.8 0.3 0.9 0.5 1.2 0.4 1.0 
Nightmares 0 0 0.1 0.3 0.5 1.9 0.6 1.4 
Constipation 0.4 0.9 1.4 2.9 0.9 2.3 1.7* 3.0 
Other symptoms 1.5 2.9 0.8 2.6 1.1 2.0 0.0 0.0 
Note: * indicates the most severe symptom reported at pw 12 in each group.    
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5.1.3  The effects of EA on the intensity and unpleasantness of pain  
5.1.3.1  Pain assessed with Visual Analogue Scale and Gracely Box Scales  
Results of paired sample t-tests for pain intensity, severity and unpleasantness, and duration of 
pain showed that there were no statically significant changes in either group during the 12-
week follow-up period when compared with the treatment week six (Table 30).   
Table 30: Pain Assessed with VAS and GBS in Each Group at tw 6, pw 1 and pw 12  
At tw 6 At  pw 1 At pw 12 
SEA REA SEA REA SEA REA 
N=14 N=12 N=14 N=12 N=14 N=12 
  
  
  Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
Present pain 
intensity -VAS 5.4 2.4 4.0 2.3 5.4 2.2 4.5 2.2 5.1 2.4 4.5 2.5 
Highest levels 
of pain - VAS 6.1 2.1 5.3 2.2 6.1 2.1 5.5 2.2 5.7 2.5 5.5 1.9 
Lowest levels 
of pain -VAS 3.6 2.5 1.8 1.3 3.6 2.3 1.9 1.5 3.2 2.2 1.6 1.3 
Average pain-
VAS  5.1 2.1 3.5 1.9 5.1 2.0 3.9 1.9 4.6 2.1 3.6 1.7 
Duration of 
pain (hrs/day) 15.6 3.7 15.7 6.6 15.8 4.5 15.6 6.6 17.7 5.3 16.3 6.2 
Severity of 
pain - GBS 
13.3 3.6 11.2 3.7 13.4 2.8 11.9 3.8 13.1 3.6 11.9 3.6 
Unpleasantness 
of pain - GBS 
11.9 4.0 9.7 3.4 12.1 2.9 10.2 3.3 11.6 3.7 9.9 3.3 
 
5.1.3.2  Pain assessed with McGill Pain Questionnaire Scores   
Results of paired sample t-tests for PRI-sensory and PRI-affective showed that there were no 
significant changes in either group during the 12-week follow-up period when compared with 
the treatment week six except for the PRI-total. In the REA group, PRI-total at pw 12 was 
significantly increased when compared with treatment week six values (t = -2.397, p = .035), 
whereas no significant difference was found in the SEA group (Table 31). PRI-evaluative and 
PRI-miscellaneous were not analysed as discussed earlier.  
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Table 31: Pain Assessed With MPQ in Each Group at tw 6 and pw 12 
At tw 6 At pw 12 
SEA REA SEA REA 
N=14 N=12 N=14 N=12 
  
  
  Mean SD Mean SD Mean SD Mean SD 
PRI - sensory  17.1 7.3 13.6 6.4 13.6 10.1 18.3 8.7 
PRI - affective  3.9 3.7 2.8 3.2 4.3 6.7 4.2 3.5 
PRI - Total 29.6 13.9 22.3 13 22 17.4 31.5* 15.6 
Note: * indicates p < 0.05 when compared with the data at tw 6.  
5.2  The effects of EA on secondary outcomes during the follow-up period 
5.2.1  Severity of depression  
The severity of depression during the 12-week follow-up period was analysed with the paired 
sample t-tests within group. The results showed that the severity of depression was not 
significantly changed during the whole follow-up period when compared with treatment week 
six for both groups. This indicated that depression in both groups was maintained during the 
follow-up period (Table 32).  
5.2.2  Quality of life (SF-36 Health survey)  
Twelve participants in the SEA group and eight in the REA group completed all items of the 
SF-36 survey during the whole study period, respectively, and were included in the analysis. 
Of these, one participant in the REA group failed to complete the general health items 
domain, and was excluded from analysis.  
Eight domains of the SF-36 were analysed individually with paired sample t-tests within 
group. The results showed that there were no significant changes on eight domains during the 
whole follow-up period compared with the treatment week six in both groups (Table 32). 
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Therefore, the improvements on bodily pain and mental health during the treatment period in 
both groups were maintained throughout the whole follow-up period (Table 32).  
Table 32: Depression and QoL in Each Group at tw 6 and pw 12 
At tw 6 At pw 12 
SEA REA SEA REA 
N=14 N=12 N=14 N=12 
  
  
  
Mean SD Mean SD Mean SD Mean SD 
Depressive 
symptoms (BDI-II) 13.7 10.0 14.2 7.5 14.7 13.2 11.6 8.5 
SF-36 Physical 
Functioning (PF)  43.1 24.1 55.4 21.5 40.7 25.6 53.3 27.5 
SF-36 Role Physical 
(RP)  28.8 33.6 33.3 38.9 19.6 32.8 19.4 27.3 
SF-36 Bodily Pain 
(BP) 32.5 20.5 35.8 16.8 32.1 19.3 32.2 21.1 
SF-36 General 
Health (GH) 47.1 22.0 45.4 17.1 43.1 28.3 46.7 17.1 
SF-36 Vitality (VT) 36.7 25.8 44.6 20.9 36.8 25.4 46.7 16.6 
SF-36 Social 
Functioning (SF) 49.1 24.5 50.2 23.8 57.3 30.9 47.3 29.7 
SF-36 Role 
Emotional (RE) 52.8 41.4 55.6 29.7 49.9 42.9 37.1 31.1 
SF-36 Mental Health 
(MH) 60.7 23.6 66.3 18.2 64.6 28.5 68.0 13.4 
5.3  Summary  
At the end of the follow-up, the reduction of OLM intake obtained during the treatment period 
in the REA group was maintained for four weeks after treatment, and significantly increased 
at post treatment week 8 and the end of the follow-up, compare to the end of the treatment. 
However, the reduction of OLM intake obtained during the treatment period in the SEA group 
was maintained throughout the follow-up period. The severity of OLM- related side effects 
was not significantly changed in both groups throughout the follow-up period.  
The intensity and unpleasantness of pain remained stable in both groups throughout the 
follow-up period. The secondary outcomes were not significantly changed in both groups 
during follow-up period.  
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6.CHAPTER SIX: DISCUSSION 
The aims of the current study were to evaluate the short and long-term effect of REA on the 
reduction of OLM consumption, related side effects, and pain in patients with chronic pain in 
comparison with SEA. The results of the present study demonstrated that REA significantly 
reduced OLM consumption and sedation related to OLM in comparison to SEA. However, the 
reduction of OLM consumption was short lasting, being maintained for only four weeks after 
REA treatment. Pain intensity and unpleasantness were reduced in both groups to a similar 
degree. Due to the small sample size, these results should be interpreted with caution.  
6.1  Population sample 
Participants were volunteers mainly referred by medical doctors in the metropolitan 
Melbourne area and the majority of them were from a multidisciplinary pain management 
centre. In comparison to other studies of acupuncture for chronic pain patients in the 
community, the present group were older and had more severe pain for a longer duration of 
time (Carlsson & Sjolund, 2001; Leibing et al., 2002; Mendelson et al., 1983). The 
consumption of OLM was, however, comparable to that of musculoskeletal pain patients in 
other studies (Kalso, McQuay et al., 2004).  
Participants of this study were all adults aged between 39 and 78 years. The mean age was 
50.8 (SD 9.7) years in the SEA group and 56.1 (SD 9.6) years in the REA group. Participant 
age was therefore similar to results of an Australian study that reported that the prevalence of 
chronic pain peaked in the 45-64 year age group (Blyth et al., 2004). The majority of 
participant’s chronic pain was in the musculoskeletal system, with conditions such as lower 
back and lumbar spine pain due to degenerative disease. Not unexpectedly, this is higher than 
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European and Australia data reporting that about 45-50 % of chronic pain patients in the 
community suffer from pain in the low back (Breivik et al., 2006; Jensen, Thomsen, & 
Hojsted, 2006).  
Pain chronicity across the participants varied greatly. The mean duration of pain was 15.6 
years (SD 12.6) in the REA group and 13.3 years (SD 11.2) in the SEA group. The median 
pain chronicity was 9.6 years and 13 participants experienced their pain for over 10 years. 
Australia wide, 21% of the population are reported to have suffered pain greater than 10 years 
(Blyth et al., 2003). The pain duration of patients included in the present study was longer 
than that of a CBT programme in the same pain management clinic, which is less than 7 years 
(Bradbury, 2003), and of other acupuncture studies of chronic pain, which were about 9.6 
years (Carlsson & Sjolund, 2001; Leibing et al., 2002; Mendelson et al., 1983).  
In the present study, chronic pain of moderate intensity occurred in 50% of participants. 
Severe pain occurred in 50% and 35.7% of the REA and SEA groups, respectively. The 
prevalence of severe pain in the present study was higher than that of other convenience 
sample studies (Kalso, McQuay et al., 2004).  
6.2  Credible sham EA design  
The blinding of participants was successful as there were no differences in the patients’ 
perception of treatment received when comparing those allocated to REA or SEA at the end of 
the treatment period. The patient’s judgement appears to have been made on the basis of 
perceived success of the treatment.  
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A series of strategies were applied in the present study to ensure the credibility of the sham 
EA intervention. Firstly, superficial needling was applied on non-acupoints without 
stimulation (Vincent & Richardson, 1986). This method attempts to mimic acupuncture 
technique and minimize afferent stimulation. This method has been successfully used as the 
control in many previous studies ( Chen et al., 1998; Chiu et al., 1999). Almost half (n =27) of 
45 RCTs identified in a systematic review employed this technique (Dincer & Linde, 2003). 
The location of sham acupoints in the present study has previously been evaluated and 
considered an effective and credible placebo control (Zaslawski et al., 1997). Secondly, 
participants with little knowledge of acupuncture were recruited so that they could not 
identify real from sham treatment on the basis of experience. Thirdly, this study employed a 
mock EA device with flashing light but no electrical current that appeared to meet the 
requirements of an appropriate control. Using non-functioning electrical acupuncture in sham 
control has been widely used as is considered a suitable and valid procedure (Chen et al., 
1998; Lin et al., 2002; Sim et al., 2002; Wang et al., 1997). Participants were told that it was 
normal that they might or might not feel any stimulation sensation. Combination of sham 
intervention and mock EA appears to be a valid approach to the issue of placebo in controlled 
studies of EA. 
6.3  Short and long term effects of electro-acupuncture on OLM 
reduction 
The main findings from the present study showed that REA produced a 64% decrease in OLM 
intake after treatment. The dose of OLM intake was 126.1±97.3 mg/week of morphine 
equivalent (i.e. 18.0 mg/day) at the end of REA treatment, which is lower than 
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musculoskeletal pain patients’ intake in other dose reduction studies (Kalso, McQuay et al., 
2004).   
The group difference in reduction of OLM consumption noticed in this study was unlikely to 
be due to an initial difference between groups. REA and SEA groups were comparable in key 
variables such as age, pain history, intensity and unpleasantness of pain at worst with the 
exception of average pain intensity. Although the REA group consumed a higher dosage of 
OLM at the baseline than the SEA group did, there was no group different in OLM dosage. In 
addition, the use of ANOVA with repeated measure reduced the between subjects variance 
and increased the sensitivity of tests. It assessed both within subject changes over time as well 
between subject differences (Hills, 2003). However, the possibility that the REA group with a 
higher initial OLM dose might have experienced a quick reduction by a large amount cannot 
be either excluded or substantiated.  
The group differences noticed in the study is also unlikely due to the blinding process inherent 
in the study design. The modified double-blind (patient/evaluator), sham-controlled design 
has eliminated the impact of patient bias on the result and, as it is not possible to blind the 
investigator (acupuncturist) in acupuncture studies, the assessor (an independent research 
assistant) collecting and summarising the data was blinded to treatment allocation. Describing 
the study design in this manner is consistent with current quality assessment of RCT 
recommendations (Jadad et al., 1996).  
6.3.1   The short term effect of EA on OLM consumption  
The present study demonstrated that the reduction of OLM consumption was statistically 
significantly rapid in the REA group (64%) compared to the SEA group (46 %) over the six-
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week trial period. This result is consistent with other clinical studies on postoperative OLM 
requirement reporting that the decrease in postoperative OLM requirement was 38%-65% in 
the EA/TAES group (Chen et al., 1998; Lin et al., 2002; Wang et al., 1997). The 46% 
reduction in the SEA is, however, higher than the 21-23% reduction reported by other studies 
in patients with acute pain (Lin et al., 2002; Wang et al., 1997). No data from chronic pain 
patients are available.   
The strong effect of SEA on OLM reduction can be attributed to several factors. The present 
study was to investigate the patients with chronic pain whereas previous studies were 
conducted in acute pain patients. An earlier review showed that chronic pain is associated 
with significant placebo analgesia effects, reducing pain in 30-35 % of patients. Moreover, 
needling in sham acupoints appears to work in nearly 33-50% of patients compared with an 
effectiveness rate of 55-85% of cases receiving needling at true acupoints (Vincent & 
Richardson, 1986). This sham acupuncture effect is rarely seen in acute laboratory-induced 
pain (Vincent & Lewith, 1995). The study shown that despite almost 40% noticed a difference 
in treatment type between needles, there were no differences in outcome between real and 
placebo needling, indicting that the latter is not an inert control as previously thought (White, 
Lewith, Hopwood, & Prescott, 2003). 
Secondly, the reduction in SEA could be caused by non-specific effects. It is reported that any 
penetration of needling on the body can produce physiological effects (Ghia et al., 1976; 
Lewit, 1979). Evidence was also found that acupuncture stimulation at non-classical acupoints 
might still produce analgesia possibly through DNIC (Le Bars, Villanueva, Bouhassira, & 
Willer, 1992; Vincent & Lewith, 1995). A few recent clinical trials in migraine, neck pain and 
fibromyalgia and OA, all shown that SEA is as effective as REA (Assefi et al., 2005; Linde et 
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al., 2005; Scharf et al., 2006; Zhu & Polus, 2002). Thirdly, prolonged superficial insertion into 
the skin might still produce a non-specific endorphin response (ter Riet, de Craen, de Boer, & 
Kessles, 1998), thereby reducing OLM intake even in the sham acupuncture group.  
Moreover, additional encouragement offered by a third researcher, despite being blinded from 
the treatment allocation, could be another factor. The researcher telephoned the participants 
four times through the trial, and this may have been viewed positively by these patients and 
improved outcome. Indeed, in some pain management clinics, encouragement is the only 
method to assist patients to reduce OLM prior to a CBT programme (Bradbury, 2003).  
All the above-mentioned factors could also be used to explain the effects of REA, which was 
associated with statistically significant 18% reduction. This can possibly be attributed to 
specific treatment characteristics, including Deqi sensation produced, the utilisation of the 
2/100 EA stimulation and the acupoints selected. These factors have been proven to be 
essential to acupuncture analgesia (Chen et al., 1994; Chen & Han, 1992; Fei et al., 1987; 
Han, 2003; Han et al., 1999; Kong et al., 2005; Wang, Yao, Xian, & Hou, 1985). Which of 
these factors, alone or in combination, cannot be confirmed from the current study.  
Apart from the percentage difference, REA had a more rapid, although shorter duration of 
action compared to the SEA group. The significant reduction in the REA appeared at 
treatment week three, while this was not evident in the SEA group until week six. The quick 
onset of REA effect parallels other studies in post-operative pain (Lin et al 2002). The REA 
group consumed less than half of morphine intake of the SEA group in the first eight hours 
following operating procedure in the study by Lin et al. 
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6.3.2  The long term effects of REA on OLM consumption  
The effect of REA lasts up to four weeks after treatment whereas the effect of SEA was 
sustained throughout the 12-week follow up period. As previous studies focused on post-
operative pain, the duration of REA effect on OLM consumption is unknown. Studies on 
chronic pain have indicated the long term effects of acupuncture vary from four to 52 weeks 
(Berman et al., 2004; Grant, Bishop-Miller, Winchester, Anderson, & Faulkner, 1999; Leibing 
et al., 2002; Vickers et al., 2004; Witt et al., 2005).   
The difference of long-term effects between REA and SEA may have been due to the high 
opioid consumption of REA at baseline and the consequent ease with which it might be 
reduced more, the number of treatments in total, or the short-term effect of EA. A lower dose 
of OLM was ingested by patients in the SEA group (212.3 ± 177.8 mg/weekly) compared to 
the REA group (348.5 ± 303.7mg/weekly) at baseline. It is possible that OLM at a low dose is 
relatively easier to maintain at lower levels.  
Repeated treatments are important to induce better and longer-term effects. Animal studies 
showed that repeated EA treatment could increase synthesis of neuropeptides in brain areas 
involved in pain control, and these began three weeks into the treatment and lasted for seven 
weeks (Bucinskaite et al., 1996). Repeated treatments also reduced mechanical hyperalgesia 
(C. Huang et al., 2004) and produced cumulative effects (Cui et al., 2005). Human clinical 
studies have also demonstrated more benefit by repetition of treatment (Martelete & Fiori, 
1985; Price, Rafii, Watkins, & Buckingham, 1984). A chronic pain treatment review indicated 
that  six or more treatments was more likely to produce significantly more positive results 
than fewer treatments (Ezzo et al., 2000). A 12-session treatment protocol in the current study 
should have been adequate to produce a long-term benefit, but this was not observed in the 
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REA group. The most parsimonious explanation is that REA has a short-term effect on OLM 
consumption.  
Two analgesic points, ST36 and LI4, were selected for electrical stimulation in the present 
study. When one or both points are stimulated, pain threshold is significantly increased (Han 
et al., 1991), the limbic system is deactivated (Chiu et al., 2003; Hui et al., 2000; Wu et al., 
1999; Wu et al., 2002), EOPs are released and postoperative analgesics requirement is 
reduced (Chen et al., 1998; Chiu et al., 1999; Lin et al., 2002; Wang et al., 1997). According 
to this hypothesis, the current study would be expected that this type of EA would stimulate 
the release of EOPs, and therefore replaced the use of exogenous OLM. The release of EOP 
often is short lasting for a few days. An animal study showed that after one session of EA, the 
preproenkephalin (PPE) mRNA expression in the brain increased at four hours after treatment, 
peaked at 48 hours, and then declined by 50% at 72 hours (Guo et al., 1996). The results 
indicate that after a single REA treatment the release of EOP could continue for more than 
three days, and therefore a treatment effect might last a similar duration. It is not clear from 
the literature whether, and for how long, repeated treatments prolong PPE mRNA expression 
and related effects.  
It appears logical that discontinuation of EA stimulation would lead to a reduction of EOP 
release and OLM consumption would therefore increase again. This is consistent with what 
was observed in the current study. The increase of OLM consumption in the REA group 
commenced at one week after the treatment, and continued to the end of the 12-week follow 
up. On the other hand, the consumption of OLM in the SEA group fluctuated, and overall 
remained the same. The discrepancy in this change indicates that the reduction seen in the 
REA may be due to specific effects of EA, whereas that in SEA is explained by either non-
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specific effects or factors other than EA. Further studies are required to replicate these 
secondary outcome observations. Such studies will need to include further controls and 
measurement of biologic substrates in order to confirm these observations and their associated 
putatative mechanisms.  
Currently CBT is considered an effective strategy for pain management and reducing OLM 
(Bradbury, 2003). The pre-requisite for entering the programme is to reduce opioid intake to 
an arbitrary predetermined level, for example, 60mg/day oral morphine. The time taken to 
reduce OLM to this level before the programme is variable and individual to each patient. No 
specific assistance is offered to achieve this goal except for patient education, counselling and 
exercise. Whatever its mode of action, EA seems to offer the potential for additional 
assistance to these patients, and could easily be incorporated in a multidisciplinary pain 
management programme.     
6.4   The effects of EA on OLM related-side effects   
The incidence of OLM related side effects was lower in the REA group than the SEA group at 
the end of the treatment. REA significantly reduced the severity of sedation compared with 
SEA treatment. This is consistent with previous study findings that reported that the real 
TAES group achieved a lower sedation score than the sham-TAES, although there were no 
statistically significant differences in the pain and nausea scores among groups (Chen et al., 
1998). The effect observed in the current study may be due to decreased Tramadol 
consumption by the majority of participants in the REA group. Tramadol is known to produce 
sedation (MIMS online). 
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The severity of drowsiness was significantly reduced in the SEA group compared with the 
REA group. This may be due to the fact that most of participants in the SEA group took 
codeine phosphate that may cause drowsiness. Previous studies have also shown that the 
incidence of other opioid-related side effects, such as nausea and dizziness, were significantly 
reduced in the real TAES group compared with the sham groups (Chen et al., 1998). However, 
the present study found that common OLM-related side effects, such as dizziness, anxiety, 
lethargy and constipation, were reduced in both groups, and the group differences were not 
significant.  
6.5  The effects of EA on pain intensity  
Average pain was reduced following treatment in both groups, and the REA group (22%) 
tended to produce greater pain reduction than the SEA group (12%). However, there was no 
significant difference between the groups. Obviously, the small sample size contributes to a 
lack of group difference.   
The reduction of pain is comparatively small in comparison to the figures reported by other 
authors, in which pain reductions were 56%, 40% and 19% in real acupuncture group, sham 
acupuncture and no treatment or standard control, respectively (Leibing et al., 2002). 
Similarly, in another epidemiological study of acupuncture for chronic headaches, pain 
reduction was about 50% after acupuncture treatment (Melchart et al., 2006).  
This discrepancy is likely to be explained by the difference of the primary aims between the 
present study and previous studies. The current study was designed to evaluate the effect of 
EA on reducing the OLM consumption rather than pain level. The acupoints selected aimed to 
effectively stimulate the release of EOPs, but not specifically pain reduction. The primary 
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acupoints electrically stimulated were LI4 and ST36 and local acupoints or trigger points at 
the site of pain were not chosen. The local points may be essential for pain relief.  
The finding in this study demonstrates that the reduction of OLM consumption is not 
necessarily related to the reduction of pain or the levels of pain intensity. This is likely due to 
a variety of psychosocial factors involved in chronic pain. As mentioned in chapter Two, 11 
studies have measured postoperative OLM requirement and pain in acute pain patients and 
nine reported significantly reduced OLM requirement. Of these, six reported a significant 
reduction in OLM requirement after REA, although pain relief was not significantly different 
between the REA and control groups (Christensen et al., 1993; Gejervall et al., 2005; 
Humaidan et al., 2004; Kho et al., 1991; Lin et al., 2002; Wang et al., 1997). Only three out of 
nine studies found both postoperative pain and OLM requirement were significantly less in 
the REA group than those in sham/standard treatment control group (Chen et al., 1998; Chiu 
et al., 1999; Stener-Victorin et al., 2003).   
In the current study, there was no correlation between the OLM consumption and pain level at 
baseline. After treatment, a weak correlation was present between reductions in OLM 
consumption and decreased pain in the REA group but not the SEA group. This may imply 
that OLM reduction maybe associated with pain relief in some patients, perhaps those with 
more evidence of activated nociceptor systems in the pathogenesis of their pain. 
The patients in the REA group took the equivalent to 18mg/day of morphine at the end of the 
treatment and the reduction of pain intensity was 22%. This compares to 30% of mean pain 
relief at daily doses of  30-120 mg morphine in chronic pain patients as studied by Kalso et al 
(Kalso, McQuay et al., 2004). The OLM usage after REA treatment in the present study seems 
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to produce stronger pain reduction per unit of morphine but with a lesser pain reduction than 
found in this study.   
The lack of a strong correlation between OLM consumption and pain might be explained by 
the complexities of pain pathogenesis and the fact that its relief cannot be simply induced by 
analgesics or acupuncture, with an associated inappropriate level of OLM intake by some 
patients.  
As discussed above and in Chapter Two, physiological, psychological and social factors all 
contribute to the presentation and intensity of pain. Pain management and reduction should 
consider a coherent and multidisciplinary approach rather than a single treatment approach, 
whether it is acupuncture, analgesics or psychological counselling alone (Coeytaux et al., 
2005; Meng et al., 2003; Stener-Victorin, Kruse-Smidje, & Jung, 2004).  
6.6  The effects of EA on depression and QoL 
The severity of depression significantly improved in both groups, however the between group 
difference was not statistically significant. This outcome was not the focus of the current 
study. Although there is evidence that acupuncture can reduce depression and anxiety 
(Leibing et al., 2002; Roschke et al., 2000), the selected acupoints used in the present study 
were not specific to depression and would be considered insufficient to produce such effects. 
A US study found that acupuncture at specific points improved depression in women more 
than those treated at non-specific acupoints (i.e. real acupoints not related to depression 
symptom) (Allen & Schnyer, 1998). The 11% and 23% reduction of depression scores in REA 
and SEA groups, respectively, might be due to the placebo effect or non specific effects of 
acupuncture. Nevertheless, the current result is consistent with recent systematic reviews, 
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which concluded there is inconsistent evidence to determine the efficacy of acupuncture 
compared to sham acupuncture in treatment for depression (Mukaino, Park, White, & Ernst, 
2005; Smith & Hay, 2005).  
Acupuncture has been reported to improve QoL in the clinical settings. Patients with chronic 
disease often reported improved sense of well being and QoL with repeated acupuncture 
treatments (Paterson & Britten, 2003). The results from clinical trials are mixed, with some 
reporting improved QoL in patients with pain after acupuncture treatment compared to control 
treatment (Carlsson & Sjolund, 2001; Coeytaux et al., 2005; Vickers et al., 2004), while 
others observing no significant differences between acupuncture and control groups (Berman 
et al., 2004; Grant et al., 1999; Kerr, Walsh, & Baxter, 2003).  
In the present study, most domains of the SF-36 were not significantly improved except for 
BP, VI and role RP after treatment in both groups, and these improvements were not 
significantly different between groups. A possible explanation for the lack of group difference 
might be due to the low level of pain reduction. The current results are consistent with a 
review report which showed that QoL, like mood, are affected by the amount of pain relief 
achieved (Kalso, McQuay et al., 2004). The same review also reported that only three of eight 
studies found improvement in function or disability using opioids in chronic pain.  
The role of acupuncture in depression and QoL and the respective contributing factors 
requires further investigation.  
  
138
6.7  Safety of EA and participants’ satisfaction  
The rate of adverse events (AE) per treatment in the REA group (21%) was greater than that 
in SEA group (10%), but the impact on the patients life reported for AE was essentially the 
same in the REA group (24%) compared with the SEA (26%) group. The most frequent 
events were needling pain and bruising in both groups. These AE did not require special 
medical management.  
Types and severity of AE in the current study are consistent with a survey (White, Hayhoe, 
Hart, & Ernst, 2001) and an electrical acupuncture clinical trial in patients with osteoarthritis 
in the knee (Berman et al., 2004). The AE rate is however higher than 6.7% and 7% reported 
by the survey and the clinical trial, respectively. The difference is likely due to the modality of 
acupuncture and frequency of assessment. The study by White et al examined the AE during 
acupuncture practice which may be manual or electrical stimulated. In the study by Berman et 
al, AE was assessed every four weeks. Because AE in that trial were minor and did not require 
any medical attention as in the current study, it is possible that patients forgot to report events 
happened a few weeks prior to the assessment. In the current study, AE was assessed weekly, 
and patients were more likely to remember to report any AE happened.  
Similarly, a recent study shows that about 80% of patients with chronic non-cancer pain 
experienced adverse events of OLM (Kalso, McQuay et al., 2004), but the current study 
indicated that only 21% had EA related adverse events. REA treatment appears to be 
relatively safe and well tolerated in the clinical management of chronic pain. 
Over 90% participants were satisfied with the interventions received and would be willing to 
refer the treatment to others, although only 61% perceived the interventions as effective. The 
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discrepancy between the satisfaction rate and perception of treatment benefit were not clear. 
The perception of treatment did not entirely depend on the success of OLM reduction or pain 
because about 15% of the participants who thought they received ineffective treatment had a 
significant reduction in OLM consumption. Why these patients reduced OLM consumption is 
unknown. Such information is often qualitative and may be better elicited by semi-structured 
interview. Future studies should elicit details of how participants perceive the treatments. 
Whether treatment success is based on meaningful OLM reduction or on the impact of OLM 
reduction is uncertain. 
6.8  Limitations of the study  
There are several limitations of the present study that need to be addressed. The most 
important of these include the small sample size, the sources of participant recruitment, 
heterogenous participant characteristics and selection of acupuncture points.  
The planned sample size was 110 (55 in the each of group). Due to the difficulty in participant 
recruitment, only 35 participants enrolled within the 18 months period in spite of intense 
effort and recourse to several recruitment strategies. There are several reasons that may 
underpin the small sample size, some of which are discussed below.  
Firstly, because acupuncture is increasingly used, it has become increasingly difficult to enrol 
acupuncture-naïve subjects. About 10% of responders had acupuncture experience and had to 
be excluded. Secondly, the sourcing of participants limited the recruitment capability. In the 
present study, participants were referred by specialists at the pain management centre and 
outpatient clinics in the hospital, and by local GPs surrounding the hospital premises. 
Advertisements were placed on the hospital website, and sent to GPs via electronic 
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newsletters. It is impossible to calculate the referral rate due to these strategies used. About 18 
patients were referred through these strategies, which may reflect clinicians’ knowledge and 
attitude to acupuncture, or patients visiting their GP at times the trial was not being 
advertised. In a paper by Australian researchers it was suggested that media release to the 
public was the most effective means of recruiting participants for acupuncture clinical trials 
(Smith & Coyle, 2006). This strategy was not used in the current study because of the 
requirement to recruit those on opioids and therefore collaboration from the patients’ regular 
doctors was considered to be most important.  
Most participants were referred from a pain management clinic. Epidemiological surveys 
suggest that pain clinic samples may differ in many ways from community samples. For 
example, the association between psychological findings and pain frequency noted in pain 
clinics is less frequently observed in epidemiological studies (Turk & Melzack, 2001)  Their 
responses to treatment may also be expected to be different from those in the community. 
Patients referred to pain clinics also have high rates of aberrant drug related behaviour 
(Portenoy, 1996) and are likely to report low quality of life with inability to cope (Kerr et al., 
2004). This is the case in the current study.  
In addition, the participants were having pain in different locations, of varying intensity and 
were taking OLM at different dosages and via oral, parenteral or intradermal routes. This 
heterogeneity might have resulted in difficulties in further decreasing OLM intake. Moreover, 
there was a large individual variation of OLM consumption in the REA group which varied 
from 26.8 to 855 mg/week, and this variation could have impacted on the ability to decrease 
the consumption unevenly. Further studies should aim to recruit patients taking similar classes 
and doses of medications and with similar types of pain.  
  
141
The selection of acupoints LI 4 and ST 36 is both an advantage and a disadvantage to the 
study. Unlike other studies, pain was not specifically addressed in the current project. On the 
basis of the principle of traditional Chinese medicine (TCM) the individualised selection of 
acupoints is an essential practice. However, it is important to point out that this principle 
restricts the ability of acupuncture clinical studies to undertake randomised, placebo 
controlled and blinded trials. Therefore, standardised treatment protocols requiring 
acupuncture at fixed acupoints remains necessary for clinical trial (Hammerschlag, 1998; 
Vincent & Richardson, 1986). However this narrow selection of acupoints would not be 
expected to substantially impact on pain located at various parts of the body, and therefore 
only small reductions in pain and other associated variables, such as depression and QoL, was 
expected.  
The two acupoints were chosen for their likely effect on the primary outcome measure and 
because of convenience in respect of the need for stimulation. In studies on post-operative 
pain, chronic musculoskeletal pain and heroin addiction (Cheng & Pomeranz, 1987; Han, 
1998; Wang et al., 1997), a TENS like device was given to patients who were taught to 
stimulate LI 4 and ST 36 daily at home. This simple protocol may decrease drop out rates due 
to the burden of travelling and may be more acceptable to chronic pain patients, and result in 
a better outcome.  
6.9  Conclusions and implications  
The conclusions drawn from this study are that REA is more effective than SEA in reducing 
self-reported exogenous opioids consumption and related sedation in patients with chronic 
pain. EA was also shown to be safe and acceptable. The duration of the observed effect, 
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however, is short term. The findings suggest that EA may be a useful adjunct therapy in 
chronic pain management.  
Chronic pain is multidimensional, and its treatment requires a multidisciplinary approach. 
Future studies should examine the benefits of using EA in combination with conventional 
therapies in pain management. This model of EA may offer patients a method for reducing 
exogenous opioid consumption so that they can participate more effectively in pain 
management programmes.  
Further studies examining the effect of acupuncture on OLM reduction should consider the 
following issues:  
•  recruitment of a large sample of participants, preferably chronic pain sufferers from 
the general community;  
• to optimise  OLM consumption in terms of types and dose prior to the study;  
• to allow self-administration of acupuncture, such as transcutaneous electrical 
acupuncture stimulation (TEAS), so that participants can treat themselves at home and 
when needed; and  
• to include a qualitative study to understand patients’ needs, perception and judgement 
of the effectiveness of  outcomes.  
 
Further studies should also examine the role of acupuncture in comprehensive pain 
management programmes, such as with CBT, and compare the performance of patients with 
and without acupuncture in that environment.  
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8.APPENDICES 
8.1  Appendix 1: EA study pamphlet  
Volunteers with  
Chronic Pain 
Needed 
Study  
of Electro- Acupuncture  (EA) for 
Chronic Pain 
 
2004  
 
Chinese Medicine Research Group 
RMIT University  & 
The Barbara Walker Centre  
for Pain Management  
St. Vincent’s Hospital Melbourne 
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 Introduction 
Chronic pain is a common complaint. Many patients with severe chronic pain take pain 
medications, such as opioid-like drugs, for pain relief. These medications may produce side 
effects, which affect their quality of life.  
This study uses EA to scientifically evaluate whether EA reduces chronic pain, as well as 
reducing the consumption of pain medications and their side effects. 
The benefit of participating in the study is that your pain and well-being will be monitored 
closely ,and your pain may be alleviated as a result of treatment given to you.  
It is necessary to have a sham group so that the effect of EA treatment can be compared with 
inactive treatment.  
This means you have 50% chance to get into the active treatment group. 
 About the research  
Acupuncture is a clinical procedure in which very fine needles are used to stimulate specific 
locations on the body surface to achieve therapeutic effects. Acupuncture is a part of Chinese 
Medicine, and has been used clinically for more than 2,000 years. Its use in western countries has 
increased over the last three decades.  
The combination of acupuncture procedure with battery-operated electrical stimulation is called 
electro-acupuncture. This treatment method has been widely used in everyday practice for many 
years. 
Electro-acupuncture (EA) is reported to be beneficial and safe for various types of acute pain, 
(such as pain after operation, pain during labour, dental extraction pain), nausea and vomiting. 
EA has been shown to be effective in reducing consumption of pain medications for acute pain 
patients. It is therefore useful to investigate the effect of EA in reducing pain medication and 
related side effects in patients with chronic pain within a multidisciplinary setting.  
 Your involvements in the study 
If you agree to participate in the study, you will be asked to: 
• Visit the clinic twice a week  (3 days between the two visits) for six weeks to receive EA 
or sham treatments. Each session will last approximately 40 minutes. 
• During the initial and treatment periods (8 weeks), you will complete a daily record of 
pain medication consumption, related side effects, pain intensity and duration, which may 
take you 5 minutes every day. 
• During the 3 months follow up, attend the clinic monthly. Each visit may take up to 30 
minutes. 
• Provide us the name and dosage of medications prescribed by your medical doctor at the 
BWCPM. 
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 Chinese Medicine Research Group, RMIT University and Barbara 
Walker Centre for Pain Management, St. Vincent’s Hospital are 
conducting a research project to evaluate the effect of electrical acupuncture on 
reducing the consumption of pain medication and pain in patients with chronic pain.  
 If you meet the following conditions, please contact us: 
• Aged between 18 and 80; 
• Suffering from non-cancer pain over more than 3 months and using opioid-like 
drugs for pain control;  
• No pprevious experience with acupuncture (in the last 5 yrs) ; 
• Have not yet undergone cognitive-behavioral therapy program; 
• No heart disease; 
• Not pregnant. 
 Research Team members: 
Jessica Run Xiang Guo 
BMed (Registered Acupuncturist, RMIT University) 
Professor Robert Helme 
FRACP, PhD (Consultant Neurologist, Barbara Walker Centre for Pain Management, St. 
Vincent’s Hospital , Melbourne) 
Dr Zhen Zheng  
BMed, PhD (RMIT University) 
A/Prof. Charlie Xue 
BMed, PhD (RMIT University) 
 If you are interested in this study, please discuss it with your doctor, 
psychologist, physiotherapist, or nurse.  
 If you would like further information, please contact: 
 
Jessica Guo  
Mobile: 0401 259 431  
Telephone: (03) 9288 4681 (Message only) 
Facsimile: (03) 9288 4660 
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8.2  Appendix 2: Invitation of patients on the waiting list to BWCPM 
 
 
Dear Patients, 
An Electro-Acupuncture Clinical Trial on Chronic Pain 
This letter is to inform you about an electro-acupuncture clinical trial on chronic pain, which 
is now being conducted at the centre.  
We understand that you are waiting for assessment at the Barbara Walker Centre for Pain 
Management (BWCPM). We are working with the Centre on a trial of electro-acupuncture, 
and agree that if people are waiting for the assessment and wish to try electro-acupuncture we 
will gladly provide treatment. 
Dr Jessica Guo, a registered acupuncturist and a research student from the RMIT University, 
conducts this trial. 
The trial attempts to evaluate the effect of electro-acupuncture on reducing pain medication 
and pain in chronic pain patients. If you are on pain medication, and you are interested in this 
trial, please make a phone call to 9925 6563 or 0401 259 431 or email: 
S3060693@student.rmit.edu.au to Dr. Jessica GUO.  
Upon receipt of your information, Dr Guo will contact you to arrange an appointment for a 
further assessment to confirm your suitability for this study.  
This is not part of the clinic assessment, you don’t need to pay for it, but please feel free to 
participate in this trial. You will be very welcome.   
I look forward to hearing from you  
Best Regards  
Yours sincerely, 
Jessica Guo     Dr Andrew Muir                                                     
Division of Chinese Medicine   Director, Barbara Walker Centre School of 
Health Science     for Pain Management   
RMIT University     St Vincent’s Hospital, Melbourne 
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8.3  Appendix 3: Expression of Interest 
2003/2005 Study of Electro-Acupuncture 
- Expression of Interest 
Dear Participants,  
Thank you for your interest in participating in the study of electro-acupuncture for chronic 
pain. Please find enclosed some information about the study. 
It contains a number of questions to be completed. Your answer will help us assess whether 
you are suitable to participate. 
In order to provide accurate information for this initial assessment, please read the 
information carefully prior to completing the forms on pages 1 and 2.  
Please return the completed Expression of Interest in the enclosed prepaid envelope. Upon 
receipt of your information I will contact you to arrange an appointment for further 
assessment to confirm your suitability for this research. 
I look forward to your participation and thank you for taking time to fill in this form. 
Yours Sincerely 
Jessica Guo 
Tel:  9925 6563 or 0401 259 431 
 
Family Name:  ____________ First name: ____________________ 
Date of birth:  _______________  
Male Female
 
Address: _____________________________________Postcode: 
Telephone No. (home): ______________Telephone No. (work): ____________   
Other Contact Person: _______________Address: __________________________________ 
Telephone No: (Home): ________________(work) ________________________
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1) How long have you had pain? 
 
2) Do you use any pain medication for pain control?   
      
Yes No
 
3) If Yes, Please tick (√) the pain medications you are taking at present. 
         
Anamorph
   
Dilaudid
  Durogesic    
Endone Panadeine Forte
 
Pethidine Hydrochloride
 
Kapanol Ordine
 
Physeptone
 
Panadeine
MS Contin OxyContin Proladone
Tramal  
         MS Mono
OxyNorm
  
Other
        
4) Do you plan to move during the next 6 months? 
             
Yes No
 
5) Can you visit the clinic twice a week for six weeks and monthly for three months?       
      
Yes No
 
6) Do you have a pacemaker?  
       
Yes No
 
7) Do you suffer from any heart disease? 
       
Yes
 
No
 
 If yes, Please give details: _____________________ 
8) Have you been diagnosed on epilepsy? 
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Yes No
 
9) Have you had acupuncture treatment in the last 5 years? 
       
Yes
 
No
 
If yes, when was the last acupuncture treatment you had?     _____________________ 
10) Have you had been through a multidisciplinary therapy program before? 
       
Yes
 
No
 
11)  Are you willing and able to participate in the study? 
       
Yes No
 
12) Are you currently participating in any research? 
            
Yes No
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8.4  Appendix 4: Screening questionnaire   
Part 1: PATIENT INFORMATION QUESTIONNAIRE  
 
Date completed:            
1. (Please circle one) Mr / Mrs / Miss / Ms / Other (Please specify):    
  
2. Surname:            
3. Other names:            
4. Address:        Postcode:    
5. Previous address (if you have moved within the last 5 years):      
        Postcode:    
6. Telephone: (H)       (W)     
7. Have you been to this hospital before? YES / NO (Please circle one) 
 If YES, please indicate your UR No. (if known):       
8. Medicare No.:           
9. Date of birth:            
10. Country of birth:           
11. Are you of Aboriginal and/or Torres Strait Island descent? YES / NO (Please circle 
one) 
 If YES, please tick one:       Aboriginal and Torres Strait 
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                                  Aboriginal not Torres Strait 
                                 Torres Strait 
12. Are you an Australian citizen or permanent resident?  YES / NO (Please circle 
one) 
 If NO, please give details:         
13. Do you need an interpreter? YES / NO (Please circle one) 
 Please list all the languages you speak:        
14. Name of your General Practitioner:         
 Address:       Postcode:    
 Telephone:       Fax:     
15. Name of your Consulting Specialist Doctor (most recently seen):     
            
 Address:       Postcode:    
 Telephone:       Fax:     
16. Are you on a Pension? YES / NO (Please circle one) 
 If YES, please indicate your Pension No.:        
17. Do you have private health cover? YES / NO (Please circle one) 
 If YES, please indicate: Name of fund:      
  
Membership No.:          
18. Is this visit related to (please tick one):  
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     a Workers’ Compensation claim? 
    a Third Party Accident Compensation claim? 
    some other legal case? 
    none of the above? 
19. If you answered “none of the above” in Question 18, move on to Question 21. 
 Otherwise, please indicate who is primarily responsible for your accounts? 
(please tick one)       Employer     Solicitor / Lawyer     
Insurer 
 Please provide the following details: 
 (a) Name of Employer:         
 Address:       Postcode:    
 Telephone:       Fax:     
 (b) Name of Solicitor / Lawyer:         
 Address:      Postcode:    
 Telephone:       Fax:     
 (c) Name of Insurer:          
 Address:      Postcode:    
 Telephone:       Fax:     
 Claim No.:           
20.  (a) Has your compensation been settled? YES / NO (Please circle one) 
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 (b) If you received compensation, was it satisfactory? YES / NO (Please circle 
one) 
(c) If your case has not been settled, when do you think it will be settled? (please tick 
one):    
    in the next 6 months    in the next 12 months 
  in the next 1-2 years    more than 2 years   no idea 
21. What is your marital status? (please tick one): 
   Married     Single    Separated     Divorced 
   De facto     Widowed 
 Spouse’s / Partner’s name:         
22. How many children do you have?   How old are your children?   
  
23. Do you live … (please tick one):  
   alone ?       with spouse / partner and child / children ? 
   with spouse / partner only ?                 with child / children only ? 
   with other relatives ?     with friends / housemates ? 
24. What is your highest level of education? (please tick one): 
   University      CAE      TAFE 
   HSC      Year 11 / Leaving Cert    Year10 / SC 
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    Year9 / Intermediate    Less than Year 9    Other (please 
specify): 
                         
       25. For how long have you lived in Australia? (please tick one): 
   All my life     More than 10 years  
   Between 6 & 10 years    Between 2 & 5 years    
   Less than 2 years 
26. What is / was your main occupation before your pain / injury? 
             
27. What is your current work status? (please tick one): 
   Full time work    Part time work    Voluntary work    Home duties
    Retired     Student    Unemployed due to pain    
Retraining 
   Unemployed due to other reasons (please specify):     
28. What is your current source of income? (please tick all that apply): 
   Workers’ Compensation insurance      Sickness Benefits 
   Age Pension       Invalid Pension 
   Wages / Salary       Spouse’s / Partner’s earnings 
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    Unemployment Benefits      Supporting Parents Benefits 
   Superannuation payments      Savings / Investments 
   Other (specify):           
Questions 29 to 34 are concerned with paid work. 
29. If you are working, is your work restricted due to pain? 
YES / NO / NOT APPLICABLE (Please circle one) 
30. If you are working, how much time have you taken off work due to pain in the last year? 
  months /   weeks / NOT APPLICABLE 
31. If you are not working (and you are not retired), how long is it since you last worked? 
    months /   weeks / NOT APPLICABLE 
32. If you are not working now, do you have a job to go back to? 
YES / NO / NOT APPLICABLE (Please circle one) 
33. If you are not working now, have you attempted to return to work in the last year? 
YES / NO / NOT APPLICABLE (Please circle one) 
If YES, how long did it last? 
(If you returned to work more than once, what was the longest period?) (please tick 
one): 
   Less than 1 week     3 - 6 months    1 - 4 weeks 
   7 months – 1 year     5 – 12 weeks    More than 1 year 
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34. If you are not working now, and you would like to return to work, do you feel you are 
currently able to work at your regular job? (please tick one): 
 As much as I could prior to my pain / injury 
 Only with reduced hours 
     Only with reduced hours and a lot of help 
    In my present condition I can’t work at all 
    Not applicable 
35. Do you know anyone with chronic (long term) pain problems? YES / NO (Please circle 
one) 
 If YES, please describe the nature of their relationship with you (e.g. father, mother, 
friends, colleagues, etc.):           
36. Do you know anyone with chronic (long term) illness which does not involve chronic 
pain? 
YES / NO (Please circle one) 
 If YES, please describe the nature of their relationship with you (e.g. father, mother, 
friends, colleagues, etc.):           
37. Have you ever smoked regularly? YES / NO (Please circle one) 
If you are still smoking regularly, how many cigarettes do you smoke in a normal day?  
  
38. Do you drink alcohol regularly?  YES / NO (Please circle one) 
If YES, (a) on how many days in a week do you usually have a drink?    
   
(b) roughly, how many drinks do you usually have on these days?    
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(c) do you ever drink alcohol to relieve your pain? YES / NO (Please circle one) 
39. How many cups of tea do you drink per day?       
  
40. How many cups of coffee do you drink per day?       
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Part 2: PAIN HISTORY 
 
1. Please describe the pain problem that brings you to the clinic. 
 
___________________________________________________________________________ 
__________________________________________________________________________ 
___________________________________________________________________________ 
2. Please indicate with an X on these figures where your main pain is.  Shade any area where 
your pain spreads.  Please number (2, 3, 4, etc) any other areas where you have pain. 
 
 
  
174 
3. When did your pain first start?  Please be as exact as possible. 
 
DAY [  ] MONTH [  ] YEAR [  ] 
4. If your pain comes and goes, when did the present episode of pain start?  (Answer this 
only if different from Question 1.) 
DAY [  ] MONTH [  ] YEAR [  ] 
5. How did your pain begin?  (tick ONE; if more than one applies, tick the one which applies 
BEST) 
1 [   ] Accident at work 
2 [   ] At work, but not involving an accident 
3 [   ] Accident at home 
4 [   ] Car accident 
5 [   ] After surgery 
6 [   ] After an illness 
7 [   ] Pain just began, no clear reason 
8 [   ] Other reason/s (please describe) 
______________________________________________ 
6. Which statement best describes your pain? (If none is exactly like your pain, please tick 
the closest statement) 
1 [   ] Always present, always the same intensity 
2 [   ] Always present, intensity varies 
3 [   ] Usually present, but have short periods without pain 
4 [   ] Often present, but have pain-free periods lasting up to several hours 
5 [   ] Often present, but am pain-free for much of the day 
6 [   ] Occasionally present for brief periods, but not every day 
7 [   ] Rarely present – have pain episodes every now and then, with days or weeks in 
between 
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7. What makes your pain worse? (you may tick more than one) 
 
sitting  household chores cold weather  sex 
standing  everything  hot weather  stress 
lying-down loud noise  wet weather  tension 
lifting  working  weather changes driving 
bending  any movement walking  going up/down stairs 
no clear reason  
Other (please describe) 
__________________________________________________________ 
8. What makes your pain better? (you may tick more than once) 
 
sitting   watching TV  cold weather  sex 
standing  working  hot weather  alcohol 
lying-down warm/hot bath  pressure  rest 
stretching  warm/hot shower massage/rubbing nothing 
relaxing  tablets   walking  being with other people 
reading  hot/cold packs  keeping busy  keeping my mind off pain 
sleep 
Other (please describe) 
__________________________________________________________ 
 
9. Please rate the intensity of your pain by circling a number on the following scales.   
For every question: 0 = “no pain at all” and 10 = “worst pain imaginable” 
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(a) How intense is your pain at this moment? 
 
0 1 2 3 4 5 6 7 8 9 10 
No pain                 Worst pain  
                 imaginable 
(b) What were the highest and lowest levels of your pain in the last week? (make 2 
circles) 
 
0 1 2 3 4 5 6 7 8 9 10 
No pain                 Worst pain  
                 imaginable 
(c) What was the usual level of pain in the last week? 
 
0 1 2 3 4 5 6 7 8 9 10 
No pain                   Worst pain  
                   imaginable 
10. Some of the words below describe your present pain.  Underline only those words which 
best describe it.  Use only one word in each group.  If more than one word in a group 
describes your pain, choose the one that describes it best.  If no words in a group describe 
your pain, leave it and go on to the next one. 
 
1 
flickering 
quivering 
pulsing 
throbbing 
beating 
pounding 
 
2 
jumping 
flashing 
shooting 
3 
pricking 
boring 
drilling 
stabbing 
lancinating 
4 
sharp 
cutting 
lacerating 
5 
pinching 
pressing 
gnawing 
cramping 
crushing 
6 
tugging 
pulling 
wrenching 
7 
hot 
burning 
scalding 
searing 
8 
tingling 
itchy 
smarting 
stinging 
9 
dull 
sore 
hurting 
aching 
heavy 
 
10 
tender 
taut 
rasping 
splitting 
11 
tiring 
exhausting 
12 
sickening 
suffocating 
13 
fearful 
frightful 
terrifying 
14 
punishing 
gruelling 
cruel 
15 
wretched 
blinding 
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vicious 
killing 
 
16 
annoying 
troublesome 
miserable 
intense 
unbearable 
17 
spreading 
radiating 
penetrating 
piercing 
18 
tight 
numb 
drawing 
squeezing 
tearing 
19 
cool 
cold 
freezing 
20 
nagging 
nauseating 
agonising 
dreadful 
torturing 
 
11. MEDICATION 
 
(a) Do you think you need more medication, or stronger medication, than you are currently 
taking? 
To answer, circle one of the numbers on the scale below. 
1 2 3 4 5 
        Agree 
strongly 
Agree Unsure Disagree Disagree 
strongly 
 
(b) Please list all of the medications you are taking at present: 
 
Medication Dose How Often? Any side effects? Date started 
     
     
     
     
     
     
 
Please list all the medications you have taken in the past for your pain: 
Medication Dose How Often? Any side effects? Comments  
     
     
     
     
     
     
     
     
     
 
(d) Please list any allergies you may have:  
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………………………………………………………………………………………………… 
………………………………………………………………………………………………… 
12. Since your pain began, which of the following people have you seen about it? 
 
1 [   ] acupuncturist 
2 [   ] anaesthetist 
3 [   ] chiropractor 
4 [   ] homeopath 
5 [   ] hypnotherapist 
6 [   ] neurologist 
7 [   ] neurosurgeon 
8 [   ] occupational therapist 
9 [   ] orthopaedic surgeon 
     10[   ] physiotherapist 
     11[   ] psychologist 
     12[   ] psychiatrist 
     13[   ] rheumatologist 
     14[   ] pain clinic 
     15[   ] general practitioner 
     16[   ] other/s (please specify) 
…………………………………………………………………… 
13. Which of the above have you found helpful so far? 
 
………………………………………………………………………………………………… 
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14. Based on your experiences so far, what do you realistically expect will happen to your 
pain in the coming months? (TICK ONE) 
 
1 [   ] It will get worse 
2 [   ] It will not change 
3 [   ] It will be reduced by 25% 
4 [   ] It will be reduced by 50% 
5 [   ] It will be reduced by 75% 
6 [   ] It will be completely relieved or cured 
15. If your pain could be reduced, but not completely, how much of a reduction would there 
need to be for you to feel you could live with it? 
 
My pain would need to be reduced by ________% for me to be able to live with it. 
16. Do you think that your pain may be due to a serious disease which your doctors have not 
found or have not told you about? (Circle one) 
 
YES / NO / NOT SURE 
 Are there any questions you would like answered after your assessment at this pain 
clinic? 
(please write) 
…………………………………………………………………………………….…… 
…………………………………………………………………………………………………
……… 
17. TIME LINE 
List by year (starting at childhood) all illnesses and operations you have had since childhood. 
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YEAR OPERATIONS (Surgical) 
(eg. cervical fusion) 
YEAR ILLNESSES (Medical) 
(eg. measles, diabetes) 
    
    
    
    
    
 
 
Thank you for completing this questionnaire.  It will help us to understand your pain problem. 
Finally, for a full assessment and applicable treatment, we need to be able to liaise with your 
treating practitioners, and where applicable, your legal and insurance representatives. Thus we 
ask you to sign the following consent: 
I give permission for the health professionals of the Barbara Walker Centre for Pain 
Management to discuss my pain problem with other professionals, and to receive information 
that is relevant to my pain management. 
Signature: __________________________________ 
Witness:  __________________________________ 
Date:   __________________________________  [   ]    [   ] 
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8.5  Appendix 5: Advertisement to website of SVH 
 
VOLUNTEERS NEEDED 
An acupuncture trial for patients with chronic pain is being conducted at the Barbara Walker 
Centre for Pain Management (BWCPM), St Vincent’s Hospital, Melbourne. This trial aims to 
reduce opioid-like medications consumption.  
This study has been approved by Human Research Ethics Committees of St. Vincent’s 
Hospital and the RMIT University. Please note that this is a research project, and not a 
clinical service provided by the BWCPM.   
The study expects to recruit patients who are suffering from non-malignant pain present for 
over 3 months and who are using opioid-like medication for pain control. Subjects must have 
had no experience of electrical acupuncture within the previous six months. 
We would appreciate it if you can refer appropriate patients to the study.  
For further information, please contact Ms Jessica Guo on 9925 6563 or 0401 259 431, or 
email: s3060693@student.rmit.edu.au  
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8.6  Appendix 6: Invite Medical Doctors at SVH to refer patients 
 
Dear Dr.  
We are writing to inform you of an electro-acupuncture clinical trial for patients with chronic 
pain, which is being conducted at the Barbara Walker Centre for Pain Management. This 
study has been approved by Human Research Ethics Committees of the St. Vincent’s Hospital 
and the RMIT University.  
This trial is a randomized, single blind and sham controlled acupuncture study. It is evaluating 
the effect of electro-acupuncture on reducing pain and pain medication in patients with 
chronic pain. The patients will receive 12 sessions of treatments in a period of six weeks, and 
will be followed up monthly for three months.  
This trial is neither a part of the clinic assessment, nor a treatment provided by the BWCPM. 
It is a research project to help better understand the use of electro-acupuncture in pain 
management. 
We would appreciate if you or your staff could refer any suitable patients to the study. We 
have attached a brochure regarding this study for your use and /or for display in the waiting 
room of your clinic.  
If you would like any further information about this study, please don’t hesitate to contact 
Jessica Guo on 9925 6563 or 0401 259 431, or by email: s3060693@student.rmit.edu.au.  
Jessica Guo (B.Med) is a Registered Acupuncturist and a Student Researcher from the 
Division of Chinese Medicine, School of Health Sciences, RMIT University. 
Yours sincerely, 
 
Professor Robert Helme       Dr Andrew Muir   
Consultant Neurologist     Director, Barbara Walker Center  
Principal Researcher     for Pain Management   
Barbara Walker Center              St. Vincent’s Hospital, Melbourne 
for Pain Management      
St Vincent’s Hospital, Melbourne  
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8.7  Appendix 7: Advertisement sent to GPs 
VOLUNTEERS NEEDED 
A randomised placebo controlled acupuncture trial for patients with chronic pain is being 
conducted at the Barbara Walker Centre for Pain Management (BWCPM), St Vincent’s 
Hospital, Melbourne. This trial aims to reduce opioid-like medications consumption.  
This study has been approved by Human Research Ethics Committees of St. Vincent’s 
Hospital and the RMIT University. Please note that this is a research project, and not a 
clinical service provided by the BWCPM.   
The study expects to recruit patients who are suffering from non-malignant pain present for 
over 3 months and who are using opioid-like medication for pain control. Subjects must have 
had no experience of electrical acupuncture within the previous six months. 
We would appreciate it if you can refer appropriate patients to the study.  
For further information, please contact Ms Jessica Guo on 9925 6563 or 0401 259 431, or 
email: s3060693@student.rmit.edu.au  
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8.8  Appendix 8: Subject Diary  
 
Subject  Diary 
 
Please circle the relevant week 
  
Pre-treatment:         Week   1 2       
During treatment:   Week   1 2 3 4 5 6    
Post treatment:        Week    4 8 12 
Period:    From           /           /             to       /        / 
 
Please complete Four Forms: 
Form 1   Pain Intensity (VAS) 
Form 2    Pain medications Taken 
Form 3   Side Effects of Pain Medications                        
Form 4   Report of Adverse Event 
We hope and expect 
you will be able to reduce your 
opioid medications during the study 
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Explanation on how to use the Subject Diary 
Welcome to the study. Please complete this diary, as it is a very important part of the 
assessment.  
Your Diary gives us information about  
• the dosage of pain medications you are taking 
• the severity of related side effects  
• the amount of pain you are experiencing and 
• aspects of your life which may be affected by the pain  
 
Please take 5 minutes each day to fill in the diary, and do so at the end of the day. 
Please only rate the intensity and unpleasantness of the pain for which you are referred to 
Barbara Walker Centre for Pain Management.   
When you finish a one-week assessment, please check whether you have filled in the date and 
your name. Return it to the Barbara Walker Centre for Pain Management, St. Vincent’s 
Hospital when you come for treatment. 
The data collected may be published as group data, and no personal information will be 
identified.  
Thanks for your co-operation. 
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The following are examples of how to use the scale enclosed and how to record the pain 
medication doses on Form 2. 
For example, if you draw a line on the scale, the distance from 0 to the line is 3.5 cm, which 
means your pain is 3.5 out of 10.  
1) How intense is your pain at this moment? 
            
         0                                                                                           10 
         No pain                                                                                 worst pain  
         At all                                                                        imaginable 
 If you draw a line from 6: 50 am to 9:10 pm, which means your pain never stops 
during this period time. You may use more than one line over the 24hrs, if you need to. 
4) When did you feel the pain today? 
               
     6am   8am    10am   12pm 2pm  4pm   6pm   8pm    10pm   12am  2am   4am  6am 
Pain Medication Taken       Form 2 
Please put the number associated the pain medications in the related columns (see the 
listed of pain medications below).  
Date 
０５／０５／０４ 
Medication 
１３ 
Medication 
15 
Medication 
17 
Medication 
18 
Medication 
Time Doses Taken Doses Taken Doses Taken Doses Taken Doses Taken 
1-2 am      
3-4 am      
5-6 am    100 mg  
7-8 am ５mg 5 mg 500 mg   
9-10 am      
11am-12 pm      
1-2 pm   500 mg   
3-4 pm      
5-6 pm    100 mg  
7-8 pm 10 mg     
9-10 pm      
11am-12 pm      
Total 15 mg 5 mg 1000 mg 200 mg  
List of Pain Medications: 
1. Anamorph            2. Dilaudid          3. Durogesic           4. Pethidine Hydrochloride  
5. Endone                  6.  Ordine                7. Physeptone         8. Panadeine Forte 
9. Kapanol                10. OxyContin        11. Proladone         12. Panadeine 
13. MS Contin          14.OxyNorm          15. Tramal               16. MS Mono          
17.Others    Aspirin__________18.Celebrex                        
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         Form 1 Day 1-7 
 
(The participants were asked to fill out this sheet daily for seven days) 
Pain Intensity (VAS) 
1) How intense is your pain at this moment? 
      
 
      
         
                                  0 No pain                                                                                                       10 worst pain  
                                            at all                                                                                     imaginable 
 
2) What are the highest and lowest levels of your pain today? 
 
          
                                     0 No pain                                                                                                   10 worst pain                                                                                   
at all                                                                                                                 imaginable 
 
3) What is the average level of pain today? 
  
          
                                      0 No pain                                                                                                  10 worst pain                                                                                                               
at all                                                                                                               imaginable 
 
4) When did you feel the pain today? 
               
         6am     8am     10am    12pm    2pm     4pm      6pm    8pm     10pm    12am   2am     4am     6am 
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Pain Medication Taken      Form 2 
Please put the number associated the pain medications in the related columns (see the 
listed pain medications below).  
Date   Medication Medication Medication Medication Medication 
Time Doses Taken Doses Taken Doses Taken Doses Taken Doses Taken 
1-2 am      
3-4 am      
5-6 am      
7-8 am      
9-10 am      
11am-12 pm      
1-2 pm      
3-4 pm      
5-6 pm      
7-8 pm      
9-10 pm      
11pm-12 am      
Total      
List of Pain Medications: 
1. Anamorph            2. Dilaudid          3. Durogesic           4. Pethidine Hydrochloride  
5. Endone                  6.  Ordine             7. Physeptone         8. Panadeine Forte 
9. Kapanol                10. OxyContin    11. Proladone          12. Panadeine 
13. MS Contin          14.OxyNorm      15. Tramal                16. MS Mono         17. Others___________  
5) How strong is the average level of your pain 
today? 
 
6) How unpleasant is the average level of your 
pain today? 
20  20  
19  19  
18   EXTREME INTENSE 18  
17   VERY INTENSE 17   VERY INTOLERABLE 
16   INTENSE  16   INTOLERABLE 
15   STRONG 15   
14  14   VERY DISTRESSING 
13   SLIGHTLY INTENSE 13   SLIGHTLY INTOLERABLE 
12   BARELY STRONG 12   VERY ANNOYING 
11   MODERATE 11   DISTRESSING 
10  10   VERY UNPLEASANT 
9  9   SLIGHTLY DISTRESSING 
8   MILD 8   ANNOYING 
7  7   UNPLEASANT 
6   VERY MILD 6   SLIGHTLY ANNOYING 
5   WEAK 5   SLIGHTLY UNPLEASNAT 
4   VERY WEAK 4  
3  3  
2  2  
1   FAINT 1  
   NO PAIN SENSATON 0   NEUTRAL 
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Form 3 
 
Side Effects of Pain Medication 
(Fill in this form at the end of the week) 
The severity of each symptom is defined by the scale below (0 = no symptom; 10 =very 
severe symptoms). Please indicate your response. 
1. Nausea    
          
         0 (No symptom at all)                                                        10 (Very severe) 
2.     Vomiting 
          
         0 (No symptom at all)                                                        10 (Very severe) 
3.      Dizziness 
          
         0 (No symptom at all)                                                        10 (Very severe) 
4. Fatigue   
          
         0 (No symptom at all)                                                        10 (Very severe) 
5.      Drowsiness 
          
         0 (No symptom at all)                                                        10 (Very severe) 
6. Blurring of vision  
          
         0 (No symptom at all)                                                        10 (Very severe) 
7. Sedation  
          
        0 (No symptom at all)                                                         10 (Very severe) 
8. Lethargy 
          
         0 (No symptom at all)                                                        10 (Very severe) 
9. Anxiety 
          
         0 (No symptom at all)                                                        10 (Very severe) 
10. Nightmares 
          
         0 (No symptom at all)                                                        10 (Very severe) 
11. Constipation 
          
        0 (No symptom at all)                                                         10 (Very severe) 
12.    Other (please describe) 
          
        0 (No symptom at all)                                                         10 (Very severe) 
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Form 4 
Report of Adverse Events for Acupuncture 
(Fill in this form at the end of the week) 
(Completed by patients) 
Please record any unexpected symptoms during your acupuncture treatment or after your 
treatment. You don’t need to fill in the form if you don’t have any discomfort, you still 
need to return this to us even it is not filled.  
 
Impact on your life 
Type of 
Event 
Date 
How long 
does it 
last 
Not at 
all 
(0) 
 
Minimal 
(1) 
 
Mild  (2) 
 
Moderate 
(3) 
 
Severe (4) 
Extremely 
Severe 
(5) 
How do 
you 
manage it? 
 
Fainting 
         
 
Infection 
         
 
Dizziness 
         
 
Bruising 
         
 
Pain 
         
 
Lethargy 
         
 
Others 
         
 
 
         
 
 
         
          
 
  
191 
8.9  Appendix 9: Perception of EA treatment 
 
Perception of EA treatment 
1) Do you think your treatment is effective? 
              Yes No  
2) Do you think you are in the real acupuncture treatment group? 
Yes No  
3) Would you like to pay for the service in the future? 
             Yes No  
4) Would you like to refer acupuncture to your friends when they suffer pain? 
              Yes No  
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8.10  Appendix 10: Participant Information 
 
ST. VINCENT’S HOSPITAL 
PARTICIPANT INFORMATION  
Version: Two  
Dated: 15 March 2004 
Site:  St. Vincent’s Hospital, Melbourne  
NAME OF PARTICIPANT: 
U.R.NO: 
FULL PROJECT TITLE: The effect of electro-acupuncture on reducing pain medication 
consumption in patients with chronic pain 
Principal Researcher:  Prof. Robert D Helme  
Associate Researcher(s):  Dr. Zhen Zheng  
                                          A/Prof. Charlie Xue  
Research student:   Jessica Run Xiang Guo 
 
This Participant Information and Consent Form is 8 pages long. Please make sure you have all 
the pages.  
1. Your Consent 
You are invited to take part in this research project.  
This Participant Information contains detailed information about the research project. Its 
purpose is to explain to you as openly and clearly as possible all the procedures involved in 
this project before you decide whether or not to take part in it.  
Please read this Participant Information carefully. Feel free to ask questions about any 
information in the document.  You may also wish to discuss the project with a relative or 
friend or your local health worker. Feel free to do this. 
Once you understand what the project is about and if you agree to take part in it, you will be 
asked to sign the Consent Form. By signing the Consent Form, you indicate that you 
understand the information and that you give your consent to participate in the research 
project. You are free to withdraw at any time but your data will be retained because it is 
necessary for the validity of this project. 
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You will be given a copy of the Participant Information and Consent Form to keep as a 
record. 
2. Purposes and Background 
The purpose of this project is to examine whether electro-acupuncture reduces chronic pain, 
as well as reducing the dosage of pain medications, in particular, opioid-like medications, and 
their related side effects. 
Many patients with severe chronic pain take strong pain medications, such as opioid-like 
medications, for pain relief. These medications may produce side effects, which affect their 
quality of life.  
Acupuncture is a clinical procedure, in which very fine needles are used to stimulate specific 
locations on the body surface to achieve therapeutic effects. Acupuncture is a part of Chinese 
Medicine, and has been used clinically for more than 2,000 years. Its use in western countries 
has increased over the last three decades. The combination of acupuncture procedure with 
battery-operated electrical stimulation is called electro-acupuncture. This treatment method 
has been widely used in everyday practice for a number of decades.  
Electro-acupuncture (EA) is reported to be beneficial and safe for various types of acute pain, 
such as pain after operation, pain during labour, dental extraction pain, nausea and vomiting, 
and has been shown to reduce the consumption of pain medications in acute pain patients. It is 
therefore useful to investigate the effect of EA in reducing pain medication dosage and their 
related side effects in patients with chronic pain within a multidisciplinary setting.  
The device is an acupuncture stimulator manufactured by the Meyer Medical Electronics. It 
has a width of 205 mm, length 175 mm and height 80 mm and consists of a black plastic box 
and 4 pairs of metal stimulator clips. This instrument will be used to stimulate acupoints with 
electrical pulses via stimulator leads. 
The electrical stimulation machine to be used in this study is a modified version of an EA 
machine that has not been approved for marketing by the Therapeutic Goods Administration 
(TGA) of Australia and therefore its use in this study is experimental.  
A total of 120 people will participate in this project. 
You are invited to participate in this research project because you suffer from chronic pain 
and take pain medications including opioid-like medication for pain relief.  This trial has been 
initiated by the above mentioned researchers.  
The results of this research project will be used to help researcher Ms Jessica Run Xiang Guo 
to obtain the degree of Master of Applied Sciences (Chinese Medicine) from the RMIT 
University.   
3. Procedures 
Participation in this project will involve a two-week initial monitoring and measurements, a 
six-week treatment and a twelve-week follow up. You will be asked to: 
 Visit the clinic twice a week (3 days between visits) for six weeks to receive electro-
acupuncture or sham treatments. Each treatment will last for 25 minutes. 
 Complete a daily record of pain medication consumption and related side effects, pain 
intensity and duration, which may take you 5 minutes daily for 6 weeks. 
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 Attend the clinic monthly, for three months, for follow-up appointments. Each 
appointment may take 30 minutes.  
 Allow us to obtain the name and dosage of medications prescribed by your medical 
doctor at the Barbara Walker Centre for Pain Management.  
It is necessary to have an inactive treatment group who will receive sham acupuncture, so that 
the true effect of electro-acupuncture treatment can be demonstrated. Sham acupuncture is a 
form of placebo treatment with minimal effect on your body. It is used to show whether the 
real treatment has a true effect. Once you have met the inclusion and exclusion criteria, you 
will be allocated randomly into one of the two groups (using real or sham acupuncture). 
Please note that you will have a 50% chance of being placed in an inactive treatment group. 
However, acupuncture in this project is not intended to replace any other therapy. 
In both treatment groups, six to ten needles for each treatment will be inserted. The area of 
insertion will depend on the location of pain and Chinese Acupuncture theory.  
Needles may be inserted in legs, arms, trunk or scalp, and then an electrical stimulator will be 
connected to the needles. 
Project will be conducted at Barbara Walker Centre for Pain Management, St. Vincent’s 
Hospital, Melbourne. 
4. Possible benefits  
The benefit of participating in the study is that your pain and well-being will be monitored 
closely, and your pain may be alleviated as a result of treatment given to you. 
We cannot guarantee or promise that you will receive benefit from this project. 
5. Possible Risks 
Possible risks, side effects and discomfort may be associated with the electro-acupuncture 
procedure.  
Acupuncture has been reported to be associated, in a very few cases, with minor risks, such as 
fainting, infection, and minor bruising, as needles may puncture small blood vessels during 
the procedure. Precautions will be taken to avoid inserting needles too deeply or into nerves, 
arteries or internal organs. There is no evidence that acupuncture treatment may result in 
psychological damage. Only disposable needles will be used and they are much thinner than 
needles used for injection. The acupuncturist is a registered practitioner with the Chinese 
Medicine Registration Board of Victoria. 
Electro acupuncture is widely used in everyday practice with an excellent safety profile. EA 
provides stronger stimulation than regular acupuncture. In a very few cases, therefore, fainting 
may happen if some people have an enhanced response to acupuncture treatment. Bending of 
needles can also happen if you alter posture too much during the treatment or if muscle 
contraction is too strong as a result of strong electrical stimulation. Caution will be taken to 
avoid such risks. In addition, any electrical current when passed through a human body may 
interfere with the human electromagnetic field. For this reason, people who have severe heart 
diseases, epilepsy or wear a pacemaker are not suitable for electro acupuncture. If you have 
any of the above-mentioned conditions, you will be excluded from the study.  
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Some people may experience minor pricking sensations during initial treatment with electro 
acupuncture. This normally is reduced in later treatment.  
The effects of electro acupuncture on the unborn child and on the newborn baby are not 
known.  Because of this, it is important that study participants are not pregnant or breast-
feeding and do not become pregnant during the first six weeks of the study. You must not 
participate in the study if you are pregnant or trying to become pregnant, or breast-feeding. If 
you do become pregnant whilst participating in the study you should advise the principal 
researcher immediately. He/she will withdraw you from the study. You must not continue in 
the study if you become pregnant.  
There may be additional unforeseen or unknown risks. 
6. Other Treatments Whilst on Study 
It is important to tell your doctor and the research staff about any treatments or medications 
you may be taking, including non-prescription medications, vitamins or herbal remedies and 
any changes to these during your participation in the study. 
7. Alternatives to Participation 
The electro-acupuncture procedure is a potential alternative to pain medications, in 
particularly opioid-like medications. In this research project, patients will able to continue 
with their routine therapies. 
8. Privacy, Confidentiality and Disclosure of Information 
Patients’ personal information and other relevant data will be stored in a password protected 
computer program. Only researchers involved in the project have the access to the data. The 
information will be retained by the RMIT University for 15 years. At the end of the period, 
the documents will be destroyed according to the University’s document disposal procedure.  
Any information obtained in connection with this research project that can identify you will 
remain confidential and will only be disclosed with your permission, except as required by 
law. If you give us your permission by signing the Consent Form, we plan to share the results 
with others researchers through conferences and publications in academic journals.  
Your health records and any information obtained during the study are subject to inspection 
(for the purpose of verifying the procedures and the data) by the Australian Government’s 
Therapeutic Goods Administration (TGA) and authorised auditors or representatives from the 
sponsor, St Vincent’s Hospital, Melbourne or as required by law. By signing the Consent 
Form, you authorise release of, or access to, this confidential information to the relevant study 
personnel and regulatory authorities as noted above.  
In any publication, information will be provided in such a way that you cannot be identified.  
9. New Information Arising During the Project 
During the research project, new information about the risks and benefits of the project may 
become known to the researchers. If this occurs, you will be told about this new information. 
This new information may mean that you can no longer participate in this research. If this 
occurs, the person(s) supervising the research will stop your participation. In all cases, you 
will be offered all available care to suit your needs and medical condition. 
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10. Results of Project 
The participants will be informed of the summary of the results in writing when the research 
project is completed. 
11. Further Information or Any Problems 
If you require further information or if you have any problems concerning this project (for 
example, any side effects), you can contact the researcher Ms Jessica Guo. The researchers 
responsible for this project are Ms Jessica Guo on 0401 259 431 or E-mail 
s3060693@student.rmit.edu.au, and Prof Robert Helme on 9288 4681. 
12. Other Issues 
If you have any complaints about any aspect of the project, the way it is being conducted or 
any questions about your rights as a research participant, then you may contact the Patient 
Representative at St Vincent’s Hospital on 9288 2211, or the Secretary of the Human 
Research Ethics Committee at the St Vincent’s Hospital on 9288 3930, or the Secretary, 
RMIT Human Research Ethics Committee, University Secretariat, RMIT, GPO Box 2476, 
Melbourne, 3001. Tel: 9925 1745.  
You will need to tell the secretary the name of one of the researchers given in section 11 
above.  
13. Participation is Voluntary 
Participation in any research project is voluntary. If you do not wish to take part you are not 
obliged to. If you decide to take part and later change your mind, you are free to withdraw 
from the project at any stage.  
Your decision whether to take part or not to take part, or to take part and then withdraw, will 
not affect your routine treatment, your relationship with those treating you or your 
relationship with the pain management clinic. 
You are free to withdraw from this study at any stage but your data will be retained because it 
is necessary for the validity of this project.  
Before you make your decision, a member of the research team will be available so that you 
can ask any questions you have about the research project. You can ask for any information 
you want. Sign the Consent Form only after you have had a chance to ask your questions and 
have received satisfactory answers. 
If you decide to withdraw from this project, please notify a member of the research team 
before you withdraw. This notice will allow that person or the research supervisor to inform 
you if there are any health risks or special requirements linked to withdrawing. 
14. Reimbursement for your costs 
You will not be paid for your participation in this trial.  
15. Ethical Guidelines 
This project will be carried out according to the National Statement on Ethical Conduct in 
Research Involving Humans (June 1999) produced by the National Health and Medical 
Research Council of Australia. This statement has been developed to protect the interests of 
people who agree to participate in human research studies. 
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The ethical aspects of this research project have been approved by the Human Research 
Ethics Committees of RMIT University and St. Vincent’s Hospital, Melbourne.  
16. Injury 
In the event that you suffer an injury as a result of participating in this research project, 
hospital care and treatment will be provided by the public health service at no extra cost to 
you. 
17. Termination of the Study 
This research project may be stopped for a variety of reasons. These may include 
unacceptable side effects, the procedure being shown not to be effective, and not needing 
further investigation.  
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8.11  Appendix 11: Consent Form 
 
St Vincent’s Hospital 
Consent Form 
 
Consent Form  
Version: Two  
Dated:    15 March 2004 
Site:      St Vincent’s Hospital, Melbourne 
 
Full Project Title: The effect of electro-acupuncture on reducing pain medication   
consumption in patients with chronic pain 
 
I have read, or have had read to me in my first language, and I understand the Participant 
Information version 2 dated 15 March 2004. 
I have had an opportunity to ask questions and I am satisfied with the answers I have 
received. 
I freely agree to participate in this project according to the conditions in the Participant 
Information.  
I will be given a copy of the Participant Information and Consent Form to keep. 
I understand that the researcher has agreed not to reveal my identity and personal details if 
information about this project is published or presented in any public form.   
 
Participant’s Name (printed) …………………………………………………… 
Signature        Date 
Name of Witness to Participant’s Signature (printed) ………………………………………   
Signature        Date 
I have given a verbal explanation of the research project, its procedures and risks and I believe 
that the participant has understood that explanation. 
Researcher’s Name (printed): Jessica Guo ……………………………………..…… 
 
Signature          Date 
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8.12  Appendix 12: Guideline of reduction of OLM  
 
Medical Doctors’ Role in the Clinical Trial of Electro- Acupuncture 
and Opioid Like Medication (OLM) Consumption in Chronic Pain 
Patients  
Dear Doctor   
Thank you for participating in this 20-week clinical trial. The following outlines how you 
might help us with this trial.  
 Assess the use of opioid like medications (OLM) regularly, at baseline, 3rd week and 6th 
week during the intervention stage, and 1st, 2nd, and 3rd month during the follow up stage.  
 Help patients to identify the targeted medication; and fill in the given Targeted 
Medication Form. Patients will be guided to reduce short acting OLM first, and then long 
acting OLM.    
 Encourage patients to reduce their analgesic intake, especially OLM at each 
consultation.  To assist you with this task, at each consultation, you will be provided with 
a summary of the analgesic consumption recorded by patients daily.  
 Patients may be encouraged to reduce their OLM when 
o Their pain has diminished in the last 2 weeks, or   
o They experience a better sense of well-being, or  
o Both.  
 The following advice can be given, such as “I suggest you reduce opioids by half to one 
tablet per day for the next week, and then think about reducing one tablet per day 
again the following week”.   
 Finally, we strongly encourage you not to discuss the acupuncture procedure with the 
patients.  
Thank you again for participating in the trial.  
Trial Team
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8.13  Appendix 13: Results analysed with Intention-to-treat  
8.13.1  Intention-to-treat analysis of baseline clinical characteristics  
8.13.1.1  Clinical characteristics at baseline 
Clinical characteristics in terms of consumption of OLM, pain history, intensity of average 
and unpleasantness of pain, depression and quality of life in the two groups were also 
comparable when the intention to treat analysis was employed in this study (Table 13 -1). The 
results are consistent with per protocol analysis. 
8.13.1.2  Side effects of opioid like medication at baseline 
The side effects of OLM were assessed at baseline. There was a higher incidence of the side 
effects in the SEA group than in the REA at baseline. On average, participants reported 6.6 
side effects per person in the SEA group and 5.4 side effects per person in REA group. The 
commonest complaint was drowsiness in the SEA group, accounting for 89% (16 
participants), and fatigue in the REA group, with 76 % (13 participants). The second most 
common complaint was fatigue and lethargy in the SEA group and constipation and lethargy 
in the REA group (Table 13 - 2). However, chi-square tests indicate that there were no 
significant difference between two groups for any side effects except for constipation (χ2= 
5.042, p = 0.025) and drowsiness (χ2 = 5.536, p = .019). 
Table 13 - 3 shows the average severity of side effects that participants experienced in each 
group at baseline. In the SEA group, most severe symptoms reported were drowsiness and 
fatigue, and in the REA group were lethargy and fatigue. There was no significant difference 
on the severity of side effects between two groups except for sedation (t = 2.533, p= .016) and 
drowsiness (t = 2.036, p = .05), with the SEA group experiencing more severe symptoms 
(Table 13 - 3). 
In summary, results about the incidence and severity of side effects related to OLM at 
baseline were similar when analysed with intention-to-treat methods to those analysed with 
per protocol methods.
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Table 13 -1: Comparison of Baseline Characteristics for Randomised Participants 
 in Each Group 
SEA  
N =18 
REA  
N=17 
t p value 
  
Baseline characteristics for 
randomised participants  
Mean          SD Mean           SD   
Consumption of OLM (mg/weekly)  295.5 288.0 461.6 462.6 -1.283 .208 
Pain history (yrs) 13.0 11.0 19.8 24.5 -1.067 2.94 
Present pain intensity -VAS 5.6 1.7 4.9 1.7 1.196 .240 
Highest levels of pain-VAS 7.0 1.4 6.5 1.4 .993 .328 
lowest levels of pain-VAS 3.8 2.2 2.6 1.8 1.675 .103 
Average pain-VAS 5.5 1.7 4.6 1.6 1.578 .122 
Duration of pain (hrs/day) 15.6 4.6 16.8 5.3 -.707 .484 
Severity of pain- GBS  14.0 2.5 12.7 3.1 1.278 .210 
Unpleasantness of pain -GBS 12.4 2.7 11.1 3.1 1.283 .208 
PRI-sensory 18.5 8.1 15.8 8.4 .956 .346 
PRI-affective 4.4 3.7 3.2 3.3 1.204 .313 
PRI-evaluative 2.8 1.6 2.5 1.7 .654 .518 
PRI-miscellaneous 5.8 4.0 4.3 3.5 1.214 .233 
PRI-total 31.6 14.5 25.8 14.0 1.200 .239 
Present Pain Intensity (PPI) 2.8 1.1 2.7 1.0 .315 .755 
Depressive symptoms (BDI-II) 19.0 8.3 18.4 7.1 .247 .806 
SF-36 Physical Functioning (PF) 36.5 22.0 52.1 24.4 -1.244 .223 
SF-36 Role Physical (RP) 12.5 29.2 10.4 16.7 -.140 .890 
SF-36 Bodily Pain (BP) 22.5 12.2 29.2 16.8 -1.001 .324 
SF-36 General Health (GH) 44.6 20.1 40.9 18.5 .582 .565 
SF-36 Vitality (VT) 26.3 21.5 38.8 19.1 -1.194 .241 
SF-36 Social Functioning (SF) 47.9 21.9 51.0 18.8 -.330 .974 
SF-36 Role Emotional (RE) 52.8 48.1 33.3 37.6 1.258 .217 
SF-36 Mental Health (MH) 56.9 18.7 63.0 17.2 -.217 .830 
 Note. p < .05 is significant, two-tailed. 
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Table 13 - 2: Number and % of Participants Who Experienced OLM Side effects  
at Baseline 
SEA  REA 
   N = 18 N = 17 
  N % N % 
Nausea   10 56 7 41 
Vomiting   3 17 4 24 
Dizziness   10 56 5 29 
Fatigue   14 78 13 76 
Drowsiness   16 89 9 53 
Blurred vision   9 50 6 35 
Sedation   11 61 5 29 
Lethargy   14 78 11 65 
Anxiety   10 56 7 41 
Nightmares   7 39 6 35 
Constipation   7 39 13 76 
Other symptoms   7 39 6 35 
Total  118   92  
Incident rate 6.6  5.4  
 
Table 13 - 3: Comparison of Average Severity of Side effects of OLM for Randomised  
Participants in Each Group at Baseline 
SEA  
N =18 
REA 
 N =17 
Side effects of OLM at baseline 
Mean SD Mean SD 
t p- value 
Nausea 1.1 1.5 1.2 2.0 -0.139 0.89 
Vomiting 0.3 0.8 0.5 1.1 -0.677 0.503 
Dizziness 1.4 2.3 0.6 1.3 1.119 0.271 
Fatigue 3.8 3.0 2.8 2.4 1.132 0.266 
Drowsiness 3.8 2.6 2.1 2.4 2.036 0.05* 
Blurred vision 1.5 2.1 0.7 1.3 1.31 0.199 
Sedation 1.8 2.2 0.4 0.8 2.533 0.016* 
Lethargy 2.7 2.4 2.1 2.4 0.739 0.465 
Anxiety 1.6 2.0 1.3 2.2 0.325 0.747 
Nightmares 0.9 1.8 0.9 2.3 0.006 0.995 
Constipation 1.9 2.9 2.1 1.8 -0.296 0.769 
Other symptoms 2.4 3.6 1.3 2.4 1.042 0.305 
         Note: * indicates p < .05 is significant, two-tailed, Independent - samples t -test.
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8.13.2   The effects of EA on the primary outcomes during the treatment period 
8.13.2.1  Dosage of opioid like medication consumption 
Dosage of OLM was a significantly reduced in both SEA and REA groups at the end of the 
treatment [SEA group: 219.1 ± 293.0 (SD) mg/ week vs. REA group: 250.5 ± 410.2(SD) mg/ 
week, F (6, 198) = 13.44, p = .000], and a significant group by time interaction occurred, 
indicating that OLM reduction of the REA group was more rapid (39 %) than that of the SEA 
group (26%) [F (6, 198) = 2.948, p = .009].  
Paired-samples t-tests showed that significant decrease were found in the REA group at the 
end of 3rd and 6th week, and the end of the 6th week in the SEA group when compared to 
baseline (p < .05). However, there was no significant difference between two groups at the 
end of six-week treatment (t = -.261, p = .795) (Figure 13- 1). 
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Figure 13- 1: Consumption of OLM (Morphine Equivalent) mg/Per Week 
 in Each Group across all of Time Points 
8.13.2.2  Side effects of opioid like medication  
Table 13-4 shows the number and percentage of participants who experienced side effects at 
the end of the treatment. The results showed that there was a higher incidence of side effects 
in the SEA group than the REA group at the end of the treatment. On the average, the incident 
rate of side effects was 3.7 in the SEA and 3.0 in the REA group after completion of the 
treatment. However, chi-square tests indicate that there were no significant differences 
between two groups for any side effects. 
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The results of GLM for repeated measure showed that the majority of the side effects were 
significantly reduced (p <.05) except the symptoms of nausea, vomiting and nightmares in 
both groups, and the reductions of severity of the side effects were similar in both groups. 
There were significant group by time inaction for sedation [F (6,198) = 3.629, p = .002], 
drowsiness [F (6,198) = 3.761, p = .001]. The results indicated that the REA group had lower 
severity of sedation and drowsiness overall than in the SEA group (Table 13-5). This is 
different from per protocol analysis where REA is better with sedation, and SEA is better 
with drowsiness. 
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Table 13-4: Number and % of Participants Who Experienced Side effects of OLM 
at the End of the Treatment 
 
SEA  REA 
N = 18 N = 17 
Side effects of  OLM at the End of the Treatment 
 
N % N % 
Nausea   5 28 3 18 
Vomiting   3 17 2 12 
Dizziness   5 28 3 18 
Fatigue   12 67 12 71 
Drowsiness   8 44 8 47 
Blurred vision   3 17 1 6 
Sedation   3 17 1 6 
Lethargy   9 50 7 41 
Anxiety   6 33 4 24 
Nightmares   3 17 2 12 
Constipation   4 22 6 35 
Other symptoms   5 28 2 12 
Total  66  51  
Incident rate 3.7  3.0  
 
 Table 13-5: Average Severity of Side effects of OLM in Each Group at the End of the Treatment  
 
Baseline At the end of the treatment 
SEA 
N=18 
REA 
N= 17 
SEA 
N=18 
REA 
N= 17 
Average severity of side effects of OLM 
Mean SD Mean SD Mean SD Mean SD 
Nausea 1.1 1.5 1.2 2.0 0.9 1.6 0.3 0.9 
Vomiting 0.3 0.8 0.5 1.1 0.3 0.6 0.3 0.9 
Dizziness 1.4 2.3 0.6 1.3 0.9 2.1 0.3 0.7 
Fatigue 3.8 3.0 2.8 2.4 2.5 2.6 1.8 1.9 
Drowsiness 3.8 2.6 2.1 2.4 1.6 2.1 1.2 1.7 
Blurred vision 1.5 2.1 0.7 1.3 0.4 1.0 0.1 0.6 
Sedation 1.8 2.2 0.4 0.8 0.2 0.5 0.1 0.4 
Lethargy 2.7 2.4 2.1 2.4 1.5 1.7 1.4 2.4 
Anxiety 1.6 2.0 1.3 2.2 0.6 1.1 0.7 1.5 
Nightmares 0.9 1.8 0.9 2.3 0.3 0.9 0.2 0.8 
Constipation 1.9 2.9 2.1 1.8 1.0 2.3 1.3 2.5 
Other symptoms 2.4 3.6 1.3 2.4 1.4 2.7 0.6 2.2 
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8.13.3  The effects of EA on Intensity and unpleasantness of pain 
8.13.3.1  Pain assessed with VAS 
The results showed that there were significant time effects of the average pain and highest 
level of pain [average pain: F (6, 198) = 3.686, p = .002; highest level of pain: F (6,198) = 
4.301, p = .000], and a non significant group by time interaction. This analysis showed that 
the intensity of average pain and highest levels of pain in both SEA and REA groups 
decreased over the six-week treatment period, and the reduction of pain was similar in both 
groups (Table 13-6).  
The lowest level of pain, present pain and duration of pain did not change over the six-week 
treatment period in both groups (Table 13-6).   
Table 13-6: Comparison of Pain Assessed With VAS at Baseline and at the End of the Treatment in Each 
Group 
 
Baseline At the end of the treatment 
SEA 
N=18 
REA 
N=17 
SEA 
N=18 
REA 
N=17 
 Mean SD Mean SD Mean SD Mean SD 
Average pain 5.5 1.7 4.6 1.6 4.9 2.0 3.8 2.0 
present pain  5.6 1.7 4.9 1.7 5.6 2.4 4.2 2.3 
Highest of pain 7.0 1.4 6.5 1.4 6.1 1.9 5.7 2.1 
Lowest of pain 3.8 2.2 2.6 1.8 3.6 2.3 2.1 1.8 
Duration of pain 15.6 4.6 16.8 5.3 14.9 4.4 16.4 5.8 
 
The findings of the paired-sample t-tests showed that the average pain in the REA group was 
significantly reduced between the 3rd and 6th week when compared to baseline (p <. 05). 
However, it was not found in the corresponding time in the SEA group (Figure13-2). It might 
be pain reduction is not significant enough to produce group by time interaction.   
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Figure 13- 2: Average of Pain Score Assessed With VAS in Each Group across Time 
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Note: † indicates significant differences within the REA group at the time points when compared 
to baseline. * indicates significant difference within the SEA group at the time points when 
compared to baseline 
8.13.3.2  Pain assessed with Gracely Box Scales 
The results showed that there was a significant time effect in the severity and unpleasantness 
of pain across all the time points [severity of pain: F (6, 198) = 3.046, p = .007); 
unpleasantness of pain: F (6, 198) = 2.575, p = .020)], without group by time interaction 
Table 13-7), indicating that the severity and unpleasantness of pain were significantly reduced 
within both groups over the treatment period when measured with the GBS and the reduction 
was similar in both groups (Figure13- 3). 
 
Table 13-7: Comparison of GBS at Baseline and at the End of the Treatment in Each Group 
  
Baseline At the end of the treatment 
  
SEA 
N=18 
REA 
N=17 
SEA 
N=18 
REA 
N=17 
  Mean SD Mean SD Mean SD Mean SD 
Severity of pain  14 2.5 12.7 3.1 13.4 3.5 11.7 3.7 
Unpleasantness of pain  12.4 2.7 11.1 3.1 11.8 3.7 10.3 3.5 
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Figure13- 3: Unpleasantness of Pain Score Assessed With GBS 
In Each Group during a Six -Week Treatment Period 
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8.13.3.3  Pain assessed with MPQ   
Weekly MPQ scores were analysed with the GLM for repeated measures. The results showed 
that there were no time effects on the following MPQ measures: PRI-s, PRI-a, PRI-m and 
PRI-Total except PRI-e [F (1, 33) = 5.439, p = .027)]. However, there was no group by time 
interaction for all MPQ measures, indicating that there were no significant changes in both 
groups on the following MPQ measures: PRI-s, PRI-a, PRI-m and PRI-Total except PRI-e, 
and the reduction of PRI-e in both groups was not significantly different (Table 13-8).  
 Table 13-8: Comparison of MPQ PRI Scale Score at Baseline and at the End of the Treatment  
in Each Group 
Baseline At the end of the treatment 
SEA REA SEA REA 
N=18 N=17 N=18 N=17 
  
  
Mean SD Mean SD Mean SD Mean SD 
PRI -sensory 18.5 8.1 15.8 8.4 14.3 8.1 14.6 8.0 
PRI -affective 4.4 3.7 3.2 3.3 2.8 3.0 3.2 3.5 
PRI - Total 31.6 14.5 25.8 14.0 24.2 14.4 24.6 15.8 
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8.14  Appendix 14: Comparison of consumption of OLM at the Baseline, 
tw 3 and tw 6 
Comparison of consumption of OLM at the Baseline, tw 3 and tw 6 week  
8.15  Appendix 15: Comparison of consumption of OLM at tw 6, pw 4, pw 
8 and pw 12 
Comparison of consumption of OLM at tw 6, pw4, pw 8 and pw 12 
At tw 6 At pw 4 At pw 8 At pw 12  
Mean SD Mean SD Mean SD Mean SD 
SEA N = 14 113.9 139.2 119.6 166.1 110.6 116.4 139.5 161.6 
REA N = 12 126.1 97.3 164.8 148.9 198.9 146.8 215.8 177.4 
 
Baseline At tw 3 At tw 6  
Mean SD Mean SD Mean SD 
SEA N = 14 212.3 177.8 140.7 155.4 113.9 139.2 
REA N = 12 348.5 303.7 240.1 213.6 126.1 97.3 
